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The role of abnormal DNA methylation in the progression of disease is a growing
area of research that relies upon the establishment of sound statistical methods. The
common method for declaring there is differential methylation between two groups at a
given CpG site, as summarized by the difference between proportions methylated ∆β=β1β2, has been through use of a Filtered Two Sample t-test, using the recommended filter of
0.17 (Bibikova et al., 2006b). In this dissertation, we performed a re-analysis of the data
used in recommending the threshold by fitting a mixed-effects ANOVA model. It was
determined that the 0.17 filter is not accurate and conjectured that application of a Filtered
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Two Sample t-test likely leads to loss of power. Further, the Two Sample t-test assumes
that data arise from an underlying distribution encompassing the entire real number line,
whereas β1 and β2 are constrained on the interval [0,1] . Additionally, the imposition of a
filter at a level signifying the minimum level of detectable difference to a Two Sample ttest likely reduces power for smaller but truly differentially methylated CpG sites.
Therefore, we compared the Two Sample t-test and the Filtered Two Sample t-test, which
are widely used but largely untested with respect to their performance, to three proposed
methods. These three proposed methods are a Beta distribution test, a Likelihood ratio
test, and a Bootstrap test, where each was designed to address distributional concerns
present in the current testing methods. It was ultimately shown through simulations
comparing Type I and Type II error rates that the (unfiltered) Two Sample t-test and the
Beta distribution test performed comparatively well.

CHAPTER 1 Overview of DNA Methylation and the Illumina Technology

Cancer is a class of diseases marked by a continuing increase in aberrant gene
function. This aberrant gene function likely arises from either a genetic mutation or an
epigenetic change. An epigenetic change is a modification to genomic DNA that has only
implications in gene expression capacity but leaves the primary sequence of the DNA
unchanged. Research has long recognized the role of genetic mutations, whether inherited
through the germ line or arising in somatic tissues later in life, in contributing to cancer.
However, more recent studies evidencing their role in the progression of tumors have
brought epigenetic changes to the forefront of cancer research (Jones, 2002).

1.1 Genetic Packaging and Epigenetic Modifications

To understand the role of epigenetic changes in contribution to cancer, one must first take a
deeper look at the mechanisms of genetic packaging and expression. The genetic
information of eukaryotic cells is stored as DNA in their nucleus. The enormous amount
of DNA is compactly stored in the nucleus of each cell by means of a complex
combination with proteins to form chromatin. The fundamental repeating storage unit of
this chromatin is called a nucleosome; each nucleosome contains approximately 146 base
pairs of DNA wrapped around it. In addition to providing a compact storage mechanism
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of DNA, chromatin also preserves the appropriate access to it through the interaction of the
nucleosome with specific protein complexes that associate with, manipulate and
epigenetically modify the nucleosome (Rountree, 2001). These epigenetic modifications,
while not affecting the primary structure of the genetic code, can have implications in the
secondary interactions that are critical to the regulation of gene expression. The interaction
of specific interest here is transcription status.
Transcription is the process of forming an equivalent RNA copy of a sequence of
DNA (MedicineNet.com, 2010). The regulation of transcription by means of an epigenetic
modification could have the ability to alter a wide range of gene function from high-level
expression to complete silencing (Rountree, 2001). Two epigenetic modifications, in
particular, have garnered much interest in their inverse roles in transcriptional regulation
and hence in their role in the progression of cancer. The first epigenetic modification,
histone acetylation involves the acetylation of the amino-terminal tails of histones H3 and
H4 by histone acetyltransferases (HATs) and is implicated in transcriptional activation.
The second epigenetic modification, which is of primary concern for study here, is DNA
methylation.

1.2 DNA Methylation: An Overview

DNA methylation is the addition of a methyl group to the 5′-carbon of a cytosine.
The only methylated base in human DNA is a 5-methylcytosine located in a cytosineguanine (CG) dinucleotide, also referred to as a CpG site. DNA methylation occurs by
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means of an S-adenosyl-methionine acting as a methyl donor by means of adding a methyl
group to the cytosine ring to form methyl cytosine (Eng, 2000). This reaction is catalyzed
by DNA methyltransferases (DNMTs), of which there are three types: Dnmt1, Dnmt3a,
and Dnmt3b (Rountree, 2001). Through the interplay of these three enzymes and their
associated factors which target and regulate their enzymatic activity, genomic methylation
patterns are established during embryogenesis.
CpG sites, and consequently DNA methylation sites, are not distributed evenly
throughout the genome. Rather, CpG sites are relatively scarce throughout the genome as
a whole, and they are clustered in regions of the DNA strand called “CpG islands,”
broadly defined as CG rich regions of DNA (Herman, 2003).

More specifically, CpG

islands are characterized as sequences longer than 200 base pairs in length with a CG
dinucleotide content of greater than 50% and an observed over expected ratio of CpG
dinucleotides of at least 0.6 (Gardiner-Garden and Frommer, 1987, Takai and Jones, 2002).
CpG islands are primarily found in the 5′-regions of housekeeping genes, spanning from
the promoter region to the first exon. The rationale behind the existence of CpG islands is
as follows: it has been shown that most (~80%) of CpG dinucleotides that are located
outside the bounds of a CpG island are methylated (Herman, 2003). Over time, this
methylation has reduced the overall frequency of CpGs in the genome as a whole due to
the fact that methylated cytosines have an increased vulnerability to deamination (Bird,
1980). On the other hand, most of the CpG dinucleotides within the bounds of CpG
islands are unmethylated, rendering them less vulnerable to deamination, hence preserving
the expected frequency of CpG dinucleotides in these regions (Rountree, 2001). However,
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while most CpG islands are normally unmethylated, areas of dense DNA methylation do
naturally occur in these regions and are primarily associated with germ line differentiation
through the inactivation of genes on the X-chromosome in somatic cells and with the
silencing of alleles of imprinted genes.

1.3 Aberrant DNA methylation

The condition of study here for its role in the progression of cancer was aberrant
DNA methylation and its effect on the transcription of RNA. Abnormal DNA methylation
in gene promoter regions is shown to interfere in the transcription of DNA to RNA,
ultimately suppressing gene expression (Michalowsky, 1989). When gene expression is
suppressed in a gene responsible for inhibiting the progression to cancer, like the tumor
suppressor gene, the chance for the development of a cancerous lesion increases. The
interaction of methylcytosine binding proteins with other structural components of the
chromatin renders the DNA inaccessible to transcription factors through histone
deacetylation and chromatin structure changes, thereby accomplishing this gene silencing
effect.

1.4 The role of environmental toxins in aberrant DNA methylation

While its exact cause is not always known, DNA methylation can be either
heritable or as a novel response to toxins (Dolinoy et al., 2007; Illumina, 2006; Liu et al.,
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2008). The incidence of aberrant DNA methylation as a response to environmental toxins
is well documented, and three recent and important studies are here highlighted.
In Dolinoy et al. (2007), the effects of maternal exposure to the estrogenic
xenobiotic chemical bisphenol A (BPA) on the fetal epigenome was explored by studying
the Agouti gene in viable yellow agouti mice. The Agouti gene controls hair color and was
studied because it is a metastable epiallele, an allele that, owing to differential methylation
patterns, can be expressed variably in genetically identical individuals. Female mice were
fed food supplemented with BPA beginning two weeks prior to mating through pregnancy
and lactation. Dolinoy et al. examined the coat color of the litter and measured DNA
methylation at nine sites in the Agouti gene. Compared to a control litter, the litter of mice
exposed maternally to BPA exhibited a different distribution of coat color that was skewed
towards a lighter coat. Furthermore, they showed that BPA exposure reduced the
percentage of cells with methylation at the nine measured sites in the Agouti gene. It was
also found that greater variability in methylation patterns existed between animals than
within a range of tissue types of a single mouse which suggested that the methylation
patterns were likely to have been established early in the embryonic development.
As a second example of the role of an environmental toxin in aberrant DNA
methylation we turn to Weihrauch et al. (2001). Here, the mechanism of the effect of
Vinyl chloride (VC) exposure on hepatocellular carcinomas (HCC) was examined. VC is
a colorless toxic gas widely employed as a refrigerant and intermediate in organic
synthesis. It is well-documented both that in VC-associated liver angiosarcomas (LAS),
mutations of the K-ras-2 gene exist and that K-ras-2 mutations induce p16 methylation
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accompanied by the inactivation of the p16 gene, i.e., the tumor suppressor gene.
Weihrauch et al. hypothesized that there was a similar relation between VC-associated
HCC and mutations of the K-ras-2 gene and subsequent methylation of the p16 gene. In
comparing a sample of patients with VC associated HCCs against a control group of
patients with HCC due to other demonstrated factors, it was determined that there was
indeed an increased proportion of K-ras-2 gene mutation and abnormal hypermethylation
of the p16 gene in the test sample. This suggested that exposure to the toxin VC does, in
fact, play an important role in the pathogenesis of VC-associated HCC by means of K-ras2 mutations and resulting p16 gene methylation.
Finally, in Liu et al. (2008), the effect of combined exposure to the inhaled diesel
exhaust particles toxin and a fungus allergen Aspergillus fumigatus on methylation levels
was observed. Resulting from a 3-week course of inhaled diesel exhaust particle exposure
while undergoing intranasal sensitization to A. fumigates, hypermethylation was induced
at CpG-45, CpG--53, and CpG-205 sites of the cytokine interferon (IFN)- γ promoter and
hypomethylation at CpG-408 of the T helper (Th) 2 interleukin (IL)-4 cytokine promoter.
The induced methylation changes of the promoters in both genes were significantly
correlated with changes in immunoglobin (Ig) E levels. While much research has
demonstrated both the role of Th 2 IL-4 cytokines in promoting allergic sensitization and
asthma and the role of Th1 cytokine IFN- γ in protecting against allergic sensitization and
asthma, this study was the first to show that inhaled environmental exposures can affect
asthma pathogenesis by altering methylation patterns of Th genes in vivo.
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Therefore, as demonstrated by the aforementioned articles, aberrant DNA
methylation is a research topic of current and specific interest. DNA methylation has been
implicated in several cancers ranging from breast cancer to Acute Lymphoblastic
Leukemia and colon cancer by means of silencing the tumor suppressor gene (Yan et al.,
2000; Roman-Gomez et al., 2002; Suzuki et al., 2002). In this thesis, aberrant DNA
methylation was examined as it relates the hepatocellular carcinoma due to hepatitis C
infection.

1.5 The Illumina Technology

Of particular interest here was the detection of methylation sites for the quantitative
analysis of differential methylation patterns. Thus, the need for a technology to accurately
and completely asses the methylation status of the large number of existing CpG sites
arises. The GoldenGate Methylation BeadArray Cancer Panel I platform is technology
developed by Illumina for cancer-focused methylation analysis. It enables the
simultaneous analysis of up to 1,505 CpG loci selected from 807 genes, and it runs two or
more CpG assays for over 74% of these genes (Illumina, 2006). This GoldenGate
BeadArray begins with a bisulfite treatment to DNA that converts unmethylated cytosines
to uracils while leaving methylated cytosines unchanged. This bisulfite treated genomic
DNA is then immobilized on paramagnetic beads. Then, for each CpG site, an allelespecific oligonucleotide and a locus specific oligonucleotide are assembled for each the
methylated and unmethylated state, where separate labels (red and green, respectively) are
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used to design each of the two states. Thus, two pairs of probes are designed for each site.
For all loci simultaneously, the pooled oligonucleotides are assayed by annealing to the
target sequence and then washed to remove excess or mishybridized oligonucleotides.
Extension of the allele specific oligonucleotides to the locus specific oligonucleotides and
subsequent ligation creates PCR templates, which are amplified with fluorescently labeled
universal primers. The resulting products are ultimately hybridized to a beadarray bearing
the complementary address sequences. The fluorescent expression for each the methylated
and unmethylated states are quantified and reported as two channel array data. Therefore,
each array consists of expression values for the methylated target sequence (Red) as well
as expression values for the unmethylated target sequence (Green).
The Illumina assay represents each CpG site as a specific beadtype, and it
incorporates approximately 30 beads (e.g. oligonucleotides) per beadtype to ensure the
assay’s reproducibility. As some examples, the Illumina GoldenGate BeadArray platform
has been used in studies to show that human embryonic stem cells are distinguished from
all other cell types by their methylation profile (Bibikova et al., 2006a), to differentiate
methylation patterns between lung adenocarcinomas and normal lung tissues (Bibikova et
al., 2006b), to identify genes that show aberrant DNA methylation in hematologic
neoplasms (Martin-Subero et al., 2009), and to identify CpG loci exhibiting de novo DNA
methylation in two molecular subtypes of diffuse large B-cell lymphoma (Wang et al.,
2010).

CHAPTER 2 Current Methods for Analyzing DNA Methylation Data

In this chapter, we introduce the application dataset that motivated this research,
identifying differentially methylated CpG sites in HCV-induced hepatocellular carcinoma.
We then describe the two current inferential methods commonly applied when comparing
two groups with respect to DNA methylation, the Two Sample t-test and the Filtered Two
Sample t-test. At the conclusion of this chapter, we also highlight their perceived
deficiencies.

2.1 Hepatitis C Virus (HCV) Data Set

Hepatitis C is an infectious disease caused by the Hepatitis C virus (HCV). The
Hepatitis C virus is an RNA virus belonging to the family of flaviviruses, which primarily
targets the hepatocytes, the main tissue of the liver (Lauer, 2001). HCV is spread by blood
to blood contact, most often through injection drug use, blood transfusion (although
increasingly unlikely), and in rare cases, sexual contact. Acute Hepatitis C, referring to the
first six months after infection with HCV, is relatively asymptomatic, with only vague
symptoms including jaundice, malaise, and nausea. This silent onset of HCV makes the
assessment of this infection difficult. In the majority of cases, the Hepatitis C virus
produces a chronic infection lasting longer than six months. Most chronic infections
9
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result in some degree of fibrosis of the liver, while 15 to 20 percent of those infected
develop cirrhosis.
The time frame in which the various stages of liver disease develop, as a result of
HCV, varies widely from patient to patient. In approximately one third of patients, serious
liver disease develops 20 years or less after infection, while in another third, serious liver
disease takes 30 years or longer to develop. Several factors have been proposed to
accelerate the clinical progression of HCV including alcohol intake, coinfection with HIV1 or HBV, male gender, or an older age at infection. However, once cirrhosis is
established, the risk of hepatocellular carcinoma (HCC) is approximately 1 to 4 percent per
year. Broadly speaking, treatment for HCV infection consists of a combination therapy of
interferon and ribavirin, although liver transplantation remains the only viable treatment
option for patients with either decompensated HCV-related cirrhosis or early stage HCC.
Current studies, such as the methylation data set used here, focus on identifying molecular
events that may be useful in the early diagnosis of the progression from HCV cirrhosis to
HCC.
This research was motivated by a subset of a published methylation data set
(Archer et al., 2010) which is publicly available at Gene Expression Omnibus, accession
number GSE 18081 (Edgar et al., 2002; Barrett et al., 2009). The subset considered in this
thesis consists of methylation data for 36 patients with either HCV cirrhosis without
concomintant Hepatocellular Carcinoma (HCC) (N=16) or HCV cirrhosis with
concomitant HCC (N=20). Each patient’s DNA sample was prepared according to the

11
Illumina technology with primers for the Methylated (Red) and Unmethylated (Green)
channels.

2.2 Analysis of Methylation Data

In methylation studies such as the one studied here, data are presented as
expression levels for both the methylated (Red) and unmethylated (Green) channels across
multiple samples for a given collection of CpG sites. The data are further divided between
samples originating from two groups of patients, one group of which presents a certain
disease. Then, it is of clinical interest to analyze differences in methylation patterns
between the two groups. Here, the first group was comprised of the samples which
demonstrated HCV cirrhosis without concomitant HCC versus the second group that was
comprised of samples which demonstrated HCV cirrhosis with concomitant HCC. These
CpG sites, once identified, would be marked for future study as locations which could
factor in the progression of HCV cirrhosis to the development of HCC.
All of the raw data were read into the R programming environment. Neither
background correction nor normalization steps were implemented on this initial read-in.
Bead summary data were created according to the default method used by Illumina as
follows:
First, beads which had intensities greater than 3 median absolute deviations
(MADs) from the bead median intensity on the original (un-logged) scale were removed
for each bead type on each array. Once outliers were removed, the mean intensity of the
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remaining beads was calculated for each the red and green channels using the unlogged
scale. More specifically, for each array (i) and beadtype (i.e. CpG site) (j), beadtype
expression for the red (methylated) and green (unmethylated) channels was estimated by
averaging the intensities over the beads within the beadtype,
Rij =

1
∑ rijk ,
k k

Gij =

1
∑ g ijk
k k

(2.1)

where i=1,2,…,36 indexes the samples, j=1,2,…,1624 indexes the beadtypes, k indexes the
number of beads per beadtype (k

), and rijk and g ijk are the red and green bead

intensities, respectively, for the ith sample, jth beadtype, and kth bead.
Illumina BeadArrays contain approximately 77 blank beadtypes which do not have
associated gene annotation data. Therefore only those 1,547 beadtypes with associated
gene information files were retained for future analyses. Note that as previously stated, the
Illumina platform enables the simultaneous analysis of up to 1,505 CpG loci, not including
control beadtypes. Thus these 1,547 retained beadtypes indeed include control beadtypes.

2.3 Hypothesis testing using the Two Sample t-test

Upon the collection and preprocessing of methylation data, it was of interest to
conduct hypothesis testing to deduce differences in methylation patterns between groups.
CpG sites with differential methylation between the two groups mark sites for future
studies as sites which possibly contributed to the progression of disease. Hypothesis tests
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were performed on a beadtype level summary statistic measuring “proportion methylated”
which is often computed as

β ijl =

max(Rijl ,0)
max(Rijl ,0) + max(Gijl ,0)

.

(2.2)

Again i indexes the array (i=1,…,36), j indexes the beadtype (j=1,…,1547), and here, l
indexes outcome group (l=1,2). Note that for the purposes of this paper, no background
subtraction was performed in this portion of the analysis. Hypothesis tests for identifying
differentially expressed CpG sites were performed using the random variable, ‘proportion
methylated.’ Currently, the two-sample t-test is a widely accepted test in this scenario. So,
for each beadtype, a two-sample t-test was applied to the sample proportion methylated to
test the null hypothesis of the equality of methylation levels in two groups of samples.
More specifically, letting β ⋅ j1 and β ⋅ j 2 represent the mean population proportion
methylated across arrays in each group for the jth CpG site, the null hypothesis is
H 0 : β ⋅ j1 = β ⋅ j 2

(2.3)

which is tested against the alternative hypothesis,

H 1 : β ⋅ j1 ≠ β ⋅ j 2 .

(2.4)

The test statistic for the two-sample t-test is

t⋅ j =

β ⋅ j1 − β ⋅ j 2
SE( β⋅ j1 − β⋅ j 2 )

=

β ⋅ j1 − β ⋅ j 2
σˆ ⋅2j1
n1

+

σˆ ⋅2j 2
n2

(2.5)
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where β . j1 , σˆ .2j1 , and n1 are the sample mean proportion methylated, the sample variance,
2
and the sample size, respectively, of the group 1 samples, and β . j 2 , σˆ . j 2 , and n 2 are those

corresponding to the group 2 samples for the jth CpG site summarized over the arrays in
the group. Next, the degrees of freedom (df) assuming unequal variances in the two
groups are calculated as

df ⋅ j =

(σˆ ⋅2j1 + σˆ ⋅2j 2 ) 2

σˆ ⋅4j1
n1

+

σˆ ⋅4j 2

.

(2.6)

n2

The two-sided p-value is calculated,

p j = 2(1 − Fdf⋅ j t ⋅ j )

(2.7)

where F is the cumulative distribution function of a t distribution.
Results of a t-test are commonly expressed in terms of a p-value, or the probability
that a test statistic computed under the condition that the null hypothesis is true is at least
as extreme as the value of the test statistic that was actually obtained. A large p-value
(close to 1) indicates a high probability that the obtained test statistic is aligned with one
that would typically be computed if the null hypothesis were true. So this is considered as
evidence in favor of not rejecting the null hypothesis. A small p-value, on the other hand,
supports rejection of the null hypothesis and the conclusion that the two means are not
equivalent.
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2.4 Filtered Two Sample T-test

In the landmark paper describing Illumina’s GoldenGate Methylation BeadArray
assay, Bibikova et al. (2006b) introduced the Filtered t-test, and this testing framework
quickly gained in popularity. Under this testing framework, a CpG site would be identified
as differentially methylated between two groups of arrays if both the p-value of the Two
Sample t-test was less than some pre-determined threshold and the difference between the
mean proportion methylated values, ∆β j = β ⋅ j1 − β ⋅ j 2 , was larger than an additionally
specified threshold. Bibikova, et al. (2006b) estimated that the Illumina technology can
discriminate between levels of differentiation that differ by 0.17 or greater, so they used ∆β
= 0.17 as the threshold for the filtered t-test. However, since this threshold
recommendation, more stringent thresholds have been used. For example, in Richter et al.
(2009), a two sample t-test was conducted at the α = 0.001 level with an additional filter of
∆β > 0.30. Additionally, responding to a concern of too little statistical power of a
performed Mann-Whitney U test, Martin-Subero et al. (2009) filtered ∆β at 0.50.

2.5 Limitations of current analysis methods

Despite a lack of study into the performance quality of these two tests on this data
type, the Two Sample t-test and the Filtered Two Sample t-test have attained widespread
use. However, the Two Sample t-test assumes that the sample data follow a normal
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distribution ranging the entire real number line. Although, considering the scale of the
proportion methylated variable (i.e., βijl∈[0,1]∀ i, j, and l), one could argue that a twosample t-test is not statistically rigorous. Furthermore, the application of a Filtered Two
Sample t-test is only as good as the accuracy of the filter. That is, applying a filter to the
two sample t-test may reduce power for many CpG sites with smaller but truly different
proportions, where power is defined as the probability that a test will reject a false null
hypothesis. Thus, in this thesis we performed a detailed analysis into the accuracy of the
0.17 estimated level of minimum discrimination between methylation levels. We also
proposed alternative inferential methods for comparing two groups with respect to
proportion methylated that utilize the scale of the proportion methylated variable (i.e.,

βijl∈[0,1]∀ i, j, and l), and to thus fully consider all known facets of the distribution. In so
doing, we both propose a new computed minimum level of discrimination, and we further
solidify recommendations for future testing methodology.
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CHAPTER 3 Determination of Minimum Level of Discernable Differential Methylation
According to the Illumina Technology

The application of a Filtered Two Sample t-test hinges on the task of identifying an
appropriate filter to apply to the delta beta, ∆β , values in conjunction with the Two
Sample t-test. Bibikova, et al. (2006b) estimated that the Illumina technology can
discriminate between levels of differentiation that differ by 0.17 or greater, so often
∆β = 0.17 has been used as a threshold for the filtered t-test. The determination of a 0.17
threshold was based on a dilution study performed by diluting female genomic DNA to
male genomic DNA at ratios of 100:0, 50:50, 20:80, 10:90, 5:95, and 0:100 prior to
bisulfite conversion. This dataset consists of 47 samples from an Illumina Universal Array
Matrix wherein the GoldenGate Methylation Cancer Panel I was used as the methylation
assay. Specifically, the 47 samples were derived by mixing male and female genomic
DNA in the previously specified proportions. Two unique female and 2 unique male
samples were used in creating the mixtures that were subsequently hybridized: Female 1
and Male 1 dilutions were each technically replicated 4 times (with exception of the 95:5
which was replicated 3 times) and Female 2 and Male 2 dilutions were each replicated 4
times. 17 CpG sites associated with X-linked genes were examined on the X chromosome
to assess methylation levels. For each of 17 genes on the X chromosome, Bibikova et al.
computed the maximum standard deviation over the replicate runs and found that the
standard deviation of the β- value obtained across the four replicates was <0.06 in 99% of
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cases. They concluded that the Illumina technology could thus discriminate levels of
methylation that differ by at least 1.96 × 2 × 0.06 ≅ 0.17.
Moreover, since this threshold recommendation, more stringent thresholds have
been used. For example, in Richter et al., a two sample t-test was conducted at the

α = 0.001 level with an additional filter of ∆β > 0.30 (2009). Additionally, responding to
a concern of too little statistical power of a performed Mann-Whitney U test, MartinSubero et al. (2009) filtered ∆β at 0.50.
However, we conjecture that a Filtered Two-Sample t-test may severely reduce
power for CpG sites with small but truly differential ∆β’s. Nevertheless, if a filter is to be
applied, the level of the filter should be computed as a function of the analyzed data since
various factors such tissue type and handling can affect the amount of variability in CpG
site methylation across technical replicates. Therefore, the application of a standard
filtering level such as that developed by Bibikova et. al. or a more “conservative” filter
level as seen in other research studies could in actuality be missing very real differential
methylation patterns present in the data.
To investigate the proposed filter, herein we perform a re-analysis of the dilution
data (Bibikova et al., 2006). This data set provided what was needed to compute a
minimum discernable level of differential methylation because it is essentially a clinical
data set in which the true outcome is known. As alluded to in Chapter 1, DNA methylation
is the means by which one of the two X chromosomes in a female is inactivated for germ
line differentiation in somatic cells. Because males only possess one X chromosome,
methylation for this purpose does not occur. Therefore, for genes linked to the X
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chromosome, one could expect approximately 50% methylation of these genes in a sample
arising from a female and 0% methylation of these genes in a sample arising from a male.
The dilution data set of Bibikova et al. consisted of 17 X linked genes measured in
mixtures of female and male genomic DNA samples where the mixtures were according to
specific proportions. It can then be expected that a sample with 100% Female: 0% Male
would exhibit approximately 50% methylation, and so on, as summarized in Table 3.1
below.

Expected
approximate
methylation level
1. 100% Female: 0% Male
50%
2. 50% Female: 50% Male
25%
3. 20% Female: 80% Male
10%
4. 10% Female: 90% Male
5%
5. 5% Female: 95% Male
2.5%
6. 0% Female: 100% Male
0%
Table 3.1 Expected approximate methylation level for X linked
genes given mixing ratio.
Mixing Ratio

To conclude a minimum level of discernable differential methylation, we sought to make
the following five comparisons to determine if differential methylation could be detected:

Mixing Ratio A versus Mixing Ratio B
100% Female : 0% Male versus 50% Female : 50% Male
50% Female : 50% Male versus 20% Female : 80% Male
20% Female : 80% Male versus 10% Female : 90% Male
10% Female : 90% Male versus 5% Female : 95% Male
5% Female : 95% Male versus 0% Female : 100% Male
Briefly, across the 17 X-chromosome linked CpG sites, it was sought to model methylation
levels as a function of the mixing ratio of female to male DNA. By means of this resulting
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model, we both obtained an accurate description of and established the significance of the
relationship between the proportion methylation level and the mixing ratio. Additionally, a
mixed ANOVA model was employed to the perform five pairwise comparisons listed
above testing for differences in the mean methylation levels between two mixing ratios. In
so doing, we can determine that differential methylation can be identified at values as
small as the minimum mixing ratio comparison showing a significant difference in
methylation. This chapter concludes with a summary of the results of these hypothesis
tests and the conclusions drawn.

3.1 Motivation and Methods: Hierarchical model building to Bibikova et al. dilution data

We sought a model to appropriately define the relationship of the proportion of
methylation across CpG sites as a function of the mixing ratio. As evidenced in Figure 3.1,
the ratio of Female to Male DNA in a sample possesses a nonlinear relation with
methylation level.
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Figure 3.1. Boxplot of proportion methylation by percent of female
genomic DNA in the hybridized sample
Moreover, it is also graphically observed that this nonlinear relation appears to depend
both on dilution order (Female 1: Male 1 vs. Female 2: Male 2; see Figure 3.2) and on the
particular CpG site within this dilution order that the methylation is measured (see Figure
3.3).
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Figure 3.2 Mean proportion methylated level across CpG site by
percent of female genomic DNA in sample for the first dilution
order (top panel) and the second dilution order (bottom panel)

Figure 3.3 Proportion methylated level by Percent of female genomic DNA
for each CpG site (1-17) within dilution order (1-2)
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By design, while neither the CpG site nor the dilution order should affect the
relationship between mixing ratio and methylation level, Figures 3.2 and 3.3 demonstrate
evidence of random differences within these grouping levels. Therefore, owing to these
differing nonlinear shapes at both the dilution order level and the CpG site level, it was
concluded that a nonlinear mixed effects model was the most appropriate model building
procedure with which to progress. Additionally, owing to the fact that four technical
replicates were produced for each mixing ratio (with exception of the 95:5 which was
replicated 3 times), we hypothesized that random differences among the order of the
replicates could potentially exist. Therefore, we chose to fit a nonlinear mixed effects
model summarizing the mean proportion of methylation at each mixing ratio while
employing random effects for the dilution order (1 or 2), the technical replicate order (1, 2,
3, or 4) nested within each dilution order, and the particular CpG site (1,…,17) within each
replicate order that was nested within each dilution order.
Given that the nature of the data was CpG site methylation from each of 17 sites
within each of two females and two males, one would expect the proportion of methylation
across each of the 17 CpG sites to be correlated. Indeed, this is the case, as illustrated in
Table 3.2, and the presence of such correlations further motivates the construction of a
single nonlinear model to summarize the proportion of methylation across the 17 CpG
sites.
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EFNB1-645
EFNB1-672
ELK1-1163
ELK1-1306
ELK1-1495
ELK1-877
FMR1-1182
FMR1-1440
G6PD-1076
G6PD-1304
G6PD-834
GLA-1158
GLA-1294
GLA-1306
GLA-1388
GLA-881
GPC3-1182

EFNB1-645 EFNB1-672 ELK1-1163ELK1-1306ELK1-1495ELK1-877FMR1-1182 FMR1-1440 G6PD-1076 G6PD-1304 G6PD-834 GLA-1158 GLA-1294 GLA-1306 GLA-1388 GLA-881 GPC3-1182
1.00
0.98
0.97
0.96
0.99
0.98
0.97
0.99
0.98
0.99
0.96
0.99
0.81
0.68
0.99
0.73
0.95
0.98
1.00
0.99
0.97
0.98
0.99
0.99
0.99
0.98
0.98
0.96
0.99
0.86
0.74
0.99
0.78
0.98
0.97
0.99
1.00
0.97
0.95
0.99
0.99
0.98
0.98
0.96
0.96
0.97
0.84
0.72
0.98
0.77
0.98
0.96
0.97
0.97
1.00
0.94
0.97
0.96
0.96
0.99
0.95
0.99
0.97
0.72
0.59
0.96
0.65
0.95
0.99
0.98
0.95
0.94
1.00
0.98
0.96
0.99
0.96
0.99
0.93
0.99
0.82
0.69
0.99
0.74
0.94
0.98
0.99
0.99
0.97
0.98
1.00
0.99
0.99
0.99
0.98
0.97
0.99
0.83
0.70
0.99
0.75
0.97
0.97
0.99
0.99
0.96
0.96
0.99
1.00
0.99
0.98
0.97
0.96
0.98
0.86
0.74
0.98
0.79
0.98
0.99
0.99
0.98
0.96
0.99
0.99
0.99
1.00
0.98
0.99
0.95
0.99
0.85
0.72
1.00
0.77
0.97
0.98
0.98
0.98
0.99
0.96
0.99
0.98
0.98
1.00
0.97
0.99
0.98
0.77
0.63
0.98
0.69
0.96
0.99
0.98
0.96
0.95
0.99
0.98
0.97
0.99
0.97
1.00
0.95
0.99
0.81
0.68
0.99
0.73
0.94
0.96
0.96
0.96
0.99
0.93
0.97
0.96
0.95
0.99
0.95
1.00
0.97
0.70
0.57
0.96
0.62
0.94
0.99
0.99
0.97
0.97
0.99
0.99
0.98
0.99
0.98
0.99
0.97
1.00
0.81
0.68
0.99
0.73
0.96
0.81
0.86
0.84
0.72
0.82
0.83
0.86
0.85
0.77
0.81
0.70
0.81
1.00
0.96
0.83
0.97
0.86
0.68
0.74
0.72
0.59
0.69
0.70
0.74
0.72
0.63
0.68
0.57
0.68
0.96
1.00
0.71
0.98
0.77
0.99
0.99
0.98
0.96
0.99
0.99
0.98
1.00
0.98
0.99
0.96
0.99
0.83
0.71
1.00
0.76
0.96
0.73
0.78
0.77
0.65
0.74
0.75
0.79
0.77
0.69
0.73
0.62
0.73
0.97
0.98
0.76
1.00
0.82
0.95
0.98
0.98
0.95
0.94
0.97
0.98
0.97
0.96
0.94
0.94
0.96
0.86
0.77
0.96
0.82
1.00

Table 3.2 Correlation among 17 CpG sites.

The model building procedure was performed using the nlme library in R version
2.11.1 (R Development Core Team, 2010). Owing to the shape of the methylation curves
in Figure 3.3, a Logistic Regression model was chosen for our model building procedure.
Model formulation for the mixed Logistic Regression model is as follows.

3.1(a) Nonlinear Mixed Model Formulation: Logistic Regression Model

An initial model (Equation 3.1) was fit including independent random effects for
the jth CpG site within the mth dilution order level and the nth technical replicate order.
Generally, the nonlinear mixed model employing three nested random effects is
represented
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y = f (ϕ mnj , x) + ε

ε ~ N (0, σ 2 )
ϕ mnj = A mnj β + B m,nj b m + B mn, j b mn + B mnj b mnj

(Eq. 3.1)

m = 1,2, n = 1,2,3,4, j = 1,...,17

b m ~ N (0, Ψ1 ), b mn ~ N (0, Ψ 2 ), b mnj ~ N (0, Ψ 3 ),
where y summarizes the mean proportion of methylation as a function of x, mixing ratio
(Pinheiro and Bates, 2000). Here, β is a vector of fixed effects, with design matrix A mnj .
The first level random effects, b m , those corresponding to the mth dilution order, are
independently distributed vectors with variance-covariance matrix Ψ1 and a corresponding
design matrix, B m,nj . The second level random effects, b mn , those corresponding to the nth
technical replicate within the mth dilution order, are independently distributed vectors with
variance-covariance matrix Ψ2 and a corresponding design matrix, B mn , j . And, the third
level random effects, b mnj , those corresponding to the jth CpG site nested within the mth
dilution order and the nth technical replicate, are independently distributed vectors with
variance-covariance matrix Ψ3 and a corresponding design matrix, B mnj .
Using the framework of the Logistic regression model, this model is expressed
f (ϕmnj , x) =

0 .5
1 + exp (ϕ2 mnj − x) / ϕ3mnj

[

]

(Eq. 3.2)

.
and the random coefficients are modeled

ϕ 2 mnj = β 2 + b2 + b2 m + b2 mn + b2 mnj
ϕ 2 mnj 
,
ϕ mnj = 

ϕ 3mnj = β 3 + b3 + b2 m + b2 mn + b2 mnj
ϕ 3mnj 

(Eq. 3.3)
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Note that in Equation 3.2, the asymptote as the percent of Female genomic DNA
approaches 100 is fixed at 0.5 because, biologically, this is the expected proportion of
methylation for this mixing ratio level. Furthermore, ϕ 2 represents the value of percent of
Female genomic DNA present in the mixture at the inflection point of the curve and ϕ 3 is a
scale parameter on the x-axis quantifying the relationship between mixing ratio and
proportion of methylation.

3.1(b) Model Selection

Now that the methodology underlying the candidate model has been outlaid, the
model was estimated and the adequacy of the model fit was evaluated by means of a
residual plot. A plot of the standardized residuals plotted as a function of the fitted values
revealed systematic departures from zero as demonstrated in Figure 3.4.
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Figure 3.4 Standardized residuals plotted
as a function of the fitted values for the
original Logistic regression model

In response to these systematic departures, an alternative Logistic regression model was fit
employing an alternative variance structure of the within group errors. This variance
model was in the form in which the variance at each CpG site increases exponentially with
the percent of Female DNA present in the mixture. This property can be graphically
observed in Figure 3.3 by noting that the curves describing the expected proportion of
methylation become much more highly variable as the percent of Female DNA increases.
Indeed the application of this structure yielded a more appropriate plot of the standardized
residuals plotted as a function of the fitted values:
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Figure 3.5 Standardized residuals plotted as a
function of the fitted values using an exponential
variance structure.

As a final verification of model adequacy, a plot of the fitted methylation values overlaid
upon the observed methylation values in the mixture data set for the updated model using
the exponential variance structure is included in Figure 3.6 below. Given that the fitted
mean curve adheres well to observed data, we concluded that the model provides an
appropriate fit.
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Figure 3.6 Mean fitted proportion methylated
curve overlaid upon observed proportion methylated
values.

Our model building procedure concluded with significance testing for the inclusion of the
three random effects in the model. We began with significance testing for the random
component associated with the jth CpG site, which was nested within the mth dilution
order and the nth technical replicate. This was assessed by fitting a new Logistic
regression model where the random effects associated with CpG site were dropped from
the model. The resulting reduced model was compared to the original full model by means
of a Likelihood Ratio Test, where the test statistic is computed

 L( H 0 ) 

D = −2 ln
 L( H 1 ) 

(3.4)

Here, L( H 0 ) is the likelihood of the of the Logistic Regression model under the null
hypothesis of a full model containing a random term for the nested CpG site effect in the
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model. And, L( H A ) is the likelihood under the alternative hypothesis of a reduced model
where either b2 mnj = 0 and b3mnj = 0. The likelihood ratio test statistic was compared to a
chi-squared distribution with n1 − n2 degrees of freedom, where n1 and n2 are the degrees
of freedom of the full and reduced models, respectively. The p-value of the performed
Likelihood Ratio test was 0.06 which was considered only marginally significant.
Therefore, it was concluded that evidence for dropping the random components for the
nested CpG site effect did not exist.

3.1(c) Establishment of a significant relationship between Proportion of Methylation and
Mixing Ratio

By means of this resulting model, we obtained an accurate description of the
relationship between the proportion methylation level and the mixing ratio. We used the
fitted mixed Logistic regression model to establish the significance of this dose-response
relationship. We examined the ϕ 3 parameter from the fitted model because this parameter
defines the slope of our nonlinear model, and thus, it describes the nature of the relation
between our independent and dependent variables. In the estimated model, ϕˆ3 = 8.40 ,
with a 95% confidence interval ( ϕˆ 3 ± 2 ∗ s.e. ) of (5.61, 11.89). Because this confidence
interval does not include zero, we conclude there is a significant relationship between
percent of female genomic (dose) and proportion methylation level (response). Therefore
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we proceeded in performing pairwise comparisons of adjacent levels for better discerning
the minimum level of detectable differential methylation,

3.2 Establishing a Minimum Level of Detectable Differentiation

Upon establishing both the nature and the significance of the relationship between
mixing ratio and the mean level of proportion of methylation at each CpG site, we wished
to establish a minimum level of detectable differentiation for the Illumina technology. In
this manner, we evaluated whether the threshold of 0.17 established in Bibikova et al.
(2006b) that was claimed to be the minimum level of differentiation that the Illumina
technology could detect was appropriate.
In establishing the minimum level of discrimination, we sought to perform the five
comparisons previously outlined, and listed again here:
Mixing Ratio A versus Mixing Ratio B
100% Female : 0% Male versus 50% Female : 50% Male
50% Female : 50% Male versus 20% Female : 80% Male
20% Female : 80% Male versus 10% Female : 90% Male
10% Female : 90% Male versus 5% Female : 95% Male
5% Female : 95% Male versus 0% Female : 100% Male
A mixed ANOVA model was employed to perform these five pairwise comparisons testing
for differences in the mean methylation levels between two mixing ratios. Because, by
biological principle, we could anticipate the methylation levels present at each mixing ratio
(see Table 3.1), we could also anticipate the differential level of methylation present for
each of the five pairwise comparisons. For example, for the comparison of 100% Female:
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0% Male versus 50% Female: 50% Male, we could have expected a difference in mean
methylation of approximately 0.50-0.25=0.25, and so on, down to the last pairwise
comparison designed to query a difference in mean methylation of 0.025. The minimum
level of discernable discrimination was then concluded to be the minimum queried
difference in mean methylation for which the pairwise comparison determined
significantly differentially methylated between the two mixing ratios.
The form of the mixed ANOVA model was as follows:
y rmnj = µ ⋅⋅⋅⋅ + α r + β m + γ n ( m ) + δ j ( mn ) + ε rmnj

(Eq. 3.5)

where:

µ⋅⋅⋅⋅ is a constant
α r are constants corresponding to the rth level of the mixing ratio
β m is an independent normal random variable with expectation zero and variance σ β2
corresponding to the effect for the mth dilution order

γ n ( m ) is an independent normal random variable with expectation zero and variance σ γ2
corresponding to the effect for the nth technical replicate nested within the
mth dilution order

δ j ( mn ) is an independent normal random variable with expectation zero and variance σ δ2
corresponding to the effect for the jth CpG site nested within the mth dilution order
and the nth technical replicate
r = 1,...,6, m = 1,2, n = 1,2,3,4, j = 1,...,17
(Kutner et al., 2005).
A likelihood ratio test for the significance of the CpG site nested effect
( H 0 : δ j ( mn ) = 0 vs. H A : δ j ( mn ) ≠ 0 ) demonstrated that we rejected the null hypothesis and
concluded that a nested random effect for the effect of the jth CpG site was valid in the

33
model fit (p-value=<0.001). A plot of the standardized residuals versus the fitted values
for the mixed ANOVA model is presented in Figure 3.7 below.
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Figure 3.7 Standardized residuals versus fitted
values in final mixed ANOVA model.

Using the mixed ANOVA model (Eq. 3.5), the previously listed pairwise comparisons for
testing differences in the factor level means of the adjacent mixing ratios were conducted.
Here, H 0 : µ r ⋅⋅⋅ − µ r′⋅⋅⋅ = 0 versus H A : µ r ⋅⋅⋅ − µ r ′⋅⋅⋅ ≠ 0 . Testing was conducted at the 95%
significance level and results for the five pairwise comparisons are summarized in Table
3.3.
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Pairwise
Comparison
µ(100%F:0%M) vs.
µ(50%F:50%M)
µ(50%F:50%M) vs.
µ(20%F:80%M)
µ(20%F:80%M) vs.
µ(10%F:90%M)
µ(10%F:90%M) vs.
µ(5%F:95%M)
µ(5%F:95%M) vs.
µ(0%F:100%M)

Expected
Differential
Methylation

Estimate

Std.
Error

t-value

p-value

0.25

0.104

0.033

3.128

0.026

0.15

0.170

0.033

5.116

0.004

0.05

0.134

0.033

4.024

0.010

0.025

0.088

0.033

2.641

0.046

0.025

0.086

0.033

2.595

0.049

Table 3.3 Pairwise comparisons across adjacent mixing ratios.

Notice first the discrepancies between the values of the expected differential methylation
level and the estimate of differential methylation from the fitted mixed ANOVA model.
The difference in these two columns is likely due to the high variation in proportion of
methylation across CpG site. Note from Figure 3.1, the boxplot of proportion methylation
by percent of female genomic DNA in the hybridized sample, the amount of overlap
among quantile boxes, especially between samples containing each 100% Female: 0%
Male and 50% Female: 50% Male. Nevertheless, at each pairwise comparison, the p-value
is less than 0.05, and so we conclude that the Illumina technology can, in fact, detect
differential methylation at levels less than 0.17. Theoretically, this analysis demonstrates
that evidence exists to support a hypothesis that the Illumina technology can detect
differences in methylation at least as low as 0.025 since differential methylation was
detected for two pairwise comparisons designed to query for this methylation level.
However, given that the observed differential methylation levels were as low as 0.086, a
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more conservative concluded estimate of the minimum detectable differential methylation
would be closer to 0.086.

3.3 Verification of fixed asymptote assumption

In the constructing the nonlinear model with nested random components in section
3.2 above, it was assumed that as the percent of Female DNA in the sample approached
100%, the asymptote of predicted methylation was fixed at 0.5. This was motivated by the
biological principle of methylation at CpG sites on the X-chromosome. We now seek to
determine if the given data support this assumption. In doing so, we fit separate nonlinear
models for each of the 17 CpG sites and used the predicted methylation level under the
conditions of 100% Female DNA: 0% Male to predict site-specific asymptotes and
associated confidence intervals. The description of the model construction follows.
CpG site-specific nonlinear mixed models were constructed under each the Logistic
regression framework previously described (Eq. 3.2) and the Asymptotic regression
framework found in Pinheiro and Bates (2000) using a random effect for dilution order (1
or 2). These two models were chosen as appropriate candidate models because the shape
of the nonlinear curve described appeared to adhere well to the shape of the dose-response
curves exhibited in the mixture data set.
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3.3(a) Nonlinear Mixed Model Formulation: Asymptotic Regression Model

For the Asymptotic Regression model, an initial model (Equation 3.6) was fit
including independent random effects for each the dilution order level (1 or 2). Generally,
the nonlinear mixed model employing one random effect is represented
y = f (ϕmj , x) + ε

ε ~ N (0,σ 2 )
ϕmj = A mjβ + B mjb mj

(Eq. 3.6)

m = 1,2, j = 1,...,17
b mj ~ N (0, Ψ ),

where y summarizes the mean proportion of methylation as a function of x, mixing ratio.
Here, β is a vector of fixed effects, with design matrix A mj . The random effects, b mj , those
corresponding to the mth dilution order for the jth CpG site, are independently distributed
vectors with variance-covariance matrix Ψ and a corresponding design matrix, B mj .
Using the framework of the Asymptotic regression model, this model is expressed
f (ϕmj , x) = ϕ1mj + (ϕ2 mj − ϕ1mj ) exp(− exp(ϕ3mj ) x),

(Eq. 3.7)

and the random coefficients are modeled

ϕ mj

ϕ1mj = β1mj + b1mj
ϕ1mj 


= ϕ2 mj  , ϕ2 mj = β 2 mj + b2 mj .
ϕ3mj = β 3mj + b3mj
ϕ3mj 

(Eq. 3.8)

ϕ1 represents the horizontal asymptote on the right side, ϕ 2 represents the proportion
methylated when the percent of Female genomic DNA present in the mixture is zero, and
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ϕ 3 represents the natural logarithm of the rate constant and so quantifies the dose response
relation.

3.3(b) Nonlinear Mixed Model Formulation: Logistic Regression Model

Again, an initial model (Equation 3.9) was fit including independent random effects
for the dilution order level. The same basic framework for the model stays the same in that
for the mean proportion methylated, y, for the mth dilution order group and the jth CpG
site is written as
y = f (ϕmj , x) + ε

ε ~ N (0,σ 2 )
ϕmj = A mjβ + B mjb mj

(3.9)

m = 1,2, j = 1,...,17
b mj ~ N (0, Ψ ),

where ε is a normally distributed within-group error term. The difference in the
Asymptotic Regression model and the Logistic Regression model lies in f (φ jmr , x jmr ), the
link function. Again, f is the real-valued, differentiable logistic function of a group
specific parameter vector φ mj containing information on dilution order and a covariate
vector x jr containing the levels of mixing ratios. But now f (φ mj , x r ), is written as
f (φ mj , x ) =

and the random coefficients are modeled

ϕ1mj
1 + exp[(ϕ2 mj − x ) ϕ3mj ]

(3.10)
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ϕ mj

ϕ1mj = β1mj + b1mj
ϕ1mj 


= ϕ2 mj  , ϕ2 mj = β 2 mj + b2 mj .
ϕ3mj = β 3mj + b3mj
ϕ3mj 

(3.11)

ϕ1 represents the horizontal asymptote, ϕ 2 represents the value of the percent of Female
genomic DNA in the sample at the inflection point of the curve, and ϕ 3 represents the
scale parameter on the x-axis.

3.3(c) Model Selection

Now that the methodology underlying both the candidate models has been outlaid,
both models were fit for each CpG site and model comparison was conducted according to
the Akaike Information Criterion (AIC). The AIC is a measure of the goodness of fit of an
estimated statistical model and is commonly used as a tool for model selection. A model
with a lower AIC is considered better. The AIC is computed,
AIC = 2η − 2 ln( L)

where η is the number of parameters in the statistical model, and L is the maximized
function of the likelihood for the estimated model. Results of the AIC analysis are
summarized in Table 3.4.

(3.12)
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AIC
Asymptotic
Logistic
CpG
Regression Regression
site
Model
Model
1
-214.24
-126.81
2
-214.86
-152.14
3
-190.65
-157.43
4
-195.82
-124.20
5
-177.35
-127.88
6
-192.56
-144.77
7
-198.72
-154.47
8
-205.08
-131.58
9
-203.98
-118.07
10
-195.46
-114.94
11
-201.70
-125.15
12
-196.10
-109.88
13
-168.16
-154.94
14
-229.57
-210.85
15
-189.13
-124.10
16
-206.59
-208.94
17
-203.94
-177.54
Table 3.4 AIC comparison by CpG site between Asymptotic
Regression and Logistic Regression models

For each CpG site, the AIC demonstrates that the Asymptotic Regression model is more
appropriate to our given dilution data. The one possible exception to this is site 16 where
the AIC of the Logistic Regression model is only slightly more negative than that of the
Asymptotic Regression model. However, since these values are so close, we conclude that
the models are relatively equivalent in fit, and for consistency purposes, we choose to
proceed with the Asymptotic Regression model for this site as well.
In the search for the most well-suited yet parsimonious model, we next explored
and modifications to the variance-covariance structures of our 17 Asymptotic Regression
models. Up to this point, we had assumed independent variance components. Given that
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plots of residuals did not show any particular trend such as with technical replicate order,
we next dropped the constraint of independent variance components and considered an
unstructured variance matrix. However, in all cases, the original constraint of
independence proved to be a better fit. A final modification explored on our models, was
to determine if each of the three random effects for the three modeling parameters were
necessary. This was assessed by fitting new Asymptotic Regression models for each CpG
site where one of the random effects was dropped from the model. The resulting reduced
models were compared to the original full model by means of a Likelihood Ratio Test,
where the test statistic is computed

 L( H 0 ) 

D = −2 ln
L
(
H
)

1 

(3.13)

Here, L( H 0 ) is the likelihood of the of the Asymptotic Regression model under the null
hypothesis of a full model containing a random term for each of the three parameters in the
model. And, L( H 0 ) is the likelihood under the alternative hypothesis of a reduced model
where either b1 jm = 0, b2 jm = 0, or b3 jm = 0. The likelihood ratio test statistic was
compared to a chi-squared distribution with n1 − n2 degrees of freedom, where n1 and n2
are the degrees of freedom of the full and reduced models, respectively.
For each CpG site, it was found that φ2 jm did not warrant a random component. Likelihood
ratios and p-values for this test are found in Table 3.2.
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CpG site

Likelihood
of Full
Model

Likelihood of
Reduced
Model (no
random term
for ϕ 2 mj )

Likelihood
Ratio

P-value of
Likelihood
Ratio Test

1: EFNB1-645
114.12
114.12
6.04E-06
0.998
2: EFNB1-672
114.41
113.05
2.77E+00
0.096
3: ELK1-1163
102.32
102.32
3.15E-09
1.000
4: ELK1-1306
104.91
104.91
1.46E-06
0.990
5: ELK1-1495
95.67
95.67
2.13E-08
1.000
6: ELK1-877
103.28
101.87
2.83E+00
0.092
7: FMR1-1182
106.36
106.36
1.04E-09
1.000
8: FMR1-1440
109.54
109.54
4.66E-08
1.000
9: G6PD-1076
108.99
108.99
3.94E-06
0.998
10: G6PD-1304
104.73
104.73
1.02E-08
1.000
11: G6PD-834
107.85
107.85
2.11E-05
0.996
12: GLA-1158
105.05
105.05
5.51E-07
0.999
13: GLA-1294
91.08
91.08
2.45E-07
1.000
14: GLA-1306
121.78
121.78
5.95E-07
0.999
15: GLA-1388
101.56
101.56
6.54E-06
0.998
16: GLA-881
110.30
110.30
6.33E-06
0.998
17: GPC3-1182
108.97
108.97
4.75E+00
1.000
Table 3.5 Results of Likelihood Ratio test to determine the significance of a
random effect for ϕ 2 mj parameter in Asymptotic Regression model.
Owing to the large p-values for the Likelihood Ratio test at each CpG site, we failed to
conclude that there was a difference between the full Asymptotic Regression Model
containing a random effect for each parameter in the model and the reduced model, which
lacks a random effect for φ2 jm . Therefore, we moved forward with the simpler reduced
model. More formally, this model can be written,
f (ϕmj , x) = ϕ1mj + (ϕ2 mj − ϕ1mj ) exp(− exp(ϕ3mj ) x),

(3.14)
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where

ϕ1mj 
ϕ mj = ϕ2 mj 
ϕ3mj 

ϕ1mj = β1mj + b1mj
,

ϕ 2 mj = β 2 mj
ϕ3mj = β 3mj + b3mj

(3.15)

The appropriateness of this resulting model in summarizing the dilution data was verified
both by plots of standardized residuals and plots of the fitted values overlaid upon
observed values.
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Figure 3.8. Standardized residuals plotted as a function of fitted values for the 17 CpG site-specific models.
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In examining the plots of the standardized residuals plotted as a function of the
fitted values for the 17 CpG site-specific models, we observed that for each model, the
residuals appear to be randomly and uniformly distributed about the horizontal zero line.
This gives confidence of the appropriateness of the fit for our models. A further check of
model fit was accomplished by examining plots of model fitted values overlaid upon the
observed values upon which the models were estimated (see Figure 3.5). We saw that for
each CpG site, the fitted curve of mean proportion methylated appeared to adhere very
well to the shape of the observed data. Therefore, we are confident in the fit of our
Asymptotic Regression models, and we moved to construct hypothesis tests for the
detection of differential methylation between mixing ratio levels at each CpG site.

Figure 3.9 Mean fitted proportion methylated curve overlaid upon observed proportion methylated values for each mixing
ratio level by CpG site.
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3.3(d) Predicted CpG site specific response asymptotes

Upon the construction of the CpG site specific nonlinear mixed models, it was of
interest to use the predicted proportion of methylation to estimate the asymptote as the
percent of Female genomic DNA in the sample approaches 100%. Therefore, using the 17
CpG site specific models, point estimates of the predicted mean proportion of methylation
were obtained where the percent of Female genomic DNA in the sample was 100%, and
95% confidence intervals were calculated using the delta method to estimate the variance
and applying a Bonferroni adjustment, i.e.,

  ∂ϕ1 j ∂ϕ 2 j

  ∂f
∂f

µˆ (100% Female : 0% Male) ± z(1− 0.05 / 17 )  σ ϕ2
0
  1j
σ ϕ22 j
 
  0
0
 

∂ϕ 3 j 
×

∂f  (100% Female :0% Male )
0 
  ∂ϕ1 j
0 ×
∂f
σ ϕ23 j  

∂ϕ 2 j
∂f

1/ 2






T
∂ϕ 3 j 



∂f  (100% Female :0% Male ) 


Point estimates and resulting 95% confidence intervals are summarized in Table 3.6 below.
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CpG site
EFNB1-645
EFNB1-672
ELK1-1163
ELK1-1306
ELK1-1495
ELK1-877
FMR1-1182
FMR1-1440
G6PD-1076
G6PD-1304
G6PD-834
GLA-1158
GLA-1294
GLA-1306
GLA-1388
GLA-881
GPC3-1182

Point
Estimate
0.719
0.644
0.588
0.545
0.860
0.679
0.551
0.736
0.638
0.819
0.535
0.812
0.456
0.223
0.747
0.297
0.500

Confidence
Interval
(0.673,0.765)
(0.551,0.737)
(0.544,0.631)
(0.423,0.668)
(0.836,0.884)
(0.636,0.723)
(0.517,0.585)
(0.677,0.794)
(0.559,0.718)
(0.796,0.842)
(0.404,0.667)
(0.778,0.845)
(0.108,0.802)
(-0.008,0.458)
(0.716,0.779)
(0.073,0.521)
(0.472,0.518)

Table 3.6 Point estimates and 95% confidence
intervals of predicted proportion methylated
for mixtures demonstrating 100% Female DNA

It is evident from the above table that the asymptote of 0.5 was not obtained by every CpG
site. This is likely due to the fact that, similar to other high-throughput genomic platforms,
probes have different hybridization affinities and therefore the theoretical 0.5 estimate was
not attained by each CpG site. However, as established in Chapter 3.1(c), an appropriate
overall model fit was achieved and a significant dose-response relationship was indeed
established.
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3.4 Concluding remarks

In this chapter, we sought to explore our hypothesis that the Illumina technology
can differentiate between levels of methylation less than 0.17. It had been previously
claimed that the Illumina technology could differentiate between levels of methylation by
0.17, however, we hypothesized that the technology could indeed detect lesser levels of
differential methylation. To demonstrate the validity of our hypothesis, we used a dilution
data set provided by the Illumina company, and we modeled the relationship between
mixing ratio and proportion of methylation in X-chromosome linked genes. This dilution
data set of X-chromosome linked genes was key because it essentially provided us with a
clinical data set in which the true methylation status was known. By modeling the
relationship between mixing ratio and proportion methylation according to nonlinear
mixed models for each X-chromosome linked CpG site, we were able to accurately
describe the nature of the relationship between the mixing ratio and proportion of
methylation while concluding that a significant relationship exists between these two
factors. Furthermore, a mixed ANOVA model accounting for random variation due to
dilution order, technical replicate order, and CpG site effect enabled hypothesis testing for
differential mean methylation between adjacent mixing ratio groups. In doing so, we
showed that the Illumina technology can, in fact, discriminate between levels of
differentiation at least as low as 0.086, rather than 0.17. This is an especially interesting
finding given the propensity of many to test differential methylation using a Filtered Two
Sample t-test with a filter greater than or equal to 0.17, as summarized in Chapter 1.
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Indeed, a filter of this magnitude likely reduces power for smaller but truly differential
CpG sites that the technology is very capable of discriminating. In Chapter 4, alternatives
to a Two Sample t-test with and without a filter to analyze CpG site methylation data will
be introduced.

CHAPTER 4 Proposed Two Group Inferential Methods For Testing Proportion Methylated

4.1 Alternative Analysis Exploration

Alternatives to the currently employed Two Sample t-test with and without a filter
were sought, and an initial alternative analysis was motivated by the well known
distributional property supposing that if Rij ~ Gamma(θ1 , κ ) and Gij ~ Gamma(θ 2 , κ ) then

β ij =

Rij
Rij + Gij

~ Beta (θ1 ,θ 2 ). Given that the formula for the proportion methylated

resembles this property, a natural initial step in the analysis was to suppose that the Red
and Green channels each follow a Gamma distribution. This seems plausible as both Rij
and Gij have a distributional range of [0, ∞) and because of the skewed shape of the
distributions of the Red and Green channels present using the Hepatitis C Virus
methylation dataset described in Chapter 2.1 (illustrated for a representative sample,
beadarray 28, in Figure 4.1). An additional artifact of the Red and Green channel data
present in Figure 4.1 is that of dye bias. The green dye is more efficient than the red,
causing it to be incorporated faster and resulting in the bulk of the Green channel signal
intensities being distributed at a much higher value than the Red channel signal intensities.
Again in Figure 4.1 this artifact is demonstrated for a representative sample, beadarray
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number 28, where it can be seen that the intensities from the Green channel are much
higher than the intensities from the Red Channel:

Figure 4.1 Histogram of Green (top panel) and Red (bottom
panel) channel intensities for a representative beadarray.

For this reason, a constant scaling normalization method was applied. Specifically, a
unique scaling factor si for each array was introduced to multiply the Green channel signal
intensities, thus scaling down closer to the red values, i.e.,

si⋅⋅ =

µR

i ⋅⋅

µG

(4.4)

i ⋅⋅

for

. Here, µ Ri .. and µ Gi .. are the arithmetic means of the Red and Green signal

intensities across all CpG sites for a single array. This array specific scaling factor was
multiplied by the Green signal intensities, thus resulting in the Red and Green Channels

52
residing on a more similar range, as evidenced by the following histogram, again for
beadarray 28.

Figure 4.2 Histogram of Green uncorrected (top panel), Green
corrected, and Red (bottom panel) channel intensities for a
representative beadarray. Green corrected intensities were
post-constant-scale normalized.

Upon computation of this scaled normalized data, β estimates were calculated for each
CpG site according to Equation 2.2. Because each the Red and Green channels were
hypothesized to be distributed as Gamma, then it follows that we assumed β is distributed
as Beta. The Beta distribution is a family of continuous probability distributions
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constrained on the interval

and defined by two positive shape parameters,

and .

The density function of a variable z , that is distributed according to a beta distribution,
, is
f ( z; p, q ) =

Γ( p + q ) p
z (1 − z ) q .
Γ ( p )Γ ( q )

Because the Beta distribution is constrained on the interval

(4.1)
, it is often a good

distribution to model variables which are measured in proportions. Further evidence in
support of the hypothesis of the distribution of the proportion methylation β according to
a Beta distribution is given that by nature of the computation of the proportion methylated
estimates, β is a continuous random variable both centered on and restricted to the range
[0,1]. Furthermore, for each CpG site in the HCV data set a Kolmogorov-Smirnov Test
was employed to determine if evidence existed to refute this hypothesis.

4.2 Kolmogorov-Smirnov Test

A Kolmogorov-Smirnov Test was conducted for each CpG site to assess whether
evidence existed to refute the hypothesis that the proportion of methylation was distributed
according to a beta distribution, i.e. H 0 : [F (t ) = H (t ), for every t ] where F (t ) is the
empirical distribution function for the 36 computed

ratios at each CpG site

( β ij ~ Beta( p j , q j ) under H 0 ), calculated using the scaled data, and H (t ) is the empirical
distribution function for the Beta distribution function (Hollander and Wolfe 1999).
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Letting Z (1) ≤ L < Z ( 72) denote the 72 = (i + h) = (36 + 36) ordered values for the combined
sample of the β 1 j ,..., β ij and the Y1 j ,..., Yhj observations of the empirical distribution
function for the Beta distribution, Hhj , the Kolmogorov-Smirnov test statistic is computed
as

{

}

Ω. j = max Fij ( Z ( s )) − H hj ( Z ( s ) ) .
s =1,...72

(4.2)

For the empirical distribution function of the Beta distribution at the jth CpG site, the
method of moments was used to estimate the parameters for the empirical distribution
function of the Beta ( p. j. , q. j . ) distribution as a function of the data at each CpG site where:
 z. j . (1 − z. j. ) 
− 1
pˆ . j . = z. j . 
2


s
. j.



(4.3)

 z. j . (1 − z. j . ) 
qˆ. j . = (1 − z. j . )
− 1 .
2


s
. j.



(4.4)

and,

Above, z. j . is the sample mean and s.2j. is the population variance of the β ij ratios at each
CpG site.
This yielded promising results: in 1438 (93%) of the

ratio distributions computed

for each CpG site, we failed to reject the null hypothesis, and so we do not have evidence
to refute the claim that the distribution of the proportion of methylation at each CpG site
follows a Beta distribution. Thus it was decided to move forward with designing a
hypothesis test that is based on a Beta distributed random variable to test for the
equivalence of the two groups. The hypothesis test based on a Beta distributed random
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variable took two forms: that of a test based on the beta distribution and that of a large
sample approximation. A description of these two forms follows.

4.3 Testing for Differentially Methylated CpG sites: Beta Distribution Motivated TwoSample Test

4.3(a) Test Based on a Beta Distributed Random Variable

To design a test for the difference between two beta distributed random variables,
assume that X ~ Beta( p1 , q1 ) and Y ~ Beta( p2 , q2 ) are two given random variables. It is
of interest to test H 0 : µ X − µ Y = 0 against the alternative H A : µ X − µ Y ≠ 0. The null
hypothesis can be equivalently expressed as H 0 : µ X = µ Y . In formulating the hypothesis
test, it must be conducted under the conditions of the null hypothesis. Therefore, given the
observed data β ⋅ j1 = ( β1 j 1 , β 2 j 1 , K , β n1 j 1 ) and β ⋅ j 2 = ( β1 j 2 , β 2 j 2 , K , β n2 j 2 ) at the jth CpG
site, under the conditions of H 0 , we form Z ⋅ j⋅ = ( β ⋅ j1 , β ⋅ j 2 ) which is used to estimate p̂
and q̂ according to the method of moments estimators described in Equations 4.3 and 4.4,
and as follows:
 z⋅ j⋅ (1 − z⋅ j⋅ ) 
pˆ ⋅ j⋅ = z⋅ j⋅ 
− 1
2


s
⋅
j
⋅


and

(4.3a)

56
 z⋅ j⋅ (1 − z⋅ j⋅ ) 
qˆ⋅ j⋅ = (1 − z⋅ j⋅ )
− 1 .
2


s
⋅ j⋅



(4.4a)

Here, s⋅2j⋅ is the population variance of Z ⋅ j⋅ . Furthermore, note that

µ⋅ j⋅ = Mean( z⋅ j⋅ ) =

p⋅ j⋅

(4.5)

p⋅ j⋅ + q⋅ j⋅

be the population mean, and that
v⋅ j⋅ = Var ( z⋅ j⋅ ) =

p⋅ j⋅ q⋅ j⋅
( p⋅ j⋅ + q⋅ j⋅ + 1)( p⋅ j⋅ + q⋅ j⋅ ) 2

(4.6)

be the population variance of Z ⋅ j⋅ ~ Beta( p⋅ j⋅ , q⋅ j⋅ ).
These values can then be used to obtain a standardized quantile value, Q0.975,⋅ j⋅ , from the
beta distribution for a two sided 95% confidence level (from 1-α/2 letting α = 0.05 ) as
follows:
Q0.975,⋅ j⋅ =

F −1 (0.975, pˆ ⋅ j⋅ , qˆ⋅ j⋅ ) − µ⋅ j⋅
v⋅ j⋅

.

(4.7)

The critical value, C0.975,⋅ j⋅ , for testing the test statistic D⋅ j⋅ = µ⋅ j1 − µ⋅ j 2 at the jth CpG site
would be computed as
C0.975,⋅ j⋅ = 0 + Q0.975,⋅ j⋅ *

v ( β ⋅ j1 )
n1

+

v( β ⋅ j 2 )
n2

,

(4.8)

and one would reject the null hypothesis of equal means between the two groups at the jth
CpG site where D⋅ j⋅ > C0.975,⋅ j⋅ .
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Under the framework just described, it is assumed that the combined data between
the two Beta distributed groups follows a Beta distribution, and it is this Beta distribution
of the combined data that is used to compute a standardized quantile and, hence, a critical
value to which a test statistic is compared. Therefore, this Beta test specifically tests if the
mean proportion methylated is equivalent between two groups at a specified CpG site.

4.3(b) Likelihood Ratio Test

As a large sample counterpart to the Beta test, an alternative test was designed
under the likelihood ratio testing framework. The likelihood ratio test was appropriate here
since two nested distributions were present. Under the likelihood ratio test, the same
question of equivalence between groups is addressed in a slightly different manner. Rather
a two sample test for comparing the ratios for each CpG site between two groups, cirrhosis
with and without concomitant HCC, reduced to testing if the ratio of the signal intensities
adhered to identical Beta distributions at each site. This was determined by testing if the
Beta distribution parameters are the same for each group at each CpG site, i.e.,
H 0 = p1 = p2 = p and q1 = q2 = q ,

H 1 = p1 ≠ p2 and / or q1 ≠ q2

(4.9)

The methodology of this large sample approximation test follows.
To test the hypothesis of identically shaped Beta distributions at each CpG site
( H 0 = p1 = p2 = p and q1 = q2 = q ), a likelihood ratio test was employed. The first
distribution, the distribution under the null hypothesis, assumed that both p and q
parameters from the two groups were equal, and hence, the likelihood equation at the jth

58
CpG site under the null hypothesis is that of a Beta distribution with sample size n, given
by
L0⋅ j⋅ ( p⋅ j⋅ , q⋅ j⋅ ; z1 j⋅ ,..., z nj⋅ ) =
are the computed

where the

1
n
B ( p⋅ j⋅ , q⋅ j⋅ )

n

z
]∏

[

i =1

p⋅ j ⋅ −1
ij ⋅

ratios and here,

(1 − zij⋅ )

q⋅ j ⋅ −1

(4.10)

. Now, the logarithm of the

likelihood is

[

log L0⋅ j⋅ ( p⋅ j⋅ , q⋅ j⋅ ; z1 j⋅ ,..., z nj⋅ ) = − n log B ( p⋅ j⋅ , q⋅ j⋅ )

]

n

n

i =1

i =1

(4.11)

+ ( p⋅ j⋅ − 1)∑ log zij⋅ +(q⋅ j⋅ − 1)∑ log(1 − zij⋅ ).

The second likelihood formed under the conditions of the alternative hypothesis, assumes
that either or both p and q parameters from the two groups are not equal, and hence the
likelihood equation of this second group is given by

L1 j ( p⋅ j1 , q⋅ j1 , p⋅ j 2 , q⋅ j 2 ; z1 j1 ,..., z nj1 , z1 j 2 ,..., z nj 2 )
=

1
n
B( p⋅ j1 , q⋅ j1 ) 1

[

]

where

n1

∏ zij1⋅ j1 (1 − zij1 )

and

p −1

q⋅ j 1 −1

i =1

are the computed

∗

z
] ∏

[

(1 − zij 2 )

q⋅ j 2 −1

(4.12)

. For the purposes of the data here, the

ratios from the HCC positive group (

from the HCC negative group (

i =1

p⋅ j 2 −1
ij 2

ratios and sample sizes, respectively for the

two groups in the jth CpG site , where
are the

n2

1
n
B ( p⋅ j 2 , q⋅ j 2 ) 2

), and the

are the

ratios

). The logarithm of this likelihood is

log L1 ( p⋅ j1 , q⋅ j1 , p⋅ j 2 , q⋅ j 2 ; z1 j1 ,..., z nj1 , z1 j 2 ,..., z nj 2 )
n1

= − n1 B ( p⋅ j1 , q⋅ j1 ) − n2 B ( p⋅ j 2 , q⋅ j 2 ) + ( p⋅ j1 − 1)∑ zij1⋅ j1

p −1

(4.13)

i =1

n1

+ (q⋅ j1 − 1)∑ (1 − zij1 )
i =1

q⋅ j 1 −1

n2

n2

+ ( p⋅ j 2 − 1)∑ zij 2⋅ j 2 + (q⋅ j 2 − 1)∑ (1 − z ij 2 )
i =1

p

−1

i =1

q⋅ j 2 −1
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Consequently, the likelihood ratio test statistic for the jth CpG site , Λ ⋅ j⋅ is
Λ ⋅ j⋅ = −2(log L0 ( pˆ ⋅ j⋅ , qˆ⋅ j⋅ ) − log L1 ( pˆ ⋅ j1 , qˆ⋅ j1 , pˆ ⋅ j 2 , qˆ⋅ j 2 ))

[

]

= 2((n1 + n2 ) log B ( pˆ ⋅ j⋅ , qˆ⋅ j⋅ ) − n1 B ( pˆ ⋅ j1 , qˆ⋅ j1 ) − n2 B ( pˆ ⋅ j 2 , qˆ⋅ j 2 )
− ( pˆ ⋅ j⋅ − 1)∑ log z ij + (qˆ⋅ j⋅ − 1)∑ log(1 − zij ) − ( pˆ ⋅ j⋅ − 1)∑ log zij
n

n

n

i =1

i =1

i =1

(4.14)

− (qˆ⋅ j⋅ − 1)∑ log(1 − zij ) − ( pˆ ⋅ j1 − 1)∑ log zij1 + (qˆ⋅ j1 − 1)∑ log(1 − zij1 )
n

i =1

n1

n1

i =1

i =1

+ ( pˆ ⋅ j 2 − 1)∑ log zij 2 + (qˆ⋅ j 2 − 1)∑ log(1 − z ij 2 )
n2

n2

i =1

i =1

where p̂⋅ j⋅ and q̂⋅ j⋅ are the maximum likelihood estimates computed under the null
hypothesis and pˆ ⋅ j1 , qˆ⋅ j1 , pˆ ⋅ j 2 , and qˆ⋅ j 2 are those computed under the alternative hypothesis.
Hence, the likelihood ratio test can be written under
is the

as: Reject

if Λ ⋅ j⋅ > C where C

percentile point of a Chi Square distribution with k degrees of

freedom and the p-value is computed as p j = 1 − Fν (Λ ⋅ j⋅ ) . Here, ν is the difference in the
number of parameters between the logarithms of the likelihood under the alternative and
null hypotheses (ν =4-2=2), and Fν is the cumulative distribution function of the
χ2 distribution. For the purposes of this analysis, tests were conducted at an
significance level.
It should be noted that in the computation of the test statistic of the likelihood ratio
test, an iterative algorithm was employed to compute the maximum likelihood estimates.
A closed form expression for the computation of the maximum likelihood estimated under
a beta distribution does not exist, so the Nelder Mead simplex was used.
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4.3(c) Nelder Mead Simplex

The Nelder Mead algorithm is a direct search method which operates on the
assumption of a simplex. More specifically, where n parameters are to be estimated, a
simplex

in ℜ n is formed by the convex hull of the n+1 vertices x0 ,..., xn ∈ ℜ n . The

corresponding objective function, f (x) is then evaluated at the vertices of the simplex,
f ( x j ), for j = 0,1,..., n, and it moves in the direction of improved response. At each step,
the transformation of the simplex is determined by computing the vertices, together with
their function values, and by comparison of these function values with those at the vertices
of the existing simplex. This process is terminated when the working simplex

becomes

sufficiently small as judged by pre-determined threshold value.
Now, for a random variable y such that a ≤ y ≤ b , the family of beta distributions
includes all probability density functions of the form
p( y) =

1
( y − a ) p −1 (b − y ) q −1
B ( p, q )
(b − a ) p + q −1

(Eq. 4.15)

where p>0 and q>0. Johnson & Kotz (1970) describe method of moments estimators for
the four parameters in Equation 4.15. Additionally, they describe an iterative method for
approximating maximum likelihood estimates of p and q when a and b are known.
Krishnamoorthy (2006) suggested that the moment estimates be used as initial values in
the iterative procedure for obtaining maximum likelihood estimates. Additionally, if one of
the values (p or q) are known, the equations simplify (Johnson & Kotz, 1970). For
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example, if q is known to be 1, the distribution actually becomes the standard power
function. Because when performing hundreds of hypothesis tests for a high-throughput
methylation dataset, it would not be practical to know a or b or make assumptions about
either p or q, when maximizing the likelihood we used the standard form of the probability
density function,
p( x) =

1
x p −1 (1 − x) q −1
B ( p, q )

(Eq. 4.16)

in which x = ( y − a ) (b − a ) which allowed us to solve for p and q. In this manner, the
maximum likelihood estimates for the above described likelihood ratio test were
determined, where the objective function was the maximum likelihood equation of the
standard form of the probability density function.
Since the methodology which underlies both our Beta test and our proposed
likelihood ratio based test has been fully developed, a third alternative analysis method is
described.

4.4 Testing for Differentially Methylated CpG sites: Bivariate Normal Distribution
Motivated Test

As another exploratory measure, it was hypothesized that each the Red and Green
channels were distributed Normal. This hypothesis, similar to the previous hypothesis of
the Gamma distribution, is a common assumption made for log2 transformed channel data
(Brody et al., 2002). One could argue that in principle, the normal distribution is not an
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appropriate fit for the Red and Green Channel intensities, values that were constrained on

[0, ∞ ) by nature.

However, given that the channel intensities were centered about a value

that was much greater than zero and that by artifact of the background phenomenon, the
intensities are clustered such that they never truly get to zero, it was considered appropriate
to continue with this line of study. Again, to see if evidence exists to refute this
hypothesis, Kolmogorov Smirnov tests were performed for the Red and the scaled Green
channel signal intensities at each CpG site in the HCV data set. Thus the null hypothesis
H 0 : [F (t ) = H (t ), for every t ] was tested where F(t) is the empirical distribution function
for each the Red and Green channels , calculated using the aforementioned scaled data, and
where R⋅ j ~ N ( µ R⋅ j , σ R2⋅ j ) and G⋅ j ~ N ( µG⋅ j , σ G2⋅ j ) under the null hypothesis. H(t) is the
empirical distribution function for the Normal distribution function. The sample mean and
sample variance for each CpG site were used to estimate the parameters for the empirical
distribution function of the N ( µ j , σ 2j ) distribution as a function of the data. Here, we
failed to reject the null hypothesis in 1,421 (92%) CpG sites in the red channel and 1,527
(99%) CpG sites in the green channel out of a total 1,547 CpG sites per channel.
Therefore, it was concluded that we did not have evidence to refute our assumption of
Normality. It was furthermore known that the correlation between the Red and Green
channels was approximately -0.62, so it was concluded that the Red and Green channels
were distributed Bivariate Normal(µ R , µ G , σ R2 , σ G2 , ρ ) .
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Again for testing purposes, the ratio β = R ( R + G ) was of particular interest.
Given that Red and Green Channels were distributed Bivariate Normal(µ R , µG , σ R2 , σ G2 , ρ ) ,
it follows then that the ratio β = R ( R + G ) has a complex distributional form.
For this reason, bootstrap methods underlay the hypothesis testing designed to
compare the ratios for each CpG site between the two groups. The bootstrap method is
especially useful because it enables one to design a hypothesis test on a set of values by
estimating all pertinent values from an approximate distribution, namely the empirical
distribution of the observed data. This proves valuable in situations such as the one
present, where the underlying distribution made the formulation of a hypothesis test
difficult.
The test formulation was as follows: first a test statistic was computed as a function
of the observed data. Here, the mean was used as the location parameter, and the statistic
used for testing was the difference in the mean β ratio between the two groups, i.e.,



 Rij 2 
 − mean
.

 R +G 
R
+
G
ij 1 
ij 2 
 ij 1
 ij 2

θˆ⋅*j⋅ = mean

Rij 1

(4.15)

This test statistic was computed for each CpG site, letting the n1 samples originating from
patients presenting cirrhosis without HCC be called Group 1 and letting the remaining n2
samples originating from patients presenting cirrhosis with HCC be called Group 2. Next
let the empirical distribution function of Group 1 be denoted F and of Group 2, G. Under
the null hypothesis, any of the n1 + n2 observations could have come from either F or G, i.e.
which implies that

. This hypothesis was tested by
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computing the empirical distribution function of the test statistic by combining the n1
observations from F and the n2 observations from G to form a single set of values of
size n1 + n2 . A sample of size n1 was drawn with replacement from the combined set of

n1 + n2 values to represent the observations from F, and the latter n2 observations
represent those from F. The statistic θˆ * was computed using these artificially created
samples. For each CpG site, this process of sampling and computing the test statistic was
repeated 2,500 times, thereby creating an empirical distribution function of the bootstrap
test statistic. A two-sided 100(1-α)% level bootstrap hypothesis test was constructed for
each CpG site by comparing θˆ.∗j to the 100(α / 2)% upper and the 100(1 - α / 2)% lower
percentiles, θ.Bj computed from the empirical distribution of the observed data. The pvalue was calculated,

{

p j = # θ ⋅Bj > θˆ⋅*j or θ ⋅Bj < − θˆ⋅*j

}.

(4.16)

This chapter has described methodology for three proposed alternatives to the
widely employed Two Sample t-test and the Filtered Two Sample t-test. These three
alternatives were in the form of a test based on a Beta distributed random variable, a
Likelihood ratio based test, and a Bootstrap-based test. In the next chapter, the properties
of all five tests will be compared and contrasted using an extensive simulation study.

CHAPTER 5 Simulation Study

In this chapter we describe a comparison of the three proposed inferential methods
with the commonly used Two-Sample t-test and the Filtered Two Sample t-test performed
using simulated data. Specifically, for each simulation scenario we examined either the
Type I or Type II error rates. A simulated data set was imperative so that knowledge as to
a certain CpG site’s true methylation status (differentially methylated between two groups,
yes or no) was certain. We chose to design our simulation study to preserve as many of the
characteristics inherent to our application dataset as possible. For this reason, data were
generated in two manners, the first of which generated proportion methylated data
according to a Beta distribution, and the second of which generated Red and Green channel
data according to a Bivariate Normal distribution with correlation coefficient equal to -0.6
upon which β proportion methylated data were computed. The Type I and Type II error
rates were calculated and compared for each inferential method under both simulation
scenarios. Under each the Beta distribution and the Bivariate Normal distribution scenario,
data were generated for 3,152 CpG sites where there were 20 samples in Group 1 and 16
samples in Group 2. This sample size was chosen through an analysis in nQuery. All
significance tests were conducted at the α = 0.05 significance level; therefore, because we
wished to estimate a Type I error rate which we expected to be 0.05 and accurate to the
hundredths decimal (+/- 0.01), the number of samples needed for a two-sided 99.0%
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confidence interval for a single proportion using the large sample normal approximation
extending 0.01 from the observed proportion for an expected proportion of 0.05 is 3,152.
For a more complete analysis, the number of samples per group was varied to
further explore the behavior of the Type I and Type II error rates due to sample size.
Methodology for testing the Type I and Type II error rates follows.

5.1 Testing Type I error rates

Type I error is the error of rejecting a null hypothesis when it indeed is true.
Comparing the Type 1 error rates of the two proposed tests along with the Two Sample ttests involved calculating the number of times a certain test found a particular CpG site
differentially methylated between two classes of outcomes when the truth was that the
CpG site, in fact, was not differentially methylated. Therefore, it was of interest to
generate a data set for two groups having no difference in proportion methylated. For a
given inferential method, the Type I error was then calculated as the proportion of CpG
sites declared significantly differentially methylated between two treatment groups.
In an effort to ensure the generation of realistic data, values from the test data were
used as a starting point. The CpG site with Illumina code 3923 was used to model nonsignificantly differentially methylated data. Note that while the Two Sample t-test found
CpG site 3923 non-significantly differentiated (p-value= 0.763), any difference in beta
values between the two outcome groups present at this CpG site would become null by
means of the data simulation method now explained.
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5.1(a) Type 1 error data simulation methods and results: Beta distribution

To study the Type I error rate, beta distributed data were generated using the same
shape and scale, p and q, parameters for both outcome groups. Thus, using all proportion
methylated observations across the two outcome groups of the CpG site with Illumina code
3923, the sample mean and variance were calculated. These moments were then used to
compute the method of moments estimators for p and q as outlined in Equations 4.6 and
4.7. Using these estimators, p̂ and q̂ , beta distributed data were generated for 3,152 CpG
sites for both a Group 1 random beta variable X ~ Beta ( pˆ , qˆ ) containing 20 observations
and a Group 2 random variable Y ~ Beta( pˆ , qˆ ) containing 16. In this manner, it was
ensured that no true statistically significant difference existed for each CpG site between
the two groups of generated data.
The simulated data set was analyzed under the assumptions of each of the five
testing measures. For the beta test, as outlined in Chapter 4, and the Type I error rate was
calculated as

{

}

# CpG sites where x j − y j > Q0.975,⋅ j⋅ / 3,152 ,

(5.1)

and under the remaining tests, the Type I error rate was calculated as

# {CpG sites whose p value < 0.05}/ 3,152 .

(5.2)

Results are presented in Table 5.1.
Note that data generated according to the beta distribution are single valued on the range

(0,1) . Because the bootstrap test relies on sampling data from the individual Red and Green
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channels, it cannot be performed on data that have been generated according to a beta
distribution, and hence results of the Type I error behavior of the Bootstrap test under the
assumption of Beta distributed data is not available.
Type I Error Rate
Two Sample
t-test
Number of
Two
Likelihood
p
value
<0.05
Samples
Sample
Beta test
ratio test
and
per Group
t-test
|∆β | > 0.17
20,16
0.048
0
0.0416
0.048
Table 5.1 Type I Error rate comparison where data has been computed
under the assumption of a Beta distribution.

Since testing was conducted at the

significance level, a Type I error rate

close to 0.05 was considered most desirable. Using this criterion, it was evident that the
Two Sample t-test, the Beta distribution test and the Likelihood Ratio test each performed
well. Meanwhile, the Type I error rate of the filtered Two Sample t-test was too low.
To gain a better understanding of the behavior of the Type I error under the four
available testing conditions, data were again generated in the aforementioned manner while
varying the number of samples per group. Results are presented below in Table 5.2:
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Type I Error Rate
Two Sample
Number of
Two
T test
Likelihood
Samples
Sample
Beta test
p-value <0.05
ratio test
per Group
t-test
and |∆β | > 0.17
20,16
0.048
0
0.0416
0.048
40,40
0.055
0
0.0495
0.063
80,80
0.054
0
0.0425
0.059
45,50
0.057
0
0.0498
0.056
15,15
0.046
0
0.0374
0.043
Table 5.2 Type I Error rate comparison across varying sample sizes where data
have been computed under the assumption of a Beta distribution.

Across a wide range of sample sizes, the Two Sample t-test, the Beta distribution
test, and the Likelihood ratio based test perform very well and very comparably. Note that
the filtered Two Sample t-test does not accurately quantify the Type I error rate. As
expected, the Type I Error Rate was furthest from the nominal 0.05 level for all tests when
the sample sizes were reduced to 15 and 15 in each group.

5.1(b) Type 1 error data simulation methods and results: Bivariate Normal distribution

As an alternative to the assumption that the proportion methylated variable follows
a Beta distribution, it was discussed in Chapter 4.4 that there is evidence to support a claim
that the Red and Green channels follow a Bivariate Normal distribution. Thus, a thorough
examination of the Type I error rate behavior for these five statistical measures involves a
comparison of the error rates when each test has been performed using data simulated
under the assumption of Bivariate Normality. Once again, the CpG site in our test data set
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with Illumina code 3923 was used to model the data. For this CpG site, the means and
variances of each the red and green channels were calculated across all samples, regardless
of classification group. This resulted in one mean and standard deviation for the red
channel data and one mean and standard deviation for the green channel data.
Furthermore, as previously stated, the chip-wide mean correlation between the Red and
Green channels was approximately -0.6, so this value, together with the computed mean
and variance parameters from CpG site 3923 were used as the parameters of the bivariate
normal distribution that generated our test set data. Upon the generation of the 36 samples
for each of the 3,152 CpG sites, any negative values were changed to zero to better
simulate the beta variable data. Kolmogorov Smirnov tests were performed to ensure that
evidence did not exist to claim that the resulting data did not preserve the Bivariate Normal
distribution, and in all cases, this proved true.
Type I error rates were computed and are presented in Table 5.3.

Number of
Samples
per Group

Two
Sample
t-test

20,16

0.044

Type I Error Rate
Two Sample ttest p value
Likelihood
Beta test
ratio test
<0.05 and |∆β |
> 0.17

0

0.0416

0.048

Bootstrap
test

0.048

Table 5.3 Type I Error rate comparison where data has been computed under the
assumption of a Bivariate Normal distribution.

Once again, the Two Sample t-test, the Beta test and the Likelihood ratio test all
three perform reasonably well under the assumption that the data are distributed Bivariate
Normal. Furthermore, neither the Filtered Two Sample t-test nor the Bootstrap test
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accurately quantify the Type I error here. With the exception of the Likelihood ratio based
test, this is a trend that continues as sample size is varied, as illustrated in Table 5.4 below.
The Likelihood ratio based test, rather, has an inflated estimate of the Type I error rate as
sample size increases, demonstrating that similar to the Filtered Two Sample t-test, it is not
an appropriate decision measure.
It is interesting to note that regardless of whether the data are assumed to follow a
Beta distribution or a Bivariate Normal Distribution, the Type I error behavior of each the
Two-Sample t-test and the Beta test is both quite comparable and accurate.
Type I Error Rate
Two Sample
Number of
Two
t-test
Likelihood Bootstrap
Beta test
Samples
Sample
p value <0.05
ratio test
test
per Group
t-test
and |∆β | > 0.17
20,16
0.044
0
0.0416
0.048
0.048
40,40
0.042
0
0.0495
0.075
0.042
80,80
0.059
0
0.0425
0.076
0.058
45,50
0.047
0
0.0498
0.070
0.045
15,15
0.040
0
0.0374
0.040
0.043
Table 5.4 Type I Error rate comparison across varying sample sizes where data has
been computed under the assumption of a Bivariate Normal distribution.

5.2 Testing Type II Error Rates

In addition to comparing the Type I error rates, a complete analysis of the five
proposed tests also involved the comparison of their Type II error rates. Type II error is
the error of failing to reject a null hypothesis when it is not true. The computation of the
Type II error resulted from calculating the number of times a certain test found no
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difference in the methylation status of particular CpG site between two classes of outcomes
when the truth was that the sites were indeed differentially methylated. Therefore, it was
of interest to generate a data set that for two outcome groups, a difference in methylation
status existed for every CpG site. The Type II error was then calculated as the proportion
of CpG sites that a certain test found non-significantly differentially methylated between
two treatment groups. All significance tests were performed at the

significance

level.
Again, to ensure the generation of realistic data, values from the test data were used
as a starting point. In Bibikova, et al. (2006b), it was estimated that the Illumina
technology can discriminate levels of methylation ( -values) that differ by 0.17 or more.
So to generate data, the means and variances of a CpG site that demonstrated significant
differential methylation were used as a starting point for generating data. Because we were
searching for a site with measurable methylation levels, a certain CpG site was considered
differentially methylated if the mean proportion methylated in each of the treatment groups
was at 0.2 or greater and if the difference in the mean proportion methylated between the
two groups was 0.17 or more. When tested by the currently accepted method of the twosample t-test, the CpG site with Illumina code 4092 had a difference in beta values
between the two groups of 0.172 with a corresponding p-value of 0.005. Furthermore, this
site demonstrated a mean methylation of 0.46 and 0.29 in the first and second outcome
groups, respectively. Thus, this site was considered differentially methylated and was used
initially to model data for simulations exploring the behavior of the Type II error. Again,
the Type II error behavior of each test was explored under the assumption that data were
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distributed according to each the Beta distribution and the Bivariate Normal distribution.
Data generation and results under these two scenarios are as follows.

5.2(a) Type II error data simulation methods and results: Beta distribution

To study the Type II error rate, data from the two outcome groups were generated
using different beta distributions. To generate data from differing beta distributions, the
method of moments estimators were calculated for each of the treatment groups of CpG
site 4092 resulting in p̂1 and q̂1 for the first treatment group and p̂ 2 and q̂ 2 for the second
treatment group. These estimators were used to generate two random beta variables,

Α ~ Beta( pˆ 1 , qˆ1 ) and Β ~ Beta( pˆ 2 , qˆ2 ) each of length 1,000. One thousand was chosen
here as a large number to give stable estimates. The standardized quantile, Q0.975 was
computed according to Equation 4.10 as a function of this combined generated data. Next,
two new beta random variables, X ~ Beta( pˆ 1 , qˆ1 ) and Y ~ Beta( pˆ 2 , qˆ 2 ) were generated of
length 20 and 16, respectively, for the 3,152 CpG sites to achieve the desired accuracy. In
this manner, it was ensured that a difference in the mean proportion methylated between X
and Y for the jth CpG site was equal to approximately 0.17, as presented in the test data
CpG site 4092.
The simulated data set was analyzed under the assumptions of each of the five
testing measures. For the beta test, as outlined in Chapter 3, and the Type II error rate was
calculated as
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Type II Error = 1 − power

{

}

= 1− # CpGsites where x j − y j > C0.975, j / 3,152,

(5.3)

and under the remaining tests, the Type II error rate was calculated as

# {CpG sites whose p value > 0.05}/ 3,152 .

(5.4)

Results are presented in Table 5.5.
Note again that data generated according to the beta distribution are single valued
on the range (0,1) . Because the bootstrap test relies on sampling data from the individual
Red and Green channels, it cannot be performed on data that have been generated
according to a beta distribution, and hence results of the Type II error behavior of the
Bootstrap test under the assumption of Beta distributed data is not available.
Furthermore, it is important to note that the Type II error rates for the Filtered Two
Sample t-test are not included in subsequent Type II error rate tables (Tables 5.5-5.12). In
the identification of a uniformly most powerful test, power should be compared among
tests at a fixed alpha-level, and the Filtered Two Sample t-test cannot attain a Type I error
of 0.05 due to the imposed threshold. Because the (Unfiltered) Two Sample t-test, the
Beta test, the Likelihood ratio-based test, and the Bootstrap-based test (where applicable)
each demonstrated a roughly equivalent Type I error rate about α = 0.05 across various
sample sizes, the Type II error rates of these tests are reported in subsequent tables with the
Type II error rate of the Filtered Two Sample t-test following in the text for informational
purposes.
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Type II Error Rate
Test
Set
∆β

Observed
∆β

Illumina
Code

X

0.17

0.17

946

0.46

Y

Test Set
p-value (t
test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

0.29

0.005

0.177

0.181

0.055

Table 5.5 Type II Error rate comparison where data has been computed under the
assumption of a Beta distribution.
In Table 5.5, the Test Set ∆β column lists the difference in mean proportion
methylated between the two outcome groups for which we sought to generate data. The
Observed ∆β column lists the actual ∆β present in our generated data. Meanwhile, the
columns denoted Illumina Code, X , Y , and Test Set p-value (t-test) describe the reference
Illumina code of the CpG site used to generate our data, the mean proportion methylated
present in our test data for the first and second outcome groups, and the p-value of this
CpG site when a Two Sample t-test is performed to test for differential methylation,
respectively. The aforementioned columns are listed to demonstrate that our data were
successfully generated using a CpG site containing both positive methylation and
significantly differentiated methylation, according to the currently accepted testing
method. The following three columns show the Type II error rates of the three applicable
proposed tests under the assumption that the data were generated according to a Beta
distribution. When assessing Type II error, a smaller rate is better, where approximately
0.20 approaches the upper limit of a Type II error rate for a well-suited test. Here, we see
that each the Two Sample t-test, the Beta Test, and the Likelihood ratio based test each
perform well. The Type II error rate for the Filtered Two Sample t-test under the
assumption of a sample size of 20 in outcome group 1 and 16 in outcome group 2 is 0.491.
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Therefore, while we cannot directly compare this error rate to those of the other three
applicable tests under the assumption of Beta distributed data, we can conclude that the
Filtered Two Sample t-test is a highly conservative testing measure that in possessing a
small Type I error rate, likely trades for it a Type II error rate that is too high. This
translates to a loss in power. This is a trend that is more fully illustrated as we vary both
the level of differential methylation (Table 5.6) and the sample size (Tables 5.7-5.8)
Table 5.6 details how the Type II error rate changes with varying levels of ∆β .
We observe that a similar trend for the Type II error rate continues across ∆β . Namely,
the Two Sample t-test, the Beta test and the Likelihood ratio based test each perform well
concerning the preservation of an acceptable error rate. The Type II error rates of the
Filtered Two Sample t-test for differential methylation levels are as follows: Type II Error
rate( ∆ β = 0 . 20 )=0.345, Type II Error rate( ∆ β = 0 . 10 , CpG site 2358 )=1.0, Type II Error
rate( ∆ β = 0 . 10 , CpG site 2208 )=0.949, and Type II Error rate( ∆ β = 0 . 05 )=1.0. These rates
are clearly consistently high and even become severely inflated, as hypothesized, when the
observed ∆ β dips below the threshold.
An additional artifact of interest in Table 5.6 is the difference in Type II Error rates
observed for each the Two Sample t-test, the Beta test and the Likelihood ratio based test
between the two sites presenting a test set ∆β =0.10. Note that while each CpG site 2358
and 2208 were used to successfully generated data with ∆β =0.10, the Type II error for the
three aforementioned tests is much higher when CpG site 2208 had been used to generate
data, rather than when CpG site 2358. Two reasons have been identified to explain this
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phenomenon. First, we noted that according to the currently accepted testing method, the
Two Sample t-test, site 2358 has a much smaller p-value than site 2208. Second, it can be
computed that the variances of the two outcome groups present in site 2358 is much
smaller than the variances present in the two outcome groups present in site 2208. This is
verified by noting that as estimated by the method of moments parameters for the Beta
distribution in Equations 4.6 and 4.7. pˆ 1 = 1.89, qˆ1 = 2.24, pˆ 2 = 4.09, and qˆ 2 = 10.22 . So,
when computing the variances of each outcome group for these two Beta-distributed sites
according to the equation,
var( z ) =

pq
,
( p + q ) ( p + q + 1)
2

(5.5)

it was determined that for site 2358, vâr( z1 ) = 0.003 and vâr( z 2 ) = 0.005 , while for site
2208, vâr( z1 ) = 0.024 and vâr( z 2 ) = 0.014. Thus, due to these two reasons, we can
conclude that while sites 2358 and 2208 both generated data to test for a ∆β =0.10, the
data of CpG site 2358 both demonstrated a more significant difference between the two
treatment groups and possessed less variation in the data, resulting in more precisely
significantly differentiated generated data on which to conduct hypothesis testing.
Therefore, it is understood that CpG site 2358 generates data that produces a more
acceptable Type II Error rate than CpG site 2208.
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Type II Error Rate

Y

Test Set
p-value
(t test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

0.46

0.29

0.005

0.177

0.181

0.055

4297

0.52

0.32

0.008

0.239

0.200

0.043

0.10

2358

0.47

0.38

<0.001

0.007

0.003

0.004

0.10

0.10

2208

0.47

0.37

0.039

0.454

0.447

0.455

-0.05

-0.05

4038

0.76

0.81

0.009

0.231

0.148

0.219

Test
Set
∆β

Observed
∆β

Illumina
Code

X

0.17

0.17

4092

0.20

0.20

0.10

Table 5.6 Type II Error rate comparison across varying levels of differential proportion
methylated where data has been generated with 20 samples in outcome group 1 and 16
samples in outcome group 2 according to a Beta distribution.
The next step in the analysis was to explore the behavior of the Type II error rate across
varying levels of differential proportion methylated for each 40 samples in outcome groups
1 and 2 and 80 samples in outcome groups 1 and 2. Results are presented in Tables 5.7
and 5.8, respectively.
Type II Error Rate
Test
Set
∆β

Observed
∆β

Illumina
Code

X

0.17
0.20
0.10
0.10
-0.05

0.17
0.20
0.10
0.10
-0.05

4092
4297
2358
2208
4038

0.46
0.52
0.47
0.47
0.76

Y

Test Set
p-value (t
test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

0.29
0.32
0.38
0.37
0.81

0.005
0.008
<0.001
0.039
0.009

0.009
0.011
<0.001
0.121
0.019

0.012
0.008
<0.001
0.120
0.009

<0.001
<0.001
<0.001
0.104
0.019

Table 5.7 Type II Error rate comparison across varying levels of differential proportion
methylated where data has been generated with 40 samples each in outcome groups 1 and
2 according to a Beta distribution.
When data have been generated according to the Beta distribution with 40 samples
in each of the treatment groups, the same trends seen previously with smaller sample sizes
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continued and became even more defined. We see that as sample size increased, the Type
II error rates of each the Two Sample t-test, the Beta distribution test, and the Likelihood
ratio based test decreased, as to be expected. We also note that the increased sample size
helped to overcome the increased error rate for the more marginally significant and highly
dispersed data generated by CpG site 2208 among the three currently well-performing
tests. The Type II error rates under the assumption of 40 samples in each outcome group
are as follows: Type II Error rate( ∆ β = 0 . 17 )=0.494,Type II Error rate( ∆ β = 0 . 20 )=0.264,
Type II Error rate( ∆ β = 0 . 10 , CpG site 2358 )=1.0, Type II Error rate
( ∆ β = 0 . 10 , CpG site 2208 )=0.991, and Type II Error rate( ∆ β = 0 . 05 )=1.0. Because of the
unbending threshold imposed upon the Filtered Two Sample t-test, the Type II error rate of
this test still remained severely inflated for levels of ∆β at or below 0.17. As seen below,
these trends become further defined as sample size increases to 80 samples in each
outcome group. Therefore, when solely observing the Type II error rate across both
varying levels of differential methylation and sample size, the Two Sample t-test, the Beta
distribution test, and the Likelihood ratio based test each perform well.
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Type II Error Rate
Test
Set
∆β

Observed
∆β

Illumina
Code

X

0.17
0.20
0.10
0.10
-0.05

0.17
0.20
0.10
0.10
-0.05

4092
4297
2358
2208
4038

0.46
0.52
0.47
0.47
0.76

Y

Test Set
p-value (t
test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

0.29
0.32
0.38
0.37
0.81

0.005
0.008
<0.001
0.039
0.009

<0.001
<0.001
<0.001
0.006
<0.001

0.012
0.008
<0.001
0.120
0.009

<0.001
<0.001
<0.001
0.003
<0.001

Table 5.8 Type II Error rate comparison across varying levels of differential proportion
methylated where data has been generated with 80 samples each in outcome groups 1 and
2 according to a Beta distribution.
We now turn to examine the behavior of the Type II error under both varying levels
of differential methylation and sample size for the proposed tests where data have been
generated according to the Bivariate Normal distribution.

5.2(b) Type II error data simulation methods and results: Bivariate Normal distribution

As in the examination of Type I error, the Type II error behavior of the five
proposed tests was explored under the assumption that it was generated both under a Beta
distribution and a Bivariate Normal distribution. Data generation under the Bivariate
Normal distribution was as follows. Again, initially using test data CpG site 4092 to
model realistic data with an approximate mean proportion methylated difference of 0.17
between the two outcome groups, the mean and variance of each the Red and Green
channels for the Group 1 were found. Together with a correlation coefficient of

,

these values were used to generate bivariate normal random variables that became the Red
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and Green channels for the first group of the simulated data. This process was repeated by
calculating the mean and variance of each the Red and Green channels for Group 2 in
selected the CpG site of the test data set. The generated bivariate normal random variables
using these values became the Red and Green channels for the second group of the
simulated data. Like when testing the Type I error rate, the generated data set was filtered
so that any negative values were changed to zero, per the formula for the calculation of

β , (β = max(R,0) (max( R,0) + max(G,0)) ) . This process was performed 3,152 times,
meaning that all CpG sites were generated to be differentially methylated between the two
groups. Then, with this fully prepared data set, the significance testing again commenced.
Results of this analysis are presented below.

Type II Error Rate
Test
Set
∆β

Obs.
∆β

Illum.
Code

X

0.17

0.15

946

0.46

Y

Test Set
p-value
(t test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

Bootstrap
Test

0.29

0.005

0.192

0.251

0.135

0.213

Table 5.9 Type II Error Rate comparison at minimum methylation discrimination level
where data has been generated according to the Bivariate Normal distribution with 20
samples in outcome group 1 and 16 samples in outcome group 2.
To reiterate, in Table 5.9, the Test Set ∆β column lists the difference in mean
proportion methylated between the two outcome groups for which we sought to generate
data.

The Observed ∆β column lists the actual ∆β present in our generated data.

Meanwhile, the columns denoted Illumina Code, X , Y , and Test Set p-value (t-test)
describe the reference Illumina code of the CpG site used to generate our data, the mean
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proportion methylated present in our test data for the first and second outcome groups, and
the p-value of this CpG site when a two sample t-test is performed to test for differential
methylation, respectively. The following four columns illustrate the Type II error rate for
the four proposed tests when data have been generated under the assumptions of the given
CpG site. Because data generated under the Bivariate Normal distribution in a sense
creates two channel data, the Type II error of the Bootstrap test can now be assessed, as it
relies on this information.
Table 5.9 already demonstrates similar results to those seen when data were
generated according to the Beta distribution--each test preserved appropriate Type II error
rates. The Type II error rate of the Filtered Two Sample t-test when testing a differential
methylation of 0.17 is 0.616.
The effect of the magnitude of the difference in methylation levels on Type II error
rate was next explored. The process of generating data and running the five tests was
repeated where different significantly differentiated CpG sites from the test data were
chosen to generate the data. These CpG sites from the test data were chosen to achieve
varying levels in the
achieve a

variable, as the CpG site with Illumina code 4092 was chosen to
. Results are presented in Table 5.10 below.
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Type II Error Rate
Test
Set
∆β

Obs.
∆β

Illum.
Code

X

Y

Test Set
p-value
(t test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

Bootstrap
Test

0.17
0.20
0.10
0.10
-0.05

0.15
0.17
0.09
0.08
-0.04

4092
4297
2358
2208
4038

0.46
0.52
0.47
0.47
0.76

0.29
0.32
0.38
0.37
0.81

0.005
0.008
<0.001
0.039
0.009

0.192
0.176
0.250
0.539
0.701

0.251
0.208
0.229
0.576
0.601

0.135
0.171
0.266
0.441
0.646

0.213
0.156
0.228
0.563
0.690

Table 5.10 Type II Error rate comparison across varying levels of differential proportion
methylated where data has been generated with 20 samples in outcome group 1 and 16
samples in outcome group 2 according to a Bivariate Normal distribution.
Here, each of the four tests included in Table 5.10 perform relatively well in respect to the
Type II error rate across most varying levels of differential proportion methylated.
However, for small ∆β (i.e., ∆β =0.05), these tests all exhibit a high Type II error.
Alternatively, the Type II error rates of the Filtered Two Sample t-test are as follows: Type
II Error rate( ∆ β = 0 . 17 )=0.616,Type II Error rate( ∆ β = 0 . 20 )=0.642, Type II Error
rate( ∆ β = 0 . 10 , CpG site 2358 )=0.994, Type II Error rate( ∆ β = 0 . 10 , CpG site 2208 )=
0.986, and Type II Error rate( ∆ β = 0 . 05 )=1.0, which are, again, inflated, especially for
∆β < 0.17 , the imposed threshold level. Again, as observed in Chapter 5.2(a), the Type II
error rates of all tests inflates when the data used to generate the data are both more
marginally significant and more variable. This is seen when comparing the Type II error
rates for data generated using the more highly significant and less variable CpG site 2358
to the less significant and more variable CpG site 2208 which are both used to test for a
difference in proportion methylated of 0.10.
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The next step in the analysis was to explore the behavior of the Type II error rate
across varying levels of differential proportion methylated for each 40 samples in outcome
groups 1 and 2 and 80 samples in outcome groups 1 and 2. Results are presented in Tables
5.11 and 5.12, respectively.
Type II Error Rate
Test
Set
∆β

Obs.
∆β

Illum.
Code

X

0.17
0.20
0.10
0.10
-0.05

0.15
0.17
0.09
0.08
-0.04

4092
4297
2358
2208
4038

0.46
0.52
0.47
0.47
0.76

Y

Test Set
p-value
(t test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

Bootstrap
Test

0.29
0.32
0.38
0.37
0.81

0.005
0.008
<0.001
0.039
0.009

0.014
0.007
0.023
0.222
0.418

0.024
0.010
0.015
0.258
0.314

0.004
0.016
0.028
0.110
0.347

0.013
0.006
0.023
0.249
0.411

Table 5.11 Type II Error rate comparison across varying levels of differential proportion
methylated where data has been generated with 40 samples in each outcome group 1 and
group 2 according to a Bivariate Normal distribution.

Type II Error Rate
Test
Set
∆β

Obs.
∆β

Illum.
Code

X

0.17
0.20
0.10
0.10
-0.05

0.15
0.17
0.09
0.08
-0.04

4092
4297
2358
2208
4038

0.46
0.52
0.47
0.47
0.76

Y

Test Set
p-value
(t test)

Two
Sample
t-test

Beta
Test

Likelihood
ratio test

Bootstrap
Test

0.29
0.32
0.38
0.37
0.81

0.005
0.008
<0.001
0.039
0.009

<0.001
<0.001
<0.001

<0.001
<0.001
<0.001

<0.001
<0.001
<0.001

0.030
0.132

0.041
0.089

0.006
0.064

0.001
<0.001
<0.001
0.044
0.130

Table 5.12 Type II Error rate comparison across varying levels of differential proportion
methylated where data has been generated with 80 samples in each outcome group 1 and
group 2 according to a Bivariate Normal distribution.
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Tables 5.11 and 5.12 illustrate that as sample size increases, the Type II error rate
of each the Two Sample t-test, the Beta test, the Likelihood ratio based test, and the
Bootstrap based test decreases. Even for testing a very small absolute difference in
proportion methylated of 0.05 does the Type II error rate become acceptably small when
sample size increases to 80 samples per outcome group. In fact, when there are 40 samples
per outcome group, the Beta test, in particular, demonstrates a Type II error rate of 0.314,
which could be considered an acceptable error rate under certain testing scenarios. The
Type II error rates of the Filtered Two Sample t-test when there are 40 samples in each
outcome groups 1 and 2 are as follows: Type II Error rate( ∆ β = 0 . 17 )=0.671,Type II Error
rate( ∆ β = 0 . 20 )=0.725, Type II Error rate( ∆ β = 0 . 10 , CpG site 2358 )=1.0, Type II Error
rate( ∆ β = 0 . 10 , CpG site 2208 )=0.999, and Type II Error rate( ∆ β = 0 . 05 )=1.0.
Furthermore, the Type II error rates of the Filtered Two Sample t-test when there are 80
samples in each outcome groups 1 and 2 are as follows: Type II Error
rate( ∆ β = 0 . 17 )=0.746,Type II Error rate( ∆ β = 0 . 20 )=0.803, Type II Error
rate( ∆ β = 0 . 10 , CpG site 2358 )=1.0, Type II Error rate( ∆ β = 0 . 10 , CpG site 2208 )=1.0, and
Type II Error rate( ∆ β = 0 . 05 )=1.0.

5.3 Application of the Beta Test to Hepatitis C Virus data set

As demonstrated by both appropriate Type I and Type II error rates, the Beta test is
a well-suited statistical measure for detecting differential methylation between two
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outcome groups. As previously stated, methodologies for the development of alternative
testing procedures were motivated by a Hepatitis C Virus data set. (Archer et al., 2010)
The full dataset consists of methylation data from 1,547 CpG sites for analysis for each of
36 patients who present either HCV cirrhosis without concomitant Hepatocellular
Carcinoma (HCC) (N=16) or HCV cirrhosis with concomitant HCC (N=20). While results
have been published applying a Filtered Two Sample t-test to this data, a re-analysis was
conducted applying the Beta test here developed. At the α = 0.05 level, it was determined
that 277 CpG sites were significantly differentially methylated, as compared with the 205
sites differentially methylated using a standard Two Sample t-test. As to be expected,
there was much overlap between sites found significantly differentially methylated under
the two testing scenarios. A table of these 277 CpG sites found differentially methylated is
found in Appendix A.

5.4 Conclusions: Determination of a well-defined statistical testing measure

In choosing an appropriate statistical testing measure for a certain class of data, it is
important to weigh both the Type I and Type II error rates. Here, we sought an appropriate
testing measure for the identification of differential CpG site methylation between two
groups of samples—a typical testing scenario concerning data collected with the Illumina
GoldenGate technology. Currently, both the Two Sample t-test and, increasingly, the
Filtered Two Sample t-test are widely used to analyze differential methylation patterns in
this class of data. After concern that both the distributional assumption of normality
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underlying the Two Sample t-test might not be appropriate for testing on a proportion
methylated variable and that the Filtered Two Sample t-test could reduce power for sites
exhibiting truly differential methylation that was below the filter level, alternative testing
measures were explored. These three alternative testing measures took the form of a test
based on the Beta distribution and on two large sample tests, a likelihood ratio based test
and a bootstrap based test. It had been hypothesized that the proportion methylated
variable, β , upon which hypothesis testing was conducted, followed a Beta distribution,
and it had also been hypothesized that the Red and Green two channel data followed a
Bivariate Normal distribution. Therefore, data were generated under each of these
distributions, and the Type I and Type II error rates were computed for each test when
applied to these simulated data sets.
For data generated under each of the distributions, both the Two Sample t-test and
the Beta distribution test accurately quantify Type I error rates across small to large sample
sizes. The Boostrap based test also accurately quantified the Type I error rate under the
distribution assumption of Bivariate normality, but by nature of the test construction, the
Type I error rates could not be applied to the single valued data generated here under a
Beta distribution. Quite notably however, the Filtered Two Sample t-test demonstrates a
Type I error rate that is too low, and so it does not accurately quantify the Type I error rate.
Additionally, the Likelihood ratio based test exhibited a Type I error rate that was slightly
inflated under the assumption of Bivariate Normal data. Concerning the Type II error
rates, the Two Sample t-test, the Beta test and the Likelihood Ratio based test preserved an
appropriate error, especially for large sample sizes, under both distributional assumptions.
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The Bootstrap based test, performed well with respect to the Type II error rate, as well,
under the testable assumption of Bivariate Normality. Owing to both its differential Type I
error rate when compared to the four alternative testing measures and its inability for fixing
this error, the Filtered Two Sample t-test could not be directly compared. Nevertheless, it
was evident that the imposition of a filter likely decreases power for truly differential sites
that exhibit ∆β less than the filtering level.
Because the Two Sample t-test and the Beta test demonstrate both appropriate Type
I and Type II error rates, these two testing measures are decided to be the most preferable
tests for CpG site methylation data. While the Bootstrap based test demonstrated both
appropriate Type I and Type II error rates under the assumption of Bivariate Normal data,
the Two Sample t-test and the Beta test have the distinct advantage that they can be
performed on data presented as either two channel array data or computed proportion
methylated data. Because the Bootstrap based test relies on sampling data from each the
Red and Green channels, it cannot be applied to data that has already been summarized as
proportion methylated data, as is frequently the case.
Concerning the Two Sample t-test and the Beta test, it cannot be claimed whether
one of these two tests is superior to the other. Rather, the Type I and Type II error rates of
both of these tests under each distributional assumption are quite comparable. A clinician
might prefer to use the Two Sample t-test because it is a well known and straightforward
testing measure that is already in use. However, despite its accuracy, it can still be claimed
that the fundamental distributional assumption of data arising from the entire real number
line is violated. It is for this reason, on the other hand, that the statistician might prefer to
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use the Beta distribution test because it is more statistically rigorous in its distributional
assumptions.
Two final points merit noting. First, one should note how poorly the Filtered Two
Sample t-test performed. As hypothesized, the application of a filter severely reduces
power for CpG sites demonstrating smaller but truly differential levels of proportion
methylation. Therefore, the application of a Filtered Two Sample t test cannot be
recommended for the analysis of CpG site methylation data. Second, one should note that
especially for larger sample sizes, the Two Sample t-test and the Beta distribution test
perform well across levels of differential methylation—even those levels of methylation
less than 0.17. This gives evidence in support of a hypothesis that the Illumina technology
can, in fact, detect differential methylation at levels less than ∆β = 0.17 . How small of a
difference in methylation that the Illumina technology can detect was addressed in Chapter
4.

CHAPTER 6 Conclusions and Recommendations

Abnormal DNA methylation has emerged as an important area of study for
understanding many clinical pathologies. As with any developing clinical theories, sound
statistical methods must be devised to analyze the new types of emerging data to ensure
accurate conclusions. In this thesis, the methods for identifying a change in methylation
pattern were studied and modifications to these methods were proposed. Specifically, a
study of abnormal DNA methylation as it relates in the progression from HCV-cirrhosis to
HCC was employed as an impetus for our analysis. For this study, data were collected
according to the GoldenGate Methylation BeadArray Cancer Panel I platform developed
by Illumina for cancer-focused methylation analysis. This technology presents data in the
form of two channel array data containing expression values for the methylation target
sequence (Red) as well as expression values for the unmethylated target sequence (Green).
Data are summarized in the form of a proportion methylated variable for each CpG site,
and current analysis methods for the identification of differential methylation between two
outcome groups at each CpG site include the performance of either a Two-Sample t-test or
a Filtered Two-Sample t-test on the proportion methylated variable.
Each the Two Sample t-test and the Filtered Two Sample t-test elicit concerns over
their statistical assumptions and thus the validity of their conclusions. The Two Sample ttest assumes that the data upon which it is being performed arise from a distribution
90
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encompassing the entire real number line, which violates the fact that the proportion
methylated variable is, in fact, a proportion on the range of 0 to 1. The Filtered Two
Sample t-test imposes the additional constraint that a CpG site can be concluded
differentially methylated between two outcome groups if the difference in the proportion
methylated variables between the two groups is greater than some threshold. Any CpG
sites that are truly differentially methylated but possess a difference in methylation that is
less than the threshold would then present no statistical power. Therefore, the validity of
the Filtered Two Sample t-test rests upon the accuracy of the imposed threshold. It was in
response to these concerns that the aims of this thesis materialized. First, we sought
statistically to demonstrate any deficiencies in the two existing testing methods while
proposing appropriate alternative testing methods. Second, we sought to establish an
accurate minimum level of discernable differential methylation for the Illumina
technology, both for reference value and for statistical use if a filter was to be imposed
upon a statistical test, as is increasingly commonly seen in literature.
In accomplishing our first aim, we proposed a test based on a Beta distributed
random variable. Our motivation behind the Beta test was based on the assumption that
the Red and Green channels followed a Gamma distribution and hence the ratio would be
beta distributed. It is important to note that this distributional property supposes that the
two Gamma distributed random variables were independent of each other. As expected
from the lack of independence between the methylated and unmethylated states of a given
CpG site, this was not the case with the given data, but rather the mean correlation of the
Red and Green channels across all 36 chips was -0.62 (standard error = 0.03).
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Nevertheless, by means of a simulation study comparing the Type I and Type II error rates
of this proposed test to that of the Two Sample t-test, we concluded that both tests, in fact,
performed equally well. Alternatively, due to such differing Type I error rates, the Type II
error rates of the Filtered Two Sample t-test could not be directly compared to those of the
remaining tests. However, we gained evidence in support of our hypothesis that the
Filtered Two-Sample t-test is not a viable testing alternative in that it appears to inflate
Type I error while diminishing Type II error, especially for the CpG sites mentioned—
those with smaller but truly differential methylation that the filter allows. As a result of
these findings, it is recommended that either the Two Sample t-test or the test based on a
Beta distributed random variable be employed in future studies. In fact, both of these
testing measures perform as well as any appropriately designed statistical test, so it is not
recommended that any type of filter needs to be applied. As far as deciding between these
two tests which testing measure to use, it is assumed that a clinician might find the Two
Sample t-test preferable to use because of its simplicity and familiarity in implementation.
On the other hand, it could be claimed that a statistician would prefer the use of the test
based on a Beta distributed random variable, since it is statistically sound in its
assumptions. For, as well as the Two Sample t-test performs, it still can be argued that it
violates a basic distributional assumption of the proportion methylated variable.
Our findings into the poor performance of the Filtered t-test further supported the
second aim—to establish an accurate minimum level of discernable differential
methylation. Again, two alternative testing measures have been well established in the
Two Sample t-test and the test based on a Beta distributed random variable to accurately
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differentiate methylation patterns between two outcome groups, and so there is no need to
apply any type of filter when simply looking for differentially methylated CpG sites.
Nevertheless, if a minimum level of differentiation is to be employed, an accurate value
must be established. While a previous estimate of 0.17 had been established based on a
dilution study of female genomic DNA into male genomic DNA, a closer look into the
analysis of the study revealed that not all known characteristics of the data had been
properly accounted for, and so it was concluded that by re-analyzing the data, a more
appropriate minimum discernable level could be established. By means of a mixed effects
Logistic regression model, it was sought to model methylation levels as a function of the
dilution ratio of Female to Male DNA while accounting for random differences among
dilution order, technical replicate order, and CpG site. This nonlinear mixed effects model
accounted for the true shape of the relationship between the percent of Female genomic
DNA in a sample and the proportion of methylation while establishing the significance of
this relation. This analysis was followed by the formulation of a mixed ANOVA model,
accounting for the same variables and random differences, for the purpose of statistical
comparisons of adjacent mixing ratios. In so doing, it was determined that the Illumina
technology was able to differentiate between levels of methylation that differed by as little
as 0.086 (comparing 5% Female: 0% Male versus 0% Female: 100% Male). Clearly, the
Illumina technology can discern levels of methylation with more accuracy than anticipated,
and so the use of filters on the order of 0.17 or greater that are seen in literature are missing
much valuable information that is ready to be used.
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In conclusion, one seeking to identify CpG sites which are differentially methylated
between two outcome groups should employ either a Two Sample t-test or a test based on
a Beta distribution. Furthermore, it has been concluded that the Illumina technology can
differentiate methylation levels that differ at least as low as 0.086. Therefore, although it is
not recommended in a traditional testing scenario, if a filter is to be applied to the Two
Sample t-test procedure, it should be on the order of 0.086.
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APPENDIX A

Table of CpG sites found significant using test based on the Beta Distribution

H 0 : ∆β = β1 − β 2 = 0
1 = reject H 0 0 = fail to
reject H 0
Mean
Proportion
Methylated
for
Cirrhosis
Group, β1

Mean
Proportion
Methylated
for HCC
Group,

β2

∆β

Beta
Test

Two
Sample ttest

Filtered
Two
Sample ttest

Gene
Symbol

Illumina ID

AATK

AATK_P709_R_01

0.021

0.031

0.010

1

1

0

ABCB4

ABCB4_E429_F_01

0.904

0.881

-0.023

1

0

0

ABCB4

ABCB4_P51_F_01

0.587

0.670

0.083

1

1

0

ABL1

ABL1_P53_F_01

0.033

0.046

0.014

1

1

0

AFF3

AFF3_P808_F_01

0.156

0.236

0.079

1

1

0

AKT1

AKT1_P310_R_01

0.946

0.968

0.022

1

1

0

ALK

ALK_P28_F_01

0.826

0.776

-0.050

1

0

0

ALPL

ALPL_P278_F_01

0.377

0.500

0.123

1

0

0

APP

APP_E8_F_01

0.975

0.963

-0.013

1

0

0

ARAF

ARAF_E38_F_01

0.953

0.966

0.012

1

0

0

ARHGDIB

ARHGDIB_P148_R_01

0.994

0.982

-0.012

1

1

0

ASCL1

ASCL1_E24_F_01

0.999

0.995

-0.003

1

0

0

ATP10A

ATP10A_P147_F_01

0.486

0.599

0.113

1

1

0

AXL

AXL_E61_F_01

0.927

0.910

-0.017

1

1

0

BCAM

BCAM_E100_R_01

0.085

0.229

0.144

1

1

0

BCL2L2

BCL2L2_E172_F_01

0.939

0.915

-0.024

1

0

0

BCL2L2

BCL2L2_P280_F_01

0.054

0.046

-0.008

1

1

0

BCR

BCR_P422_F_01

1.000

0.998

-0.002

1

0

0

BMP3

BMP3_E147_F_01

0.009

0.020

0.011

1

1

0

BMP3

BMP3_P56_R_01

0.033

0.057

0.024

1

1

0

CAPG

CAPG_E228_F_01

0.344

0.287

-0.057

1

1

0
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Symbol

Illumina ID

CASP6

CASP6_P230_R_01

0.932

0.891

-0.042

1

1

0

CAV2

CAV2_E33_R_01

0.110

0.284

0.174

1

1

1

CCKAR

CCKAR_E79_F_01

0.041

0.092

0.050

1

1

0

CD81

CD81_P211_F_01

0.988

0.937

-0.051

1

0

0

CD9

CD9_E14_R_01

0.979

0.972

-0.007

1

0

0

CDH1

CDH1_P45_F_01

0.628

0.550

-0.077

1

1

0

CDH13

CDH13_E102_F_01

0.994

0.979

-0.015

1

0

0

CDH17

CDH17_P532_F_01

0.409

0.356

-0.053

1

1

0

CDKN1A

CDKN1A_E101_F_01

0.048

0.119

0.071

1

1

0

CDKN1B

CDKN1B_P1161_F_01

0.972

0.958

-0.014

1

0

0

CDKN2B

CDKN2B_E220_F_01

0.999

1.000

0.000

1

0

0

CEBPA

CEBPA_P706_F_01

0.019

0.030

0.011

1

1

0

CHD2

CHD2_P667_F_01

0.990

0.997

0.006

1

0

0

CLDN4

CLDN4_P1120_R_01

0.008

0.033

0.026

1

1

0

COL1A2

COL1A2_E299_F_01

0.935

0.899

-0.035

1

0

0

COL6A1

COL6A1_P425_F_01

0.973

0.979

0.007

1

0

0

COMT

COMT_E401_F_01

0.974

0.963

-0.011

1

0

0

CPNE1

CPNE1_P138_F_01

0.017

0.024

0.007

1

1

0

CREBBP

CREBBP_P712_R_01

0.714

0.756

0.041

1

1

0

CRIP1

CRIP1_P274_F_01

0.600

0.544

-0.056

1

1

0

CSF1

CSF1_P339_F_01

0.314

0.443

0.129

1

1

0

CSF1R

CSF1R_P73_F_01

0.165

0.277

0.111

1

1

0

CSF2

CSF2_E248_R_01

0.944

0.954

0.010

1

0

0

CSF2

CSF2_P605_F_01

0.987

0.981

-0.007

1

1

0

CSF3R

CSF3R_P8_F_01

0.938

0.924

-0.014

1

0

0

CSK

CSK_P740_R_01

0.046

0.083

0.036

1

1

0

CTAG2

CTAG2_P1426_F_01

0.882

0.860

-0.022

1

1

0

CTSH

CTSH_P238_F_01

0.003

0.009

0.006

1

1

0

DAB2

DAB2_P35_F_01

0.993

0.998

0.005

1

0

0
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DAB2IP

DAB2IP_E18_R_01

0.995

0.992

-0.003

1

0

0

DAPK1

DAPK1_P345_R_01

0.974

0.981

0.007

1

0

0

DBC1

DBC1_E204_F_01

0.997

0.992

-0.006

1

1

0

DCC

DCC_E53_R_01

0.751

0.720

-0.031

1

0

0

DCC

DCC_P471_R_01

0.965

0.949

-0.016

1

1

0

DKC1

DKC1_E101_F_01

0.975

0.958

-0.017

1

0

0

DLG3

DLG3_P62_R_01

0.798

0.737

-0.062

1

1

0

DNAJC15

DNAJC15_E26_R_01

0.006

0.014

0.008

1

1

0

DNASE1L1

DNASE1L1_P39_R_01

0.626

0.553

-0.073

1

1

0

DST

DST_E31_F_01

0.989

0.930

-0.060

1

0

0

DST

DST_P262_R_01

1.000

0.997

-0.003

1

1

0

EDNRB

EDNRB_P148_R_01

0.037

0.072

0.034

1

1

0

EFNA1

EFNA1_P591_R_01

0.840

0.874

0.034

1

1

0

EFNB1

EFNB1_E69_F_01

0.276

0.421

0.145

1

1

0

EFNB3

EFNB3_P442_R_01

1.000

1.000

0.000

1

0

0

EGF

EGF_P413_F_01

0.958

0.949

-0.009

1

0

0

ELK1

ELK1_E156_F_01

0.108

0.146

0.038

1

1

0

ELK3

ELK3_P514_F_01

0.955

0.937

-0.018

1

0

0

EMR3

EMR3_E61_F_01

0.073

0.120

0.047

1

1

0

ENC1

ENC1_P484_R_01

0.880

0.904

0.024

1

1

0

EPHA3

EPHA3_E156_R_01

0.897

0.810

-0.087

1

1

0

EPHA5

EPHA5_E158_R_01

0.821

0.780

-0.040

1

0

0

EPHA8

EPHA8_P256_F_01

0.371

0.468

0.097

1

1

0

EPHB4

EPHB4_P313_R_01

0.807

0.754

-0.053

1

1

0

EPHX1

EPHX1_P22_F_01

0.216

0.358

0.142

1

1

0

ESR1

ER_seq_a1_S60_F_01

0.959

0.923

-0.037

1

1

0

ERBB3

ERBB3_E331_F_01

0.982

0.971

-0.011

1

0

0

ERG

ERG_E28_F_01

0.999

0.998

-0.001

1

0

0

ERN1

ERN1_P809_R_01

0.689

0.625

-0.064

1

1

0
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Filtered
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Symbol

Illumina ID

F2R

F2R_P839_F_01

0.378

0.474

0.096

1

1

0

FABP3

FABP3_P598_F_01

0.680

0.751

0.072

1

1

0

FAT

FAT_P279_R_01

0.119

0.167

0.048

1

1

0

FES

FES_P223_R_01

0.961

0.934

-0.026

1

1

0

FGF2

FGF2_P229_F_01

0.079

0.118

0.039

1

1

0

FGF6

FGF6_E294_F_01

0.702

0.775

0.073

1

1

0

FGFR1

FGFR1_P204_F_01

0.873

0.844

-0.030

1

0

0

FGFR2

FGFR2_P266_R_01

0.290

0.533

0.243

1

1

1

FHIT

FHIT_P93_R_01

0.908

0.852

-0.056

1

1

0

FLI1

FLI1_P620_R_01

0.936

0.984

0.047

1

0

0

FMR1

FMR1_P484_R_01

0.178

0.208

0.030

1

1

0

FZD7

FZD7_E296_F_01

0.018

0.028

0.010

1

1

0

FZD9

FZD9_P15_R_01

1.000

0.999

-0.001

1

0

0

GABRA5

GABRA5_P862_R_01

0.841

0.800

-0.041

1

1

0

GABRG3

GABRG3_P75_F_01

0.137

0.100

-0.036

1

1

0

GAS1

GAS1_P754_R_01

0.042

0.078

0.036

1

1

0

GAS7

GAS7_P622_R_01

0.989

0.982

-0.007

1

0

0

GFI1

GFI1_P45_R_01

0.999

0.995

-0.003

1

1

0

GLI2

GLI2_E90_F_01

0.973

0.961

-0.012

1

0

0

GLI3

GLI3_P453_R_01

0.997

0.999

0.002

1

0

0

GNG7

GNG7_E310_R_01

0.967

0.946

-0.021

1

1

0

GPR116

GPR116_E328_R_01

0.178

0.137

-0.041

1

1

0

GSTM2

GSTM2_P453_R_01

0.092

0.123

0.031

1

1

0

GSTP1

GSTP1_P74_F_01

0.803

0.832

0.029

1

0

0

HBII-13

HBII-13_P991_R_01

0.010

0.025

0.015

1

1

0

HBII-52

HBII-52_P659_F_01

0.850

0.872

0.022

1

0

0

HCK

HCK_P46_R_01

0.637

0.572

-0.066

1

1

0

HDAC6

HDAC6_P153_F_01

0.289

0.247

-0.042

1

0

0

HDAC9

HDAC9_E38_F_01

0.995

0.984

-0.010

1

0

0
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HGF

HGF_E102_R_01

0.990

0.985

-0.006

1

0

0

HIC2

HIC2_P498_F_01

0.979

0.956

-0.024

1

1

0

HLA-DOB

HLA-DOB_E432_R_01

0.046

0.092

0.046

1

1

0

HOXA9

HOXA9_P1141_R_01

0.744

0.812

0.069

1

1

0

HOXB2

HOXB2_P488_R_01

0.094

0.128

0.034

1

1

0

HPN

HPN_P823_F_01

0.999

1.000

0.001

1

0

0

HPSE

HPSE_P93_F_01

0.999

0.995

-0.004

1

0

0

HTR1B

HTR1B_P222_F_01

0.876

0.849

-0.027

1

0

0

HTR2A

HTR2A_P853_F_01

0.110

0.148

0.038

1

1

0

IAPP

IAPP_E280_F_01

0.986

0.966

-0.019

1

1

0

ICAM1

ICAM1_P119_R_01

0.455

0.593

0.139

1

1

0

IFNG

IFNG_P459_R_01

0.973

0.988

0.015

1

0

0

IFNGR2

IFNGR2_E164_F_01

0.364

0.522

0.157

1

1

0

IGF1R

IGF1R_E186_R_01

0.589

0.509

-0.080

1

1

0

IGF2R

IGF2R_P396_R_01

0.391

0.485

0.094

1

1

0

IGFBP1

IGFBP1_E48_R_01

0.367

0.451

0.084

1

1

0

IGFBP6

IGFBP6_P328_R_01

0.052

0.085

0.033

1

1

0

IGSF4C

IGSF4C_P533_R_01

0.552

0.470

-0.082

1

1

0

IHH

IHH_P246_R_01

0.387

0.343

-0.044

1

1

0

IL13

IL13_E75_R_01

0.168

0.351

0.183

1

1

1

IL16

IL16_P226_F_01

0.252

0.335

0.083

1

1

0

IL18BP

IL18BP_E285_F_01

0.410

0.465

0.055

1

1

0

IL4

IL4_P262_R_01

0.945

0.958

0.013

1

1

0

IL6

IL6_E168_F_01

0.439

0.411

-0.027

1

1

0

IL6

IL6_P213_R_01

0.994

0.988

-0.006

1

0

0

IMPACT

IMPACT_P186_F_01

0.801

0.766

-0.035

1

1

0

IMPACT

IMPACT_P234_R_01

0.999

0.995

-0.004

1

0

0

IRAK1

IRAK1_P312_F_01

0.039

0.044

0.005

1

1

0

IRAK1

IRAK1_P455_R_01

0.105

0.080

-0.025

1

1

0

IRF5

IRF5_E101_F_01

0.940

0.956

0.015

1

1

0
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IRF7

IRF7_E236_R_01

0.680

0.729

0.049

1

1

0

ITGA6

ITGA6_P298_R_01

0.133

0.195

0.062

1

1

0

ITGB1

ITGB1_P451_F_01

0.819

0.784

-0.036

1

0

0

KCNK4

KCNK4_P171_R_01

0.999

0.998

-0.001

1

0

0

KCNQ1

KCNQ1_E349_R_01

1.000

0.999

-0.001

1

0

0

KRAS

KRAS_P651_F_01

0.128

0.169

0.041

1

1

0

LAMB1

LAMB1_E144_R_01

0.195

0.243

0.048

1

1

0

LAMC1

LAMC1_E466_R_01

0.286

0.406

0.119

1

1

0

LAMC1

LAMC1_P808_F_01

0.412

0.459

0.047

1

0

0

LCN2

LCN2_P86_R_01

0.952

0.937

-0.014

1

0

0

LEFTY2

LEFTY2_P561_F_01

0.093

0.130

0.038

1

1

0

LIG4

LIG4_P194_F_01

0.992

0.903

-0.088

1

0

0

LOX

LOX_P71_F_01

0.448

0.515

0.067

1

1

0

MAF

MAF_P826_R_01

0.062

0.141

0.078

1

1

0

MAP3K1

MAP3K1_E81_F_01

0.283

0.391

0.108

1

1

0

MAP3K1

MAP3K1_P7_F_01

0.004

0.011

0.007

1

1

0

MAP3K9

MAP3K9_E17_R_01

0.767

0.706

-0.061

1

0

0

MAPK12

MAPK12_P416_F_01

0.211

0.258

0.047

1

1

0

MAPK14

MAPK14_P327_R_01

0.998

0.997

-0.002

1

0

0

MAS1

MAS1_P469_R_01

0.989

0.981

-0.008

1

0

0

MAS1

MAS1_P657_R_01

0.966

0.953

-0.014

1

1

0

MCF2

MCF2_P445_F_01

0.954

0.942

-0.012

1

0

0

ABCB1

MDR1_seq_42_S300_R_01

0.996

0.997

0.001

1

0

0

MFAP4

MFAP4_P10_R_01

0.013

0.023

0.010

1

1

0

MKRN3

MKRN3_P108_F_01

0.985

0.978

-0.007

1

0

0

MLH3

MLH3_E72_F_01

0.218

0.275

0.057

1

1

0

MLLT4

MLLT4_P1400_F_01

0.130

0.188

0.058

1

1

0

MME

MME_E29_F_01

0.800

0.757

-0.043

1

0

0

MMP1

MMP1_P397_R_01

0.739

0.779

0.040

1

0

0
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H 0 : ∆β = β1 − β 2 = 0
1 = reject H 0 0 = fail to
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Symbol

Illumina ID

MMP9

MMP9_E88_R_01

0.992

0.985

-0.007

1

0

0

MMP9

MMP9_P237_R_01

0.814

0.764

-0.050

1

1

0

MPO

MPO_E302_R_01

0.038

0.062

0.024

1

1

0

MST1R

MST1R_P87_R_01

0.110

0.090

-0.021

1

1

0

MT1A

MT1A_E13_R_01

0.791

0.832

0.042

1

0

0

MYBL2

MYBL2_P354_F_01

0.286

0.457

0.172

1

1

1

MYCL1

MYCL1_P502_R_01

0.946

0.964

0.018

1

1

0

MYCN

MYCN_P464_R_01

0.393

0.582

0.188

1

1

1

MYLK

MYLK_E132_R_01

0.551

0.800

0.249

1

1

1

NAT2

NAT2_P11_F_01

0.999

1.000

0.001

1

0

0

NCL

NCL_P1102_F_01

0.998

0.996

-0.002

1

0

0

NES

NES_P239_R_01

0.017

0.023

0.006

1

1

0

NOTCH2

NOTCH2_P312_R_01

0.753

0.709

-0.044

1

0

0

NOTCH3

NOTCH3_P198_R_01

0.050

0.068

0.018

1

1

0

NPR2

NPR2_P1093_F_01

0.079

0.066

-0.014

1

1

0

NPR2

NPR2_P618_F_01

0.034

0.078

0.044

1

1

0

NRG1

NRG1_P558_R_01

0.986

0.976

-0.010

1

0

0

NTRK1

NTRK1_E74_F_01

0.015

0.020

0.005

1

1

0

NTRK2

NTRK2_P395_R_01

0.943

0.908

-0.035

1

1

0

OSM

OSM_P34_F_01

0.997

0.979

-0.018

1

0

0

PAX6

PAX6_E129_F_01

0.911

0.868

-0.043

1

1

0

PAX6

PAX6_P1121_F_01

0.315

0.220

-0.095

1

1

0

PCTK1

PCTK1_E77_R_01

0.900

0.853

-0.047

1

1

0

PDE1B

PDE1B_E141_F_01

0.488

0.444

-0.044

1

0

0

PDGFB

PDGFB_P719_F_01

0.994

0.979

-0.014

1

1

0

PECAM1

PECAM1_E32_R_01

0.317

0.515

0.199

1

1

1

PEG3

PEG3_E496_F_01

0.901

0.919

0.018

1

1

0

PENK

PENK_E26_F_01

0.816

0.864

0.048

1

1

0

PENK

PENK_P447_R_01

1.000

1.000

0.000

1

0

0

PGF

PGF_E33_F_01

0.940

0.958

0.018

1

0

0
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1 = reject H 0 0 = fail to
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PGF

PGF_P320_F_01

0.058

0.092

0.034

1

1

0

PGR

PGR_E183_R_01

0.925

0.900

-0.024

1

1

0

PLAGL1

PLAGL1_P236_R_01

0.993

0.986

-0.007

1

0

0

PLAGL1

PLAGL1_P334_F_01

0.862

0.879

0.017

1

1

0

PLAUR

PLAUR_P82_F_01

0.266

0.301

0.034

1

1

0

POMC

POMC_E254_F_01

0.991

0.984

-0.006

1

0

0

PSCA

PSCA_P135_F_01

0.908

0.882

-0.026

1

0

0

PSIP1

PSIP1_P163_R_01

0.964

0.930

-0.034

1

1

0

PTCH2

PTCH2_P568_R_01

0.879

0.836

-0.043

1

1

0

PTGS2

PTGS2_P308_F_01

0.998

0.996

-0.002

1

0

0

PTHLH

PTHLH_P15_R_01

0.966

0.934

-0.032

1

1

0

PTK2B

PTK2B_P673_R_01

0.898

0.879

-0.020

1

1

0

PTPN6

PTPN6_E171_R_01

0.998

0.997

-0.001

1

0

0

PTPN6

PTPN6_P282_R_01

0.044

0.074

0.030

1

1

0

PTPNS1

PTPNS1_P301_R_01

0.039

0.050

0.011

1

1

0

PTPRG

PTPRG_E40_R_01

0.962

0.947

-0.014

1

0

0

PTPRG

PTPRG_P476_F_01

0.942

0.859

-0.083

1

0

0

PTPRH

PTPRH_P255_F_01

0.999

1.000

0.001

1

0

0

PYCARD

PYCARD_P150_F_01

0.822

0.864

0.041

1

0

0

RAD50

RAD50_P191_F_01

0.810

0.766

-0.044

1

1

0

RAN

RAN_P581_R_01

0.959

0.919

-0.040

1

1

0

RET

RET_seq_53_S374_F_01

0.227

0.342

0.115

1

1

0

RYK

RYK_P493_F_01

0.978

0.945

-0.034

1

1

0

S100A2

S100A2_E36_R_01

0.171

0.238

0.067

1

1

0

S100A4

S100A4_P194_R_01

0.996

0.998

0.002

1

0

0

SCGB3A1

SCGB3A1_P103_R_01

0.909

0.932

0.023

1

0

0

SEMA3B

SEMA3B_P110_R_01

0.006

0.016

0.010

1

1

0

SEPT5_P464_R_01

0.117

0.159

0.042

1

1

0

SERPINE1_E189_R_01

0.039

0.080

0.041

1

1

0

5-Sep
SERPINE1
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H 0 : ∆β = β1 − β 2 = 0
1 = reject H 0 0 = fail to
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SFN

SFN_P248_F_01

0.992

0.982

-0.010

1

1

0

SFTPB

SFTPB_P689_R_01

0.890

0.847

-0.043

1

0

0

SGCE

SGCE_E149_F_01

0.163

0.185

0.022

1

1

0

SGCE

SGCE_P250_R_01

0.013

0.023

0.010

1

1

0

SH3BP2

SH3BP2_P771_R_01

0.080

0.110

0.030

1

1

0

SHB

SHB_P473_R_01

0.209

0.274

0.065

1

1

0

SIN3B

SIN3B_P607_F_01

0.999

0.999

0.000

1

0

0

SLIT2

SLIT2_E111_R_01

0.950

0.963

0.012

1

1

0

SMO

SMO_E57_F_01

0.908

0.930

0.023

1

1

0

SNRPN

SNRPN_E14_F_01

0.999

0.999

0.000

1

0

0

SNURF

SNURF_P2_R_01

0.650

0.599

-0.051

1

0

0

SPARC

SPARC_P195_F_01

0.980

0.968

-0.012

1

0

0

SPDEF

SPDEF_P6_R_01

0.696

0.749

0.053

1

0

0

SPI1

SPI1_P48_F_01

1.000

0.999

0.000

1

0

0

SPP1

SPP1_E140_R_01

0.998

0.996

-0.002

1

0

0

SPP1

SPP1_P647_F_01

0.851

0.791

-0.060

1

0

0

SRC

SRC_E100_R_01

0.602

0.530

-0.072

1

0

0

STAT5A

STAT5A_P704_R_01

0.950

0.933

-0.017

1

0

0

TAL1

TAL1_P817_F_01

0.160

0.130

-0.030

1

1

0

TDG

TDG_E129_F_01

0.996

0.992

-0.004

1

0

0

TFDP1

TFDP1_P543_R_01

0.916

0.935

0.019

1

0

0

TFF2

TFF2_P178_F_01

0.997

0.999

0.002

1

0

0

TFRC

TFRC_P414_R_01

0.942

0.920

-0.022

1

0

0

TIMP1

TIMP1_E254_R_01

0.964

0.943

-0.021

1

0

0

TIMP3

TIMP3_P1114_R_01

0.782

0.839

0.057

1

1

0

TJP2

TJP2_P518_F_01

0.505

0.649

0.144

1

1

0

TMEFF1

TMEFF1_E180_R_01

0.009

0.019

0.009

1

1

0

TMEFF1

TMEFF1_P234_F_01

0.030

0.090

0.059

1

1

0

TMEFF2

TMEFF2_P152_R_01

0.152

0.193

0.041

1

1

0
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H 0 : ∆β = β1 − β 2 = 0
1 = reject H 0 0 = fail to
reject H 0
Mean
Proportion
Methylated
for
Cirrhosis
Group, β1

Mean
Proportion
Methylated
for HCC
Group,

β2

∆β

Beta
Test

Two
Sample ttest

Filtered
Two
Sample ttest

Gene
Symbol

Illumina ID

TNFRSF10B

TNFRSF10B_E198_R_01

0.108

0.087

-0.021

1

1

0

TNFRSF1B

TNFRSF1B_E5_F_01

0.200

0.232

0.032

1

1

0

TNFSF10

TNFSF10_P2_R_01

0.855

0.831

-0.024

1

1

0

TP73

TP73_P496_F_01

0.988

0.992

0.005

1

0

0

TSC2

TSC2_E140_F_01

0.753

0.685

-0.068

1

0

0

TSG101

TSG101_P257_R_01

0.831

0.902

0.072

1

1

0

UGT1A1

UGT1A1_P564_R_01

1.000

1.000

0.000

1

0

0

UGT1A7

UGT1A7_P751_R_01

1.000

0.994

-0.006

1

0

0

VAMP8

VAMP8_P241_F_01

0.966

0.932

-0.034

1

1

0

VAV2

VAV2_E58_F_01

0.982

0.969

-0.013

1

1

0

VIM

VIM_P811_R_01

0.001

0.008

0.007

1

1

0

WNT1

WNT1_E157_F_01

0.683

0.732

0.049

1

0

0

YES1

YES1_P600_F_01

0.994

0.979

-0.015

1

1

0

ZAP70

ZAP70_P220_R_01

0.993

0.980

-0.013

1

1

0

ZIM3

ZIM3_E203_F_01

0.338

0.283

-0.055

1

1

0

ZNF264

ZNF264_P397_F_01

0.460

0.396

-0.065

1

1

0

ZNFN1A1

ZNFN1A1_E102_F_01

0.609

0.658

0.049

1

0

0

CC 8 (3433)

PCR16_HK3_1321_F

1.000

0.999

-0.001

1

0

0

Negative

Neg7_PPIH_9972_R

0.158

0.311

0.153

1

1

0

Negative

Neg15_HK3_8743_R

0.029

0.049

0.021

1

1

0

Negative

Neg16_PPIF_4992_R

0.942

0.895

-0.047

1

1

0

Negative

Neg48_PPIG_45960_R

0.999

0.997

-0.002

1

0

0
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APPENDIX B

Source Code for the construction of the nonlinear mixed model in Chapter 3
#########################################################################
#### # This file constructs the most appropriate hierarchical model and #############
##### establishes a dose response relation.
#############
#########################################################################

setwd("C://Documents and Settings//Laptop User//Desktop//Research")
xchrom.new<-read.csv('XchromBeta.new.csv')
library(nlme)
names(xchrom.new)
#[1] "index" "site"
"TargetID" "meth"
"dose"
"sample" "trep"
"SampleRep" "trep2"
attach(xchrom.new)
site<-as.factor(site);dose<-as.factor(dose);sample<-as.factor(sample)
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion
Methylated")

CpGdata<-xchrom.new
#dilution<-groupedData(meth~dose|sample,data=CpGdata)
dilution<-groupedData(meth~dose|sample/Rep/site,data=xchrom.new)
plot(dilution,display=1,collapse=1,ylab="Proportion Methylated",xlab="Percent of female
genomic DNA in sample")

#Simple Logistic Model
model1<-nlme(meth~.5/(1+exp(-(dose-mid)/scal)),data=dilution,start=c(5,5),fixed = mid
+ scal ~ 1,random=list(sample=pdDiag(mid+scal~1),Rep= pdDiag(mid+scal~1),site=
pdDiag(mid+scal~1)))
model1a<-update(model1, weights=varExp(form=~dose|site)) #Variance model in which
the site variance increases exponentially with age
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model1b<-update(model1a, random=list(sample=pdDiag(mid+scal~1),Rep=
pdDiag(mid+scal~1),site= pdDiag(scal~1)))
model1c<-update(model1a, random=list(sample=pdDiag(mid+scal~1),Rep=
pdDiag(mid+scal~1)))
#> anova(model1a,model1c)
#

Model df

AIC

BIC logLik Test L.Ratio p-value

#model1a

1 26 -1222.222 -1100.454 637.1108

#model1c

2 24 -1231.735 -1119.334 639.8674 1 vs 2 5.513169 0.0635

p3.est<-summary(model1a)$tTable[2,]
#

Value

Std.Error

DF

t-value

p-value

#8.398883e+00 1.394291e+00 5.940000e+02 6.023765e+00 2.988831e-09

dimnames(p3.est)[[2]]<-dimnames(summary(model1a)$tTable)[[2]]
lower.ci<-p3.est[1]-2*p3.est[2]
upper.ci<-p3.est[1]+2*p3.est[2]
p3.est2<-cbind(p3.est,lower.ci,upper.ci)
p3.est2[1,]
# p3.est lower.ci upper.ci
#8.398883 5.610301 11.187466

fitted.mean<-numeric()
fitted.mean[1]<-mean(fitted(model1a)[CpGdata$dose=="100"])
fitted.mean[2]<-mean(fitted(model1a)[CpGdata$dose=="50"])
fitted.mean[3]<-mean(fitted(model1a)[CpGdata$dose=="20"])
fitted.mean[4]<-mean(fitted(model1a)[CpGdata$dose=="10"])
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fitted.mean[5]<-mean(fitted(model1a)[CpGdata$dose=="5"])
fitted.mean[6]<-mean(fitted(model1a)[CpGdata$dose=="0"])
dose.mean<-c(100,50,20,10,5,0)
plot(fitted.mean~dose.mean,type='l',ylab="Proportion Methylated",xlab="Percent of
female genomic DNA in sample",ylim=c(0,1),main=" ")
points(CpGdata$meth~CpGdata$dose)

# Nonlinear method for testing significance of dose-response
dilution<-groupedData(meth~dose|sample/Rep/site,data=CpGdata)
p3.est[i,]<-summary(model2b)$tTable[3,]
}
dimnames(p3.est)[[2]]<-dimnames(summary(model1a)$tTable)[[2]]
lower.ci<-p3.est[,1]-2*p3.est[,2]
upper.ci<-p3.est[,1]+2*p3.est[,2]
p3.est2<-cbind(p3.est,lower.ci,upper.ci)

112

APPENDIX C

Source code for the establishment of a minimum level of detectable differential level of
methylation
#########################################################################
##### This file computes the correlation matrix among the 17 CpG sites and ##########
##### fits a mixed ANOVA model including nested effects. Pairwise ##############
##### comparisons are calculated for the determination the minimum level ##########
##### of detectable differential methylation
##############
#########################################################################
setwd("C://Documents and Settings//Laptop User//Desktop//Research")
xchrom.new<-read.csv('XchromBeta.new.csv')
xchrom.cor<-read.csv('XchromBeta.csv')
#Correlation matrix
xchrom.cor<-read.csv('XchromBeta.csv',row.names=1)
correlation<-round(cor(t(xchrom.cor)),3)
dimnames(correlation)[[1]]<-rownames(xchrom.cor)
dimnames(correlation)[[2]]<-rownames(xchrom.cor)
write.table(correlation,"Correlation.csv",sep=",")
library(nlme)
names(xchrom.new)
#[1] "index" "site"
"TargetID" "meth"
"dose"
"sample" "trep"
"SampleRep" "trep2"
attach(xchrom.new)
site<-as.factor(site);dose<-as.factor(dose);sample<-as.factor(sample)
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion
Methylated")

##Fit one anova model for all CpG sites using dose as fixed effect and site nested within
sample as random effects
# Since model is function of categorical variable (dose), regression and anova same here
xchrom.new<-read.csv('XchromBeta.new.csv')
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xchrom.new$site<-as.factor(xchrom.new$site)
xchrom.new$dose<-as.factor(xchrom.new$dose)
xchrom.new$sample<-as.factor(xchrom.new$sample)
xchrom.new$Rep<-as.factor(xchrom.new$Rep)
attach(xchrom.new)
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion
Methylated")
detach()
library(nlme)
overall<-lme(meth~dose,random=~1|sample/Rep/site,data=xchrom.new)
overall.reduced<-lme(meth~dose,random=~1|sample/Rep,data=xchrom.new)
anova(overall,overall.reduced)
overall.reduced2<-lme(meth~dose,random=~1|sample,data=xchrom.new)
anova(overall.reduced,overall.reduced2)
anova(overall)
plot(overall)
##Linear Contrasts for pairwise comparisons
library(gmodels)
contrast.0.5<-c(-1,1,0,0,0,0)
contrast.5.10<-c(0,-1,1,0,0,0)
contrast.10.20<-c(0,0,-1,1,0,0)
contrast.20.50<-c(0,0,0,-1,1,0)
contrast.50.100<-c(0,0,0,0,-1,1)
fit<-lme(meth~dose,random=~1|sample/Rep/site,data=xchrom.new)
all.contrasts<rbind(contrast.0.5,contrast.5.10,contrast.10.20,contrast.20.50,contrast.50.100)
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pairwise.result<-fit.contrast(model=fit, varname="dose", all.contrasts)
#Since pvalues<0.05, each contrast significant, so we reject H0:equal mean methylation in
two groups
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APPENDIX D

Source code for Chapter 3.3 CpG site specific hierarchical models
#########################################################################
##### This file constructs hierarchical models per CpG site
#############
##### It creates diagnostic plots for these models and computes point
#############
##### estimates at dose=100 and corresponding confidence intervals
#############
#########################################################################

setwd("C://Documents and Settings//Laptop User//Desktop//Research")
xchrom.new<-read.csv('XchromBeta.new.csv')
library(nlme)
names(xchrom.new)
#[1] "index" "site"
"TargetID" "meth"
"dose"
"sample" "trep"
"SampleRep" "trep2"
attach(xchrom.new)
site<-as.factor(site);dose<-as.factor(dose);sample<-as.factor(sample)
plot(meth~dose,xlab="Percent of female genomic DNA in sample",ylab="Proportion
Methylated")

#Change site depending on for which CpG site the model is being formulated
CpGdata<-xchrom.new[site==17,]
dilution<-groupedData(meth~dose|sample,data=CpGdata)
#Simple Logistic Model
model1<-nlme(meth~Asym/(1+exp(-(dose-mid)/scal)),data=dilution,start=c(.8,5,5),fixed =
Asym + mid + scal ~ 1,random=list(sample=pdDiag(Asym+mid+scal~1)))
model1a<-nlme(meth~Asym/(1+exp(-(dose-mid)/scal)),data=dilution,start=c(.72,5,5),fixed
= Asym + mid + scal ~ 1,random=list(sample=~Asym+mid+scal~1))
#Asymptotic Regression Model
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model2<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1+p2+p3~1)))
anova(model1,model2)
model2a<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1+p2~1)))
model2b<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1+p3~1)))
model2c<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p2+p3~1)))
model2d<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,3),fixed = p1 + p2 + p3~ 1,random=list(sample=pdDiag(p1~1)))
model3<-nlme(meth~p1+(p2-p1)*exp(-exp(p3)*dose),data=dilution,start=c(.72,.03,3),fixed = p1 + p2 + p3~ 1,random=list(sample=~p2+p3~1))
anova(model2,model2a,model2b,model2c,model2d)
#calculating predicted value and confidence interval at dose=100 for each CpG site
out<-summary(model2b)
### Extract Point estimate ###
mean(predict(model2b,newdata=dilution[dilution$dose==100,]))
### Extract the estimates ###
a<-model2b$coefficients$fixed[1]
b<-model2b$coefficients$fixed[2]
c<-model2b$coefficients$fixed[3]
### Construct Jacobian (at x=100) ####
da<- 1-exp(-100*exp(c))
db<- exp(-100*exp(c))
dc<- b*exp(-100*exp(c))*(-100*exp(c))+a*exp(-100*exp(c))*(100*exp(c))
vec<-matrix(c(da,db,dc),ncol=3)
### Estimate CI with Bonferroni adjustment ###
### Using the delta method to estimate variance JV(t)J^T where J is Jacobian, V(t) is
variance-covariance matrix, ^T is transpose.
### and use in constructing the CI with a Bonferroni adjustment
mean(predict(model2b,newdata=dilution[dilution$dose==100,])) - qnorm(10.05/17)*sqrt(vec%*%out$varFix%*%t(vec))
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mean(predict(model2b,newdata=dilution[dilution$dose==100,])) + qnorm(10.05/17)*sqrt(vec%*%out$varFix%*%t(vec))

#################
## Residual Plots ##
#################

par(mfrow=c(4,5))
ident<-rep(0,2)
other<-c(-.5,1.5)

# Residuals vs fitted values
#Change main depending on CpG site
#plot(resid(model2b)~fitted(model2b),xlab="Fitted Values",ylab="Standardized
Residuals",main="CpG Site 1: EFNB1-645",ylim=c(-.08,.08),xlim=c(0,1))
# lines(ident~other)

# Fitted mean methylation vs dose
fitted.mean<-numeric()
fitted.mean[1]<-mean(fitted(model2b)[CpGdata$dose=="100"])
fitted.mean[2]<-mean(fitted(model2b)[CpGdata$dose=="50"])
fitted.mean[3]<-mean(fitted(model2b)[CpGdata$dose=="20"])
fitted.mean[4]<-mean(fitted(model2b)[CpGdata$dose=="10"])
fitted.mean[5]<-mean(fitted(model2b)[CpGdata$dose=="5"])
fitted.mean[6]<-mean(fitted(model2b)[CpGdata$dose=="0"])
dose.mean<-c(100,50,20,10,5,0)
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plot(fitted.mean~dose.mean,type='l',ylab="Proportion Methylated",xlab="Percent of
female genomic DNA in sample",ylim=c(0,1),main="CpG Site 1: EFNB1-645")
points(CpGdata$meth~CpGdata$dose)
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APPENDIX E

Source code for Chapter 5 data simulations for the computation of Type I error under the
assumption of Beta distributed data
#########################################################################
##### This file tests type I error according to the ttest, the filtered
#############
##### ttest, the LRT, the bootstrap test and the beta test under the
#############
##### condition that the data has been generated according to the
#############
##### Beta distribution.
#############
#########################################################################
library(beadarray)
setwd("D:/")
## Read in data with no normalization or background correction
targets <- read.csv("phenotype.csv", header=T)
liver<readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none")

## Bead Summary Data
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R")
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G")
dim(R) #there are 1624 beadtypes in the Red Channel
dim(G) #there are 1624 beadtypes in the Green Channel
##Merging Red Channel Data with associated gene information
codeR<-featureNames(R)
M<-exprs(R)
RedData<-data.frame(M,codeR)
dim(RedData)
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE)
RedOMA<merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE)
dim(RedOMA)
#There are 1547 beadtypes in the red channel summaries that also have gene annotation
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info
##Merging Green Channel Data with associated gene information
codeG<-featureNames(G)
U<-exprs(G)
GreenData<-data.frame(U,codeG)
dim(GreenData)
GreenOMA<merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E)
dim(GreenOMA)
#There are 1547 beadtypes in the green channel summaries that also have gene annotation
info
#There are 22 negative control beads
#Red Channel
#create dataframe of negative control beads
indR<-grep("Negative",RedOMA$Gene_Symbol)
negR<-RedOMA[indR,]
#create vector of length 36, where each entry is the sample mean of the neg control
beadtype in a particular array
RedMean<-numeric()
for (i in 1:36) {
RedMean[i]<-mean(negR[,i+1])
i<-i+1
}
#Frequency histogram of the means
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated)
Channel"),col="red")
#Green Channel
#create dataframe of negative control beads
indG<-grep("Negative",GreenOMA$Gene_Symbol)
negG<-GreenOMA[indG,]
#create vector of length 36, where each entry is the sample mean of the
#negative control beadtype in a particular array
GreenMean<-numeric()
for (i in 1:36) {
GreenMean[i]<-mean(negG[,i+1])
i<-i+1
}
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#Frequency histogram of the means
x11()
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated)
Channel"),col="green")
###Compute beta variable
# initialize beta data frame to store values
beta<-data.frame()
# isolating average intensity for each beadtype for R and G channels
RedAvg<-RedOMA[,2:37]
GreenAvg<-GreenOMA[,2:37]
#compute beta
a<-0
for (i in 1:36) {
j<-1
for (j in 1:1547) {
diff1<-RedAvg[j,i]-RedMean[i]
diff2<-GreenAvg[j,i]-GreenMean[i]
num<-max(diff1,0)
den<-num+max(diff2,0)
n<-num/den
a<-ifelse(n=="NaN",a+1,a)
beta[j,i]<-n
j<-j+1
}
i<-i+1
}
# This produces NaN values where beta=0/(0+0)
##Apply Scaling factor
RedMean<-apply(RedOMA[,2:37],2,mean)
GreenMean<-apply(GreenOMA[,2:37],2,mean)
scale2<-numeric()
for (i in 1:36) {
scale2[i]<-RedMean[i]/GreenMean[i] ### KJA changes MRed to RedMean[i]
}
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36)
for (i in 1:36){
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1]
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}
### Two sample t-test to determine differentially methylated sites
library(multtest)
#Compute t-test test statistic
liver.results<-mt.teststat(beta,targets$Diagnosis)
#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta,class=targets$Diagnosis) {
var1<-var(beta[class=="Cirrhosis HCC"])
var2<-var(beta[class=="Cirrhosis non-HCC"])
n1<-length(beta[class=="Cirrhosis HCC"])
n2<-length(beta[class=="Cirrhosis non-HCC"])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta,1,df.func)
##p values for t distn
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f))
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
#################
### Generating Data Null case data:Non-differentially methylated
#################
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set.seed(123)
test<-as.character(deltabeta)
site<-1493
sig.beta<-beta[site,]
beta.positive<-as.numeric(sig.beta)
mu.beta<-mean(beta.positive)
s2.beta<-var(beta.positive)
a<-mu.beta*(mu.beta*(1-mu.beta)/s2.beta-1)
p<-(1-mu.beta)*(mu.beta*(1-mu.beta)/s2.beta-1)

n1<-20
n2<-16
set.seed(234)
for (i in 1:3152){
beta.new[i,1:20]<-rbeta(n1,a,p)
beta.new[i,21:36]<-rbeta(n2,a,p)

####################
#### T Test###########
####################
library(multtest)
#Compute t-test test statistic
##0 is HCC pos group; 1 is HCC neg group
#Change these values depending on tested sample size
indicator<-rep(0:1,c(20,16))
#indicator<-rep(0:1,c(15,15))
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liver.results<-mt.teststat(beta.new,indicator)
#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta.new,class=indicator) {
var1<-var(beta.new[class==0])
var2<-var(beta.new[class==1])
n1<-length(beta.new[class==0])
n2<-length(beta.new[class==1])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta.new,1,df.func)
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn
sig.level<-0.05
type1<-numeric()
not.sig.ttest<-p0.liver[1:3152]
for (i in 1:3152){
type1[i]<-ifelse(not.sig.ttest[i]<sig.level,1,0)
}
type1error.ttest<-sum(type1)/3152

##################
#####Bibikova######
##################
type1.bib<-numeric()
for (i in 1:3152){
delta.beta<-mean(beta.new[i,1:20])-mean(beta.new[i,21:36])
type1.bib[i]<-ifelse(not.sig.ttest[i]<sig.level & delta.beta>0.17,1,0)
}
type1error.bib<-sum(type1.bib)/3152
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####################
#### LR Test#########
####################
# derivative using R
null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)*
log(input)+(q-1)*log(1-input))
dx.null<-deriv(null.expression,c('p','q'))
# grr is the gradient for the null likelihood
grr<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
c(n*(digamma(p+q)/gamma(p+q)-digamma(p)/gamma(p))+sum(log(input)),
n*(digamma(p+q)/gamma(p+q)-digamma(q)/gamma(q))+sum(log(1-input))
)
}
# grr1 is the gradient for the alt likelihood
grr1<-function(par,input1,input2) {
p1<-par[1]
q1<-par[2]
n1<-length(input1)
p2<-par[3]
q2<-par[4]
n2<-length(input2)
c(n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(p1)/gamma(p1))+sum(log(input1)),
n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(q1)/gamma(q1))+sum(log(1-input1)),
n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(p2)/gamma(p2))+sum(log(input2)),
n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(q2)/gamma(q2))+sum(log(1-input2))
)
}
# This is the null function to be minimized
null.function<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p1)*sum(log(input))+(q-1)*sum(log(1-input))
-null.like
}
# Alternative function
alt.function<-function(par,input1,input2) {
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p1<-par[1]
q1<-par[2]
n1<-length(input1)
p2<-par[3]
q2<-par[4]
n2<-length(input2)
log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p11)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2))
-log.like
}
null<-numeric()
alt<-numeric()
for (i in 1:3152){
null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='NelderMead')$value
#Change indices depending on sample size
alt[i]<optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:20],input2=beta.new[i,21:36],met
hod='Nelder-Mead')$value
}
like.test<--2*(alt-null)
pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE)
#Type 1: say not equal when are equal
type1.like<-numeric()
not.sig.like<-pvals.like[1:3152]
for (i in 1:3152){
type1.like[i]<-ifelse(not.sig.like[i]<sig.level,1,0)
}
type1error.like<-sum(type1.like)/3152

####################
#### Bstrap###########
####################
Red<-red.nonsig
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Green<-green.nonsig
#Change limits depending on sample size
Red.pos<-Red[,1:20]
Red.neg<-Red[,21:36]
Green.pos<-Green[,1:20]
Green.neg<-Green[,21:36]
teststat<-numeric()
for (i in 1:3152){
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,]))
}
# Number of bootstrap samples
B<-2500
# Compute bootstrap test statistic
b.teststat<-matrix(ncol=B,nrow=3152)
for (b in 1:B) {
bsample<-sample(1:36,replace=TRUE)
red<-Red[,bsample]
green<-Green[,bsample]
#Change limits depending on sample size
Red.positive<-red[,1:20]
Green.positive<-green[,1:20]
Red.negative<-red[,21:36]
Green.negative<-green[,21:36]
for (i in 1:3152){
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,]))
}
}
b.teststat.sort<-matrix(ncol=B,nrow=3152)
for (i in 1:3152){
b.teststat.sort[i,]<-sort(b.teststat[i,])
}
result<-numeric()
for (i in 1:3152){
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0)
}
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#Achieved significance level
asl<-numeric()
for (i in 1:3152){
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B
}
sig.level<-0.05
#Type 1: say not equal when are equal
type1.bstrap<-numeric()
not.sig.bstrap<-asl[1:3152]
for (i in 1:3152){
type1.bstrap[i]<-ifelse(not.sig.bstrap[i]<sig.level,1,0)
}
type1error.bstrap<-sum(type1.bstrap)/3152
#####################
#### Beta Test #########
#####################
set.seed(123)
test<-as.character(deltabeta)
site<-1493
sig.beta<-beta[site,]
beta.positive<-as.numeric(sig.beta)
mu.beta<-mean(beta.positive)
s2.beta<-var(beta.positive)
a<-mu.beta*(mu.beta*(1-mu.beta)/s2.beta-1)
p<-(1-mu.beta)*(mu.beta*(1-mu.beta)/s2.beta-1)
mean <- a/(a + p)
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2)
Q <- (qbeta(0.975, a, p) - mean)/sqrt(variance(a, p))
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set.seed(123)
reject <- numeric()
#Change n1 and n2 depending on sample size
n1 <- 20
n2 <- 16
for (i in 1:10000) {
x <- rbeta(n1, a, p)
y <- rbeta(n2, a, p)
Critical <- 0 + Q * sqrt(variance(a, p)/n1 + variance(a,p)/n2)
reject[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1,0)
}
#Type I error according to Beta Test
type1error.beta<-sum(reject)/10000
type1error.ttest
type1error.bib
type1error.like
type1error.bstrap
type1error.beta
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APPENDIX F

Source code for Chapter 5 data simulations for the computation of Type I error under the
assumption of Bivariate Normal distributed data
#########################################################################
##### This file tests type I error according to the ttest, the filtered
#############
##### ttest, the LRT, the bootstrap test and the beta test under the
#############
##### condition that the data has been generated according to the
#############
##### Bivariate Normal distribution.
#############
#########################################################################
library(beadarray)
setwd("D:/")
## Read in data with no normalization or background correction
targets <- read.csv("phenotype.csv", header=T)
liver<readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none")

## Bead Summary Data
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R")
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G")
dim(R) #there are 1624 beadtypes in the Red Channel
dim(G) #there are 1624 beadtypes in the Green Channel
##Merging Red Channel Data with associated gene information
codeR<-featureNames(R)
M<-exprs(R)
RedData<-data.frame(M,codeR)
dim(RedData)
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE)
RedOMA<merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE)
dim(RedOMA)
#There are 1547 beadtypes in the red channel summaries that also have gene annotation
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info
##Merging Green Channel Data with associated gene information
codeG<-featureNames(G)
U<-exprs(G)
GreenData<-data.frame(U,codeG)
dim(GreenData)
GreenOMA<merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E)
dim(GreenOMA)
#There are 1547 beadtypes in the green channel summaries that also have gene annotation
info
#There are 22 negative control beads
#Red Channel
#create dataframe of negative control beads
indR<-grep("Negative",RedOMA$Gene_Symbol)
negR<-RedOMA[indR,]
#create vector of length 36, where each entry is the sample mean of the neg control
beadtype in a particular array
RedMean<-numeric()
for (i in 1:36) {
RedMean[i]<-mean(negR[,i+1])
i<-i+1
}
#Frequency histogram of the means
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated)
Channel"),col="red")
#Green Channel
#create dataframe of negative control beads
indG<-grep("Negative",GreenOMA$Gene_Symbol)
negG<-GreenOMA[indG,]
#create vector of length 36, where each entry is the sample mean of the
#negative control beadtype in a particular array
GreenMean<-numeric()
for (i in 1:36) {
GreenMean[i]<-mean(negG[,i+1])
i<-i+1
}
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#Frequency histogram of the means
x11()
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated)
Channel"),col="green")
###Compute beta variable
# initialize beta data frame to store values
beta<-data.frame()
# isolating average intensity for each beadtype for R and G channels
RedAvg<-RedOMA[,2:37]
GreenAvg<-GreenOMA[,2:37]
#compute beta
a<-0
for (i in 1:36) {
j<-1
for (j in 1:1547) {
diff1<-RedAvg[j,i]-RedMean[i]
diff2<-GreenAvg[j,i]-GreenMean[i]
num<-max(diff1,0)
den<-num+max(diff2,0)
n<-num/den
a<-ifelse(n=="NaN",a+1,a)
beta[j,i]<-n
j<-j+1
}
i<-i+1
}
# This produces NaN values where beta=0/(0+0)
##Apply Scaling factor
RedMean<-apply(RedOMA[,2:37],2,mean)
GreenMean<-apply(GreenOMA[,2:37],2,mean)
scale2<-numeric()
for (i in 1:36) {
scale2[i]<-RedMean[i]/GreenMean[i] ### KJA changes MRed to RedMean[i]
}
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36)
for (i in 1:36){
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1]
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}
### Two sample t-test to determine differentially methylated sites
library(multtest)
#Compute t-test test statistic
liver.results<-mt.teststat(beta,targets$Diagnosis)
#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta,class=targets$Diagnosis) {
var1<-var(beta[class=="Cirrhosis HCC"])
var2<-var(beta[class=="Cirrhosis non-HCC"])
n1<-length(beta[class=="Cirrhosis HCC"])
n2<-length(beta[class=="Cirrhosis non-HCC"])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta,1,df.func)
##p values for t distn
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f))
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
#################
### Generating Data Null case data:Non-differentially methylated
#################
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set.seed(123)
site<-703
library(MASS)
## Differentially expressed CpG sites
nreps<-3152
#Change ncol depending on desired sample size
red.nonsig<-matrix(nrow=nreps,ncol=36)
green.nonsig<-matrix(nrow=nreps,ncol=36)
nonsig.green<-CorrectedGreenOMA2[site,]
green<-as.numeric(nonsig.green)
mu.green.nonsig<-mean(green)
s2.green.nonsig<-var(green)
nonsig.red<-RedOMA[site,2:37]
red<-as.numeric(nonsig.red)
mu.red.nonsig<-mean(red)
s2.red.nonsig<-var(red)
covar<-(-0.6)*sqrt(s2.green.nonsig)*sqrt(s2.red.nonsig)
for (i in 1:nreps){
#Change length depending on desired sample size
nonsig<mvrnorm(36,mu=c(mu.red.nonsig,mu.green.nonsig),Sigma=matrix(c(s2.red.nonsig,covar,c
ovar,s2.green.nonsig),nrow=2))
red.nonsig[i,]<-nonsig[,1]
green.nonsig[i,]<-nonsig[,2]
}
beta.new<-red.nonsig/(red.nonsig+green.nonsig)
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####################
#### T Test###########
####################
library(multtest)
#Compute t-test test statistic
##0 is HCC pos group; 1 is HCC neg group
#Change these values depending on tested sample size
indicator<-rep(0:1,c(20,16))
#indicator<-rep(0:1,c(15,15))
liver.results<-mt.teststat(beta.new,indicator)
#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta.new,class=indicator) {
var1<-var(beta.new[class==0])
var2<-var(beta.new[class==1])
n1<-length(beta.new[class==0])
n2<-length(beta.new[class==1])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta.new,1,df.func)
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn
sig.level<-0.05
type1<-numeric()
not.sig.ttest<-p0.liver[1:3152]
for (i in 1:3152){
type1[i]<-ifelse(not.sig.ttest[i]<sig.level,1,0)
}
type1error.ttest<-sum(type1)/3152

##################
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#####Bibikova######
##################

type1.bib<-numeric()
for (i in 1:3152){
delta.beta<-mean(beta.new[i,1:20])-mean(beta.new[i,21:36])
type1.bib[i]<-ifelse(not.sig.ttest[i]<sig.level & delta.beta>0.17,1,0)
}
type1error.bib<-sum(type1.bib)/3152

####################
#### LR Test#########
####################
# the derivative using R
null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)*
log(input)+(q-1)*log(1-input))
dx.null<-deriv(null.expression,c('p','q'))
# grr is the gradient for the null likelihood
grr<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
c(n*(digamma(p+q)/gamma(p+q)-digamma(p)/gamma(p))+sum(log(input)),
n*(digamma(p+q)/gamma(p+q)-digamma(q)/gamma(q))+sum(log(1-input))
)
}
# grr1 is the gradient for the alt likelihood
grr1<-function(par,input1,input2) {
p1<-par[1]
q1<-par[2]
n1<-length(input1)
p2<-par[3]
q2<-par[4]
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n2<-length(input2)
c(n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(p1)/gamma(p1))+sum(log(input1)),
n1*(digamma(p1+q1)/gamma(p1+q1)-digamma(q1)/gamma(q1))+sum(log(1-input1)),
n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(p2)/gamma(p2))+sum(log(input2)),
n2*(digamma(p2+q2)/gamma(p2+q2)-digamma(q2)/gamma(q2))+sum(log(1-input2))
)
}
# This is the null function to be minimized
null.function<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p1)*sum(log(input))+(q-1)*sum(log(1-input))
-null.like
}
# Alternative function
alt.function<-function(par,input1,input2) {
p1<-par[1]
q1<-par[2]
n1<-length(input1)
p2<-par[3]
q2<-par[4]
n2<-length(input2)
log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p11)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2))
-log.like
}
null<-numeric()
alt<-numeric()
for (i in 1:3152){
null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='NelderMead')$value
#Change limits depending on sample size
alt[i]<optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:20],input2=beta.new[i,21:36],met
hod='Nelder-Mead')$value
}
like.test<--2*(alt-null)
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pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE)
#Type 1: say not equal when are equal
type1.like<-numeric()
not.sig.like<-pvals.like[1:3152]
for (i in 1:3152){
type1.like[i]<-ifelse(not.sig.like[i]<sig.level,1,0)
}
type1error.like<-sum(type1.like)/3152

####################
#### Bstrap###########
####################
Red<-red.nonsig
Green<-green.nonsig
#Change indices depending on sample size
Red.pos<-Red[,1:20]
Red.neg<-Red[,21:36]
Green.pos<-Green[,1:20]
Green.neg<-Green[,21:36]
teststat<-numeric()
for (i in 1:3152){
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,]))
}
# Number of bootstrap samples
B<-2500
# Compute bootstrap test statistic
b.teststat<-matrix(ncol=B,nrow=3152)
for (b in 1:B) {
bsample<-sample(1:36,replace=TRUE)
red<-Red[,bsample]
green<-Green[,bsample]
#Change indices depending on Sample size
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Red.positive<-red[,1:20]
Green.positive<-green[,1:20]
Red.negative<-red[,21:36]
Green.negative<-green[,21:36]
for (i in 1:3152){
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,]))
}
}
b.teststat.sort<-matrix(ncol=B,nrow=3152)
for (i in 1:3152){
b.teststat.sort[i,]<-sort(b.teststat[i,])
}
result<-numeric()
for (i in 1:3152){
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0)
}
#Achieved significance level
asl<-numeric()
for (i in 1:3152){
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B
}
sig.level<-0.05
#Type 1: say not equal when are equal
type1.bstrap<-numeric()
not.sig.bstrap<-asl[1:3152]
for (i in 1:3152){
type1.bstrap[i]<-ifelse(not.sig.bstrap[i]<sig.level,1,0)
}
type1error.bstrap<-sum(type1.bstrap)/3152
#################################
###### Beta Test ###################
##################################
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set.seed(123)
site<-1493
library(MASS)
nonsig.green<-CorrectedGreenOMA2[site,]##
green<-as.numeric(nonsig.green)
mu.green.nonsig<-mean(green)
s2.green.nonsig<-var(green)
nonsig.red<-RedOMA[site,2:37]
red<-as.numeric(nonsig.red)
mu.red.nonsig<-mean(red)
s2.red.nonsig<-var(red)
covar<-(-0.6)*sqrt(s2.green.nonsig)*sqrt(s2.red.nonsig)
nonsig<mvrnorm(1000,mu=c(mu.red.nonsig,mu.green.nonsig),Sigma=matrix(c(s2.red.nonsig,cova
r,covar,s2.green.nonsig),nrow=2))
red.nonsig<-nonsig[,1]
green.nonsig<-nonsig[,2]
beta<-red.nonsig/(red.nonsig+green.nonsig)
mu.beta<-mean(beta)
s2.beta<-var(beta)
a<-mu.beta*(mu.beta*(1-mu.beta)/s2.beta-1)
p<-(1-mu.beta)*(mu.beta*(1-mu.beta)/s2.beta-1)
mean <- a/(a + p)
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2)
Q <- (qbeta(0.975, a, p) - mean)/sqrt(variance(a, p))
set.seed(123)
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reject <- numeric()
# Change n1 and n2 depending on sample size
n1 <- 20
n2 <- 16
for (i in 1:10000) {
x <- rbeta(n1, a, p)
y <- rbeta(n2, a, p)
Critical <- 0 + Q * sqrt(variance(a, p)/n1 + variance(a,p)/n2)
reject[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1,0)
}
type1error.beta<-sum(reject)/10000
type1error.ttest
type1error.bib
type1error.like
type1error.bstrap
type1error.beta
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APPENDIX G

Source code for Chapter 5 data simulations for the computation of Type II error under the
assumption of Beta distributed data
#########################################################################
##### This file tests type II error according to the ttest, the filtered
#############
##### ttest, the LRT, the bootstrap test and the beta test under the
#############
##### condition that the data has been generated according to the
#############
##### Beta distribution. Concludes with the application of the Beta
#############
##### test to HCV data set.
#############
#########################################################################
library(beadarray)
setwd("D:/")
## Read in data with no normalization or background correction
targets <- read.csv("phenotype.csv", header=T)
liver<readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none")

## Bead Summary Data
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R")
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G")
dim(R) #there are 1624 beadtypes in the Red Channel
dim(G) #there are 1624 beadtypes in the Green Channel
##Merging Red Channel Data with associated gene information
codeR<-featureNames(R)
M<-exprs(R)
RedData<-data.frame(M,codeR)
dim(RedData)
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE)
RedOMA<merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE)
dim(RedOMA) #There are 1547 beadtypes in the red channel summaries that also have
gene annotation info
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##Merging Green Channel Data with associated gene information
codeG<-featureNames(G)
U<-exprs(G)
GreenData<-data.frame(U,codeG)
dim(GreenData)
#OMA<-read.csv("GS0007005-OMA.csv",header=TRUE)
GreenOMA<merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E)
dim(GreenOMA) #There are 1547 beadtypes in the green channel summaries that also
have gene annotation info
#There are 22 negative control beads
#Red Channel
#create dataframe of negative control beads
indR<-grep("Negative",RedOMA$Gene_Symbol)
negR<-RedOMA[indR,]
#create vector of length 36, where each entry is the sample mean of the negative control
beadtype in a particular array
RedMean<-numeric()
for (i in 1:36) {
RedMean[i]<-mean(negR[,i+1])
i<-i+1
}
#Frequency histogram of the means
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated)
Channel"),col="red")
#Green Channel
#create dataframe of negative control beads
indG<-grep("Negative",GreenOMA$Gene_Symbol)
negG<-GreenOMA[indG,]
#create vector of length 36, where each entry is the sample mean of the negative control
beadtype in a particular array
GreenMean<-numeric()
for (i in 1:36) {
GreenMean[i]<-mean(negG[,i+1])
i<-i+1
}
#Frequency histogram of the means
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x11()
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated)
Channel"),col="green")
#Compute beta
# initialize beta data frame to store values
beta<-data.frame()
# isolating average intensity for each beadtype for R and G channels
RedAvg<-RedOMA[,2:37]
GreenAvg<-GreenOMA[,2:37]
#compute beta
a<-0
for (i in 1:36) {
j<-1
for (j in 1:1547) {
diff1<-RedAvg[j,i]-RedMean[i]
diff2<-GreenAvg[j,i]-GreenMean[i]
num<-max(diff1,0)
den<-num+max(diff2,0)
n<-num/den
a<-ifelse(n=="NaN",a+1,a)
beta[j,i]<-n
j<-j+1
}
i<-i+1
}
# This produces NaN values where beta=0/(0+0)
# Set NaN values to 0 ??

#################
##Scale
RedMean<-apply(RedOMA[,2:37],2,mean)
GreenMean<-apply(GreenOMA[,2:37],2,mean)
scale2<-numeric()
for (i in 1:36) {
scale2[i]<-RedMean[i]/GreenMean[i] ### KJA changes MRed to RedMean[i]
}
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36)
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for (i in 1:36){
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1]
}
#################
### Two sample t-test to determine differentially methylated sites
####################
library(multtest)
#Compute t-test test statistic
liver.results<-mt.teststat(beta,targets$Diagnosis)
#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta,class=targets$Diagnosis) {
var1<-var(beta[class=="Cirrhosis HCC"])
var2<-var(beta[class=="Cirrhosis non-HCC"])
n1<-length(beta[class=="Cirrhosis HCC"])
n2<-length(beta[class=="Cirrhosis non-HCC"])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta,1,df.func)
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
#To identify sites with specific deltabetas
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#Compute delta beta
delbeta<-numeric()
mu.HCCpos<-numeric()
mu.HCCneg<-numeric()
abs.delbeta<-numeric()
for (i in 1:1547){
mu.HCCpos[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"]))
mu.HCCneg[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"]))
delbeta[i]<-mu.HCCpos[i]-mu.HCCneg[i]
abs.delbeta[i]<-abs(delbeta[i])
}
index<-1:1547
new.data<-cbind(index,mu.HCCpos,mu.HCCneg,delbeta,abs.delbeta,rawp0.liver)
#sites of interest are those where both means>0.2
ind<-numeric()
ind.a<-numeric()
for (i in 1:1547){
ind[i]<-ifelse(mu.HCCpos[i]>0.2 & mu.HCCneg[i]>0.2,1,0)}
of.interest<-new.data[ind==1,]
#sort by increasing values of absolute value of delta beta
of.interest<-of.interest[order(of.interest[,5]),]
#843 sites where both means >0.2
#for testing about 0.17
ind2<-numeric()
for (i in 1:843){
ind2[i]<-ifelse(.15<of.interest[i,5] & of.interest[i,5]<.18,1,0)}
sub2<-of.interest[ind2==1,]
#site 946
#for testing about .2
ind3<-numeric()
for (i in 1:843){
ind3[i]<-ifelse(.18<of.interest[i,5],1,0)}
sub3<-of.interest[ind3==1,]
#site 1051
#for testing about .1
ind4<-numeric()
for (i in 1:843){
ind4[i]<-ifelse(.08<of.interest[i,5] && of.interest[i,5]<.12,1,0)}
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sub4<-of.interest[ind4==1,]
# site 441
#for testing about .5
ind5<-numeric()
for (i in 1:843){
ind5[i]<-ifelse(.049<of.interest[i,5] && of.interest[i,5]<.055,1,0)}
sub5<-of.interest[ind5==1,]
#site 920
##################
#Generate beta data###
###################
##Type II error
##Generate significantly differentially expressed data
nreps<-3152
set.seed(123)
test<-as.character(deltabeta)
site<-946
sig.beta<-beta[site,]
beta.positive<-as.numeric(sig.beta[targets$Diagnosis=="Cirrhosis HCC"])
mu.beta.positive<-mean(beta.positive)
s2.beta.positive<-var(beta.positive)
a.positive<-mu.beta.positive*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive-1)
p.positive<-(1-mu.beta.positive)*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive1)
beta.negative<-as.numeric(sig.beta[targets$Diagnosis=="Cirrhosis non-HCC"])
mu.beta.negative<-mean(beta.negative)
s2.beta.negative<-var(beta.negative)
a.negative<-mu.beta.negative*(mu.beta.negative*(1-mu.beta.negative)/s2.beta.negative-1)

148
p.negative<-(1-mu.beta.negative)*(mu.beta.negative*(1mu.beta.negative)/s2.beta.negative-1)
#Change ncol depending on sample size
beta.new<-matrix(nrow=nreps,ncol=36)
set.seed(123)
for (i in 1:nreps){
#change length of data depending on sample size
beta.new[i,1:20]<-rbeta(20,a.positive,p.positive)
beta.new[i,21:36]<-rbeta(16,a.negative,p.negative)
}

####################
#### T Test###########
####################
library(multtest)
#Compute t-test test statistic
##0 is HCC pos group; 1 is HCC neg group
#Change these numbers depending on sample size
indicator<-rep(0:1,c(20,16))
#indicator<-rep(0:1,c(80,80))
liver.results<-mt.teststat(beta.new,indicator)

#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta.new,class=indicator) {
var1<-var(beta.new[class==0])
var2<-var(beta.new[class==1])
n1<-length(beta.new[class==0])
n2<-length(beta.new[class==1])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
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}
degrees.f<-apply(beta.new,1,df.func)
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn
sig.level<-0.05
type2<-numeric()
not.sig.ttest<-p0.liver
type2<-numeric()
for (i in 1:nreps){
type2[i]<-ifelse(p0.liver[i]>sig.level,1,0)
}
type2error.ttest<-sum(type2)/nreps

##################
#####Bibikova######
####Filtered ttest#####
##################
type2.bib<-numeric()
for (i in 1:nreps){
#Change indices depending on sample size
delta.beta<-abs(mean(beta.new[i,1:20])-mean(beta.new[i,21:36]))
type2.bib[i]<-ifelse(not.sig.ttest[i]>sig.level | delta.beta<0.17,1,0)
}
type2error.bib<-sum(type2.bib)/nreps

####################
#### LR Test#########
####################
# derivative using R
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null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)*
log(input)+(q-1)*log(1-input))
dx.null<-deriv(null.expression,c('p','q'))
# grr is the gradient for the null likelihood
grr<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
c(n*(gamma(p+q)*digamma(p+q)/gamma(p+q)gamma(p)*digamma(p)/gamma(p))+sum(log(input)),
n*(gamma(p+q)*digamma(p+q)/gamma(p+q)gamma(q)*digamma(q)/gamma(q))+sum(log(1-input))
)
}
# null function to be minimized
null.function<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p1)*sum(log(input))+(q-1)*sum(log(1-input))
-null.like
}
# Alternative function
alt.function<-function(par,input1,input2) {
p1<-par[1]
q1<-par[2]
n1<-length(input1)
p2<-par[3]
q2<-par[4]
n2<-length(input2)
log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p11)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2))
-log.like
}
null<-numeric()
alt<-numeric()
for (i in 1:nreps){
null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='NelderMead')$value
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alt[i]<optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:20],input2=beta.new[i,21:36],met
hod='Nelder-Mead')$value
}
like.test<--2*(alt-null)
pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE)
#Type 2: say equal when not equal
sig.like<-pvals.like
type2.like<-numeric()
for (i in 1:nreps){
type2.like[i]<-ifelse(sig.like[i]>sig.level,1,0)
}
type2error.like<-sum(type2.like)/nreps

####################
#### Bstrap###########
####################
Red<-red.data.new
Green<-green.data.new
#Change indices depending on sample size
Red.pos<-Red[,1:20]
Red.neg<-Red[,21:36]
Green.pos<-Green[,1:20]
Green.neg<-Green[,21:36]
teststat<-numeric()
for (i in 1:nreps){
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,]))
}
# Number of bootstrap samples
B<-2500
b.teststat<-matrix(ncol=B,nrow=nreps)
set.seed(123)
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for (b in 1:B) {
bsample<-sample(1:36,replace=TRUE)
red<-Red[,bsample]
green<-Green[,bsample]
Red.positive<-red[,1:20]
Green.positive<-green[,1:20]
Red.negative<-red[,21:36]
Green.negative<-green[,21:36]
for (i in 1:nreps){
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,]))
}
}
b.teststat.sort<-matrix(ncol=B,nrow=nreps)
for (i in 1:nreps){
b.teststat.sort[i,]<-sort(b.teststat[i,])
}
result<-numeric()
for (i in 1:nreps){
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0)
}

asl<-numeric()
for (i in 1:nreps){
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B
}
sig.level<-0.05

#Type 2: say equal when not equal
sig.bstrap<-asl
type2.bstrap<-numeric()
for (i in 1:nreps){
type2.bstrap[i]<-ifelse(sig.bstrap[i]>sig.level,1,0)
}
type2error.bstrap<-sum(type2.bstrap)/nreps
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############################
######## Beta Test ############
############################

variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2)
mean.beta <- function(x,y) {
#xbar <- (length(x)*mean(x)+length(y)*mean(y))/(length(x)+length(y))
xbar<-mean(c(x,y))
#v <(length(x)*(var(x)+(mean(x))^2)+length(y)*(var(y)+(mean(y))^2))/(length(x++length(y))xbar^2
v<-var(c(x,y))*(length(c(x,y))-1)/length(c(x,y))
a <- xbar * (xbar * (1 - xbar)/v - 1)
b <- (1 - xbar) * (xbar * (1 - xbar)/v - 1)
var <- variance(a, b)
list(xbar = xbar, alpha = a, beta = b, var = var)
}
set.seed(123)
x.pos<-rbeta(3152,a.positive,p.positive)
set.seed(123)
x.neg<-rbeta(3152,a.negative,p.negative)
combined <- mean.beta(x.pos, x.neg)
Q <- (qbeta(0.975, combined$alpha, combined$beta) - combined$alpha/(combined$alpha
+ combined$beta))/sqrt(variance(combined$alpha, combined$beta))
set.seed(123)
power <- numeric()
n1 <- 20
n2 <- 16
set.seed(123)
for (i in 1:3152) {
x <- rbeta(n1, a.positive, p.positive)
y <- rbeta(n2, a.negative, p.negative)
Critical <- 0 + Q * sqrt(variance(a.positive, p.positive)/n1 +
variance(a.negative,p.negative)/n2)
power[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1, 0)
}
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type2error.beta<-1-sum(power)/3152
type2error.ttest
type2error.bib
type2error.beta
type2error.like
type2error.bstrap

############################
######## Applying Beta test to Archer data############
############################

variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2)
mean.beta <- function(x,y) {
#xbar <- (length(x)*mean(x)+length(y)*mean(y))/(length(x)+length(y))
xbar<-mean(c(x,y))
#v <(length(x)*(var(x)+(mean(x))^2)+length(y)*(var(y)+(mean(y))^2))/(length(x++length(y))xbar^2
v<-var(c(x,y))*(length(c(x,y))-1)/length(c(x,y))
a <- xbar * (xbar * (1 - xbar)/v - 1)
b <- (1 - xbar) * (xbar * (1 - xbar)/v - 1)
var <- variance(a, b)
list(xbar = xbar, alpha = a, beta = b, var = var)
}
Q<-numeric()
for (i in 1:1547){
x.pos<-as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"])
x.neg<-as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"])
combined <- mean.beta(x.pos, x.neg)
Q [i]<- (qbeta(0.975, combined$alpha, combined$beta) combined$alpha/(combined$alpha + combined$beta))/sqrt(variance(combined$alpha,
combined$beta))
}
Critical<-numeric()
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a.positive<-numeric()
p.positive<-numeric()
a.negative<-numeric()
p.negative<-numeric()
reject<-numeric()
index<-numeric()
beta.pval<-numeric()
for (i in 1:1547) {
x <- as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"])
y <- as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"])
v.x<-var(x)*(length(x)-1)/length(x)
v.y<-var(y)*(length(y)-1)/length(y)
a.positive[i]<- mean(x)* (mean(x) * (1 - mean(x))/v.x - 1)
p.positive [i]<- (1 - mean(x)) * (mean(x) * (1 - mean(x))/v.x - 1)
a.negative[i]<-mean(y) * (mean(y) * (1 - mean(y))/v.y - 1)
p.negative [i]<- (1 -mean(y)) * (mean(y) * (1 -mean(y))/v.y - 1)
Critical[i]<- 0 + Q[i] * sqrt(variance(a.positive[i], p.positive[i])/length(x) +
variance(a.negative[i],p.negative[i])/length(y))
reject[i]<-ifelse(abs(mean(x)-mean(y))>Critical[i],1,0)
}
sum(reject,na.rm=TRUE) #277 significant sites for two sided test at 0.05 significance level
versus 227 with ttest
ttest.sig<-ifelse(rawp0.liver<0.05,1,0) #205 significant
filt.sig<-ifelse(rawp0.liver>0.05|deltabeta<0.17,0,1) #7 significant
index<-1:1547
compare<-cbind(index,ttest.sig,reject) #see that for the most part, the two tests find the
same CpG sites significantly differentially methylated
results<cbind(as.numeric(mu.HCCpos),as.numeric(mu.HCCneg),as.numeric(delbeta),as.numeric(r
eject),as.numeric(ttest.sig),as.numeric(filt.sig),as.vector(OMA$Gene_Symbol),as.vector(O
MA$Ilmn_ID))
keep<-results[results[,4]==1,]
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APPENDIX H

Source code for Chapter 5 data simulations for the computation of Type II error under the
assumption of Bivariate Normal distributed data
#########################################################################
##### This file tests type II error according to the ttest, the filtered
#############
##### ttest, the LRT, the bootstrap test and the beta test under the
#############
##### condition that the data has been generated according to the
#############
##### Bivariate Normal distribution.
#############
#########################################################################

library(beadarray)
setwd("D:/")
## Read in data with no normalization or background correction
targets <- read.csv("phenotype.csv", header=T)
liver<readIllumina(arrayNames=targets$FileName,useImages=FALSE,singleChannel=FALSE,ta
rgets=targets,backgroundMethod="none")

## Bead Summary Data
R<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="R")
G<-createBeadSummaryData(liver,log=FALSE,imagesPerArray=1,what="G")
dim(R) #there are 1624 beadtypes in the Red Channel
dim(G) #there are 1624 beadtypes in the Green Channel
##Merging Red Channel Data with associated gene information
codeR<-featureNames(R)
M<-exprs(R)
RedData<-data.frame(M,codeR)
dim(RedData)
OMA<-read.csv("GS0007005-OMA.csv",header=TRUE)
RedOMA<merge(RedData,OMA,by.x="codeR",by.y="IllumiCode.name",all.x=FALSE,all.y=TRUE)
dim(RedOMA)
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#There are 1547 beadtypes in the red channel summaries that also have gene annotation
info
##Merging Green Channel Data with associated gene information
codeG<-featureNames(G)
U<-exprs(G)
GreenData<-data.frame(U,codeG)
dim(GreenData)
GreenOMA<merge(GreenData,OMA,by.x="codeG",by.y="IllumiCode.name",all.x=FALSE,all.y=TRU
E)
dim(GreenOMA)
#There are 1547 beadtypes in the green channel summaries that also have gene annotation
info
#There are 22 negative control beads
#Red Channel
#create dataframe of negative control beads
indR<-grep("Negative",RedOMA$Gene_Symbol)
negR<-RedOMA[indR,]
#create vector of length 36, where each entry is the sample mean of the neg control
beadtype in a particular array
RedMean<-numeric()
for (i in 1:36) {
RedMean[i]<-mean(negR[,i+1])
i<-i+1
}
#Frequency histogram of the means
hist(RedMean,main=paste(" "),xlab=paste("mean of Red (Methylated)
Channel"),col="red")
#Green Channel
#create dataframe of negative control beads
indG<-grep("Negative",GreenOMA$Gene_Symbol)
negG<-GreenOMA[indG,]
#create vector of length 36, where each entry is the sample mean of the
#negative control beadtype in a particular array
GreenMean<-numeric()
for (i in 1:36) {
GreenMean[i]<-mean(negG[,i+1])
i<-i+1
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}
#Frequency histogram of the means
x11()
hist(GreenMean,main=paste(" "),xlab=paste("mean of Green (Unmethylated)
Channel"),col="green")
###Compute beta variable
# initialize beta data frame to store values
beta<-data.frame()
# isolating average intensity for each beadtype for R and G channels
RedAvg<-RedOMA[,2:37]
GreenAvg<-GreenOMA[,2:37]
#compute beta
a<-0
for (i in 1:36) {
j<-1
for (j in 1:1547) {
diff1<-RedAvg[j,i]-RedMean[i]
diff2<-GreenAvg[j,i]-GreenMean[i]
num<-max(diff1,0)
den<-num+max(diff2,0)
n<-num/den
a<-ifelse(n=="NaN",a+1,a)
beta[j,i]<-n
j<-j+1
}
i<-i+1
}
# This produces NaN values where beta=0/(0+0)
##Apply Scaling factor
RedMean<-apply(RedOMA[,2:37],2,mean)
GreenMean<-apply(GreenOMA[,2:37],2,mean)
scale2<-numeric()
for (i in 1:36) {
scale2[i]<-RedMean[i]/GreenMean[i] ### KJA changes MRed to RedMean[i]
}
CorrectedGreenOMA2<-matrix(nrow=1547,ncol=36)
for (i in 1:36){
CorrectedGreenOMA2[,i]<-scale2[i]*GreenOMA[,i+1]
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}
### Two sample t-test to determine differentially methylated sites
library(multtest)
#Compute t-test test statistic
liver.results<-mt.teststat(beta,targets$Diagnosis)
#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta,class=targets$Diagnosis) {
var1<-var(beta[class=="Cirrhosis HCC"])
var2<-var(beta[class=="Cirrhosis non-HCC"])
n1<-length(beta[class=="Cirrhosis HCC"])
n2<-length(beta[class=="Cirrhosis non-HCC"])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta,1,df.func)
##p values for t distn
rawp0.liver<-2*(1-pt(abs(liver.results),degrees.f))
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
code<-data.frame(GreenOMA$codeG)
class<-targets$Diagnosis
deltabeta<-numeric()
for (i in 1:1547){
deltabeta[i]<-mean(as.numeric(beta[i,class=="Cirrhosis HCC"]))mean(as.numeric(beta[i,class=="Cirrhosis non-HCC"]))
}
data<-cbind(code,deltabeta,rawp0.liver)
###To identify sites with specific delta betas
#Compute delta beta
delbeta<-numeric()
mu.HCCpos<-numeric()
mu.HCCneg<-numeric()
abs.delbeta<-numeric()
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for (i in 1:1547){
mu.HCCpos[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis HCC"]))
mu.HCCneg[i]<-mean(as.numeric(beta[i,targets$Diagnosis=="Cirrhosis non-HCC"]))
delbeta[i]<-mu.HCCpos[i]-mu.HCCneg[i]
abs.delbeta[i]<-abs(delbeta[i])
}
index<-1:1547
new.data<-cbind(index,mu.HCCpos,mu.HCCneg,delbeta,abs.delbeta,rawp0.liver)
#sites of interest are those where both means>0.2
ind<-numeric()
ind.a<-numeric()
for (i in 1:1547){
ind[i]<-ifelse(mu.HCCpos[i]>0.2 & mu.HCCneg[i]>0.2,1,0)}
of.interest<-new.data[ind==1,]
#sort by increasing values of absolute value of delta beta
of.interest<-of.interest[order(of.interest[,5]),]
#843 sites where both means >0.2
#for testing about 0.17
ind2<-numeric()
for (i in 1:843){
ind2[i]<-ifelse(.15<of.interest[i,5] & of.interest[i,5]<.18,1,0)}
sub2<-of.interest[ind2==1,]
#site 946
#for testing about .2
ind3<-numeric()
for (i in 1:843){
ind3[i]<-ifelse(.18<of.interest[i,5],1,0)}
sub3<-of.interest[ind3==1,]
#site 1051
#for testing about .1
ind4<-numeric()
for (i in 1:843){
ind4[i]<-ifelse(.08<of.interest[i,5] && of.interest[i,5]<.12,1,0)}
sub4<-of.interest[ind4==1,]
# site 441
#for testing about .5
ind5<-numeric()
for (i in 1:843){

161
ind5[i]<-ifelse(.049<of.interest[i,5] && of.interest[i,5]<.055,1,0)}
sub5<-of.interest[ind5==1,]
#site 920
#########################################
#########################################
#########################################
## Generating Data that's significantly differently expressed: bivariate normal
#Set seed so data is replicable
set.seed(123)
test<-as.character(deltabeta)
### Change this site depending on site that data is being modeled after
site<-946
sig.green<-CorrectedGreenOMA2[site,]
green.positive<-as.numeric(sig.green[targets$Diagnosis=="Cirrhosis HCC"])
mu.green.positive<-mean(green.positive)
green.negative<-as.numeric(sig.green[targets$Diagnosis=="Cirrhosis non-HCC"])
mu.green.negative<-mean(green.negative)
s2.green.positive<-var(green.positive)
s2.green.negative<-var(green.negative)

sig.red<-RedOMA[site,2:37]
red.positive<-as.numeric(sig.red[targets$Diagnosis=="Cirrhosis HCC"])
mu.red.positive<-mean(red.positive)
red.negative<-as.numeric(sig.red[targets$Diagnosis=="Cirrhosis non-HCC"])
mu.red.negative<-mean(red.negative)
s2.red.positive<-var(red.positive)
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s2.red.negative<-var(red.negative)
cov.positive<-(-.6)*sqrt(s2.red.positive)*sqrt(s2.green.positive)
cov.negative<-(-.6)*sqrt(s2.red.negative)*sqrt(s2.green.positive)
library(MASS)
## Differentially expressed CpG sites
nreps<-3152
set.seed(123)
## Change ncol depending on sample size being tested
red.pos.sig<-matrix(nrow=nreps,ncol=40)
green.pos.sig<-matrix(nrow=nreps,ncol=40)
red.neg.sig<-matrix(nrow=nreps,ncol=40)
green.neg.sig<-matrix(nrow=nreps,ncol=40)
for (i in 1:nreps){
## Change length of generated data depending on sample size
positive.sig<mvrnorm(40,mu=c(mu.red.positive,mu.green.positive),Sigma=matrix(c(s2.red.positive,cov
.positive,cov.positive,s2.green.positive),nrow=2))
red.pos.sig[i,]<-positive.sig[,1]
green.pos.sig[i,]<-positive.sig[,2]
negative.sig<mvrnorm(40,mu=c(mu.red.negative,mu.green.negative),Sigma=matrix(c(s2.red.negative,c
ov.negative,cov.negative,s2.green.negative),nrow=2))
red.neg.sig[i,]<-negative.sig[,1]
green.neg.sig[i,]<-negative.sig[,2]
}
beta1.positive<-red.pos.sig/(red.pos.sig+green.pos.sig)
beta2.negative<-red.neg.sig/(red.neg.sig+green.neg.sig)
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delta.beta<-numeric()
sd.beta1.positive<-numeric()
sd.beta2.negative<-numeric()
for (i in 1:nreps){
delta.beta[i]<-mean(beta1.positive[i,])-mean(beta2.negative[i,])
sd.beta1.positive[i]<-sqrt(var(beta1.positive[i,]))
sd.beta2.negative[i]<-sqrt(var(beta2.negative[i,]))
}
summary(delta.beta)
summary(sd.beta1.positive)
summary(sd.beta2.negative)
###Combine data
red.data<-cbind(red.pos.sig,red.neg.sig)
green.data<-cbind(green.pos.sig,green.neg.sig)
beta<-red.data/(red.data+green.data)

##Change negative values to positive
#Change ncol and limit of loop depending on sample size
red.data.new<-matrix(nrow=nreps,ncol=80)
green.data.new<-matrix(nrow=nreps,ncol=80)
for (i in 1:nreps){
for (j in 1:80){
red.data.new[i,j]<-ifelse(red.data[i,j]<0,(-red.data[i,j]),red.data[i,j])
green.data.new[i,j]<-ifelse(green.data[i,j]<0,(-green.data[i,j]),green.data[i,j])
}
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}
beta.new<-red.data.new/(red.data.new+green.data.new)

##Conduct KS test to ensure still follow biv norm
mu.green<-apply(green.data.new,1,mean)
s2.green<-apply(green.data.new,1,var)
mu.red<-apply(red.data.new,1,mean)
s2.red<-apply(red.data.new,1,var)
red.data.norm<-numeric()
green.data.norm<-numeric()
for (i in 1:nreps){
red.data.norm[i]<ks.test(red.data.new[i,],"pnorm",mean=mu.red[i],sd=sqrt(s2.red[i]))$p.value
green.data.norm[i]<ks.test(green.data.new[i,],"pnorm",mean=mu.green[i],sd=sqrt(s2.green[i]))$p.value
}
sum(ifelse(green.data.norm>0.05,1,0))
sum(ifelse(red.data.norm>0.05,1,0))
## This demonstrates that vast majority of generated CpG site still follow normal
distribution
##Conduct subsequent analysis on red.data.new, green.data.new,beta.new

####################
#### T Test###########
####################
library(multtest)
#Compute t-test test statistic
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##0 is HCC pos group; 1 is HCC neg group
#Change these numbers depending on sample size
#indicator<-rep(0:1,c(20,16))
indicator<-rep(0:1,c(40,40))
liver.results<-mt.teststat(beta.new,indicator)

#Compute adjusted degrees of freedom for unequal sample size
rawp0.liver<-2*(1-pnorm(abs(liver.results)))
df.func<-function(beta.new,class=indicator) {
var1<-var(beta.new[class==0])
var2<-var(beta.new[class==1])
n1<-length(beta.new[class==0])
n2<-length(beta.new[class==1])
df<-(var1+var2)^2/(var1^2/(n1-1)+var2^2/(n2-1))
df
}
degrees.f<-apply(beta.new,1,df.func)
p0.liver<-2*(1-pt(abs(liver.results),degrees.f)) ##p values for t distn
sig.level<-0.05
type2<-numeric()
not.sig.ttest<-p0.liver
type2<-numeric()
for (i in 1:nreps){
type2[i]<-ifelse(p0.liver[i]>sig.level,1,0)
}
type2error.ttest<-sum(type2)/nreps

##################
#####Bibikova######
####Filtered ttest#####
##################
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type2.bib<-numeric()
for (i in 1:nreps){
#Change limits depending on sample size
delta.beta<-abs(mean(beta.new[i,1:40])-mean(beta.new[i,41:80]))
type2.bib[i]<-ifelse(not.sig.ttest[i]>sig.level | delta.beta<0.17,1,0)
}
type2error.bib<-sum(type2.bib)/nreps

####################
#### LR Test#########
####################
# Getting the derivative using R
null.expression<-expression(n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p-1)*
log(input)+(q-1)*log(1-input))
dx.null<-deriv(null.expression,c('p','q'))
# grr is the gradient for the null likelihood
grr<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
c(n*(gamma(p+q)*digamma(p+q)/gamma(p+q)gamma(p)*digamma(p)/gamma(p))+sum(log(input)),
n*(gamma(p+q)*digamma(p+q)/gamma(p+q)gamma(q)*digamma(q)/gamma(q))+sum(log(1-input))
)
}
# null function to be minimized
null.function<-function(par,input) {
p<-par[1]
q<-par[2]
n<-length(input)
null.like<- n*(log(gamma(p+q))-log(gamma(p))-log(gamma(q)))+(p1)*sum(log(input))+(q-1)*sum(log(1-input))
-null.like
}
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# Alternative function
alt.function<-function(par,input1,input2) {
p1<-par[1]
q1<-par[2]
n1<-length(input1)
p2<-par[3]
q2<-par[4]
n2<-length(input2)
log.like<- n1*(log(gamma(p1+q1))-log(gamma(p1))-log(gamma(q1)))+(p11)*sum(log(input1))+(q1-1)*sum(log(1-input1)) + n2*(log(gamma(p2+q2))log(gamma(p2))-log(gamma(q2)))+(p2-1)*sum(log(input2))+(q2-1)*sum(log(1-input2))
-log.like
}
null<-numeric()
alt<-numeric()
for (i in 1:nreps){
null[i]<-optim(par=c(.5,.5),fn=null.function,gr=grr,input=beta.new[i,],method='NelderMead')$value
#Change limits depending on sample size
alt[i]<optim(par=rep(.5,4),fn=alt.function,input1=beta.new[i,1:40],input2=beta.new[i,41:80],met
hod='Nelder-Mead')$value
}
like.test<--2*(alt-null)
pvals.like<-pchisq(like.test,df=2,lower.tail=FALSE)
#Type 2: say equal when not equal
sig.like<-pvals.like
type2.like<-numeric()
for (i in 1:nreps){
type2.like[i]<-ifelse(sig.like[i]>sig.level,1,0)
}
type2error.like<-sum(type2.like)/nreps

####################
#### Bstrap###########
####################
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Red<-red.data.new
Green<-green.data.new
#Change limits depending on sample size
Red.pos<-Red[,1:40]
Red.neg<-Red[,41:80]
Green.pos<-Green[,1:40]
Green.neg<-Green[,41:80]
teststat<-numeric()
for (i in 1:nreps){
teststat[i]<-mean((Red.pos[i,])/(Red.pos[i,]+Green.pos[i,]))mean((Red.neg[i,])/(Red.neg[i,]+Green.neg[i,]))
}
#Number of bootstrap samples
B<-2500
b.teststat<-matrix(ncol=B,nrow=nreps)
set.seed(123)
for (b in 1:B) {
#Change limits depending on sample size
bsample<-sample(1:80,replace=TRUE)
red<-Red[,bsample]
green<-Green[,bsample]
Red.positive<-red[,1:40]
Green.positive<-green[,1:40]
Red.negative<-red[,41:80]
Green.negative<-green[,41:80]
for (i in 1:nreps){
b.teststat[i,b]<-mean((Red.positive[i,])/(Red.positive[i,]+Green.positive[i,]))mean((Red.negative[i,])/(Red.negative[i,]+Green.negative[i,]))
}
}
b.teststat.sort<-matrix(ncol=B,nrow=nreps)
for (i in 1:nreps){
b.teststat.sort[i,]<-sort(b.teststat[i,])
}
result<-numeric()
for (i in 1:nreps){
result[i]<-ifelse(teststat[i]<b.teststat.sort[i,25]|teststat[i]>b.teststat.sort[i,975],1,0)
}
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asl<-numeric()
for (i in 1:nreps){
asl[i]<-sum(ifelse(b.teststat[i,]>abs(teststat[i]) | b.teststat[i,]< -abs(teststat[i]),1,0))/B
}
sig.level<-0.05

#Type 2: say equal when not equal
sig.bstrap<-asl
type2.bstrap<-numeric()
for (i in 1:nreps){
type2.bstrap[i]<-ifelse(sig.bstrap[i]>sig.level,1,0)
}
type2error.bstrap<-sum(type2.bstrap)/nreps

########################
##### Beta Test###########
########################

## Differentially expressed CpG sites
#Generate many observations to get more stable estimate
set.seed(123)
positive.sig<mvrnorm(3152,mu=c(mu.red.positive,mu.green.positive),Sigma=matrix(c(s2.red.positive,c
ov.positive,cov.positive,s2.green.positive),nrow=2))
red.positive<-positive.sig[,1]
green.positive<-positive.sig[,2]
negative.sig<mvrnorm(3152,mu=c(mu.red.negative,mu.green.negative),Sigma=matrix(c(s2.red.negative
,cov.negative,cov.negative,s2.green.negative),nrow=2))
red.negative<-negative.sig[,1]
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green.negative<-negative.sig[,2]
beta.positive<-red.positive/(red.positive+green.positive)
beta.negative<-red.negative/(red.negative+green.negative)
mu.beta.positive<-mean(beta.positive)
s2.beta.positive<-var(beta.positive)
a.positive<-mu.beta.positive*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive-1)
p.positive<-(1-mu.beta.positive)*(mu.beta.positive*(1-mu.beta.positive)/s2.beta.positive1)
mu.beta.negative<-mean(beta.negative)
s2.beta.negative<-var(beta.negative)
a.negative<-mu.beta.negative*(mu.beta.negative*(1-mu.beta.negative)/s2.beta.negative-1)
p.negative<-(1-mu.beta.negative)*(mu.beta.negative*(1mu.beta.negative)/s2.beta.negative-1)
variance <- function(a, b) a * b/((a + b + 1) * (a + b)^2)
mean.beta <- function(x,y) {
xbar<-mean(c(x,y))
v<-var(c(x,y))*(length(c(x,y))-1)/length(c(x,y))
a <- xbar * (xbar * (1 - xbar)/v - 1)
b <- (1 - xbar) * (xbar * (1 - xbar)/v - 1)
var <- variance(a, b)
list(xbar = xbar, alpha = a, beta = b, var = var)
}
set.seed(123)
x.pos<-rbeta(3152,a.positive,p.positive)
set.seed(123)
x.neg<-rbeta(3152,a.negative,p.negative)
combined <- mean.beta(x.pos, x.neg)
#Compute Quantile value under null hypothesis of equality
Q <- (qbeta(0.975, combined$alpha, combined$beta) - combined$alpha/(combined$alpha
+ combined$beta))/sqrt(variance(combined$alpha, combined$beta))
set.seed(123)
power <- numeric()
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#Change n1 and n2 based on sample size
n1 <- 40
n2 <- 40
set.seed(123)
for (i in 1:3152) {
x <- rbeta(n1, a.positive, p.positive)
y <- rbeta(n2, a.negative, p.negative)
Critical <- 0 + Q * sqrt(variance(a.positive, p.positive)/n1 +
variance(a.negative,p.negative)/n2)
power[i] <- ifelse(abs(mean(x) - mean(y)) > Critical, 1, 0)
}
type2error.beta<-1-sum(power)/3152
#Type 2 error rates and parameter estimates (for use in calculating variance of beta
distribution)
type2error.ttest
type2error.bib
type2error.beta
type2error.like
type2error.bstrap
a.positive
p.positive
a.negative
p.negative
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